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Thesis Summary 
Tissue transglutaminase (TG2) has been suggested to be a key player in the progression and 
metastasis of chemoresistant breast cancer. One of the foremost survival signalling pathways 
implicated in causing drug resistance in breast cancer is the constitutive activation of NFκB 
(Nuclear Factor -kappa B) induced by TG2. This study provides a mechanism by which TG2 
constitutively activates NFκB which in turn confers chemoresistance to breast cancer cells 
against doxorubicin. Breast cancer cell lines with varying expression levels of TG2 as well as 
TG2 null breast cancer cells transfected with TG2 were used as the major cell models for this 
study. This study made use of cell permeable and impermeable TG2 inhibitors, specific TG2 
and Rel A/ p65 targeting siRNA, TG2 functional blocking antibodies, IKK inhibitors and a 
specific targeting peptide against Rel A/p65 to investigate the pathway of activation involved in 
the constitutive activation of NFκB by TG2 leading to drug resistance. Crucial to the activation 
of Rel A/p65 and drug resistance in the breast cancer cells is the interaction between the 
complex of IκBα and Rel A/p65 with TG2 which results in the dimerization of Rel A/p65 and 
polymerization of IκBα. The association of TG2 with the IκBα-NFκB complex was determined 
to be independent of IKKα/β function. The polymerized IκBα is degraded in the cytoplasm by 
the μ-calpain pathway which allows the cross linked Rel A/ p65 dimers to translocate into the 
nucleus. Using R283 and ZDON (cell permeable TG2 activity inhibitors) and specific TG2 
targeting siRNA, the Rel A/ p65 dimer formation could be inhibited. Co-immunoprecipitation 
studies confirmed that the phosphorylation of the Rel A/p65 dimers at the Ser536 residue by 
IKKε took place in the cell nucleus. Importantly, this study also investigated the transcriptional 
regulation of the TGM2 gene by the pSer536 Rel A/ p65 dimer and the importance of this TG2-
NFκB feedback loop in conferring drug resistance to breast cancer cells. This data provides 
evidence that TG2 could be a key therapeutic target in the treatment of chemoresistant breast 
cancer. 
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1. Introduction 
Breast cancer still remains as one of the most commonly diagnosed diseases among women and 
the social as well as economic impact of this malignancy is still enormous (Youlden, et al. 
2012). Preventing breast cancer progression is an idea that dates back through history and there 
has been a lot of proof to show that the interaction between the independent and the 
environment they live in, can impact on the risk of breast cancer development (Cazzaniga & 
Bonanni, 2012). In spite of the development of numerous anticancer drugs, chemoresistance 
remains a major obstacle that results in the failure of treatment regimens. Some breast cancer 
cells maybe inherently resistant to drugs while others develop the resistance post chemotherapy. 
Chemoresistance can be caused by multiple factors: inactivation of the drug by detoxifying 
enzymes, changes in tumour suppressor genes, drug efflux by transport mechanisms, altered 
expression of anti and pro apoptotic proteins as well as protection from DNA damage 
mechanisms (LaPensee & Jonathan, 2010). Overcoming this chemoresistance has become a 
major focus of many studies.     
Previously it has been shown that breast cancer cells selected out for drug resistance have high 
levels of the multifunctional protein cross linking enzyme tissue transglutaminase (TG2), 
however, no direct link has been established between TG2 and drug resistance. Studies 
undertaken in numerous breast cancer cell lines have shown that higher expression of TG2 
makes the cancer cells more invasive and metastatic as well as conferring resistance to various 
drugs (Chen, et al. 2002).  Many hypotheses have been put forward indicating that this could be 
due to the interaction between TG2 and the transcription factor Nuclear Factor-kappa B 
(NFκB). Literature has shown that TG2 expression leads to constitutive activation of NFκB via 
a pathway independent of IKK (Inhibitor-kappa Kinase). In numerous cancers such as breast, 
ovarian, cervical etc., the expression of TG2 has been correlated with constitutive activation of 
NFκB (Mann, et al. 2006) 
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1.1 Transglutaminases: A family portrait 
Transglutaminases or TGs are a family of enzymes predominantly found in plants, micro-
organisms, invertebrates and mammals. Multiple distinct forms of TGs have been identified in 
mammals. The term Transglutaminases was first coined by Clarke and colleagues in 1957 to 
illustrate the transamidating activity observed in guinea-pig liver (Clarke, et al. 1957). Studies 
done later showed that TGs cross linked proteins through an acyl-transfer reaction involving the 
γ-carboxamide group of a peptide-bound glutamine and the ε-amino group of a peptide bound 
lysine, which results in the formation of  ε-(γ-glutamyl) lysine isopeptide bond (Griffin, et al. 
2002) (Figure 1.1). 
 
(Chandrashekar & Mehta, 2000) 
Figure 1.1 Cross linking reaction catalysed by Transglutaminases 
TGs are known to accelerate the post-translation modification of proteins by transamidation of 
the free glutamine residues. The resulting covalent stable isopeptide bond is resistant to 
proteolysis, chemical, mechanical and enzymatic disruption (Greenberg, et al. 1991). So far 
nine members of the family have been identified all of which have now been characterized at 
the protein level. In mammals other than erythrocyte band 4.2 which is inactive, the other TG 
family members require Ca
2+
 for the transamidating activity.  The family members are Factor 
XIII A, keratinocyte transglutaminase (TG1), tissue transglutaminase (TG2), epidermal 
transglutaminase (TG3), prostate transglutaminase (TG4), Transglutaminases X, Y and Z (TG5, 
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TG6 and TG7) and the non-catalytically active erythrocyte band 4.2 (Iismaa, et al. 2009) (Table 
1.1). 
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(Iismaa, et al. 2009)  
Table 1.1 Functions of members of Transglutaminase (TG) family  
Chapter 1: Introduction 
26 | 
 
Some of the common features seen in each of the members include the lack of glycosylation 
sites and cysteine bonds in spite of the presence of N-linked glycosylation sites and large 
numbers of cysteine residues in such proteins. Also, of the TGs, that are secreted, TG2 and 
Factor XIIIA that are associated with the plasma membrane lack the presence of the N-terminal 
hydrophobic sequence and are not secreted via the Golgi /ER pathway. The overall primary 
structure of the TG enzymes varies among the members; however, they all share the same 
amino acid sequence in the active site (Griffin, et al. 2002).  
1.1.1 Factor XIII 
Factor XIII (FXIII) is a major blood coagulation factor which is a pro-transglutaminase that 
circulates in the plasma in a tetrameric form (FXIII-A2-B2) (Muszbek, et al. 2008). FXIII 
comprises of two catalytically active A subunits, FXIIIA (~83kDa) and two inhibitor or carrier 
B subunits, FXIIIB (~80kDa). In the plasma, FXIIIB is found in excess and almost half of this 
exists in a non-complex free form. Dimers of FXIIIA denoted as FXIIIA2 are present within the 
cytoplasm of numerous cells such as macrophages and platelets, which is not characteristic of 
FXIIIB. FXIII is a well-known zymogen, which in its active form (FXIIIA) can function as a 
transglutaminase that catalyses the formation of ε(γ-glutamyl) lysyl bonds between polypeptide 
chains. FXIIIA plays a very important role in the regulation of fibrinolysis and homeostasis as 
well as in a wide range of physiological and pathological processes (Muszbek, et al. 2011).  
Factor XIII A forms a dimeric structure (unlike the other transglutaminase members) and 
comprises of five major structural domains: an activation peptide at the NH2- terminal, β- 
sandwich, catalytic core and β-barrel 1 and 2. The monomers of FXIIIA subunit are arranged as 
a dimeric structure wherein the central core domains are surrounded by β-sheet domains 
(Facchiano & Facchiano, 2009). On the other hand FXIIIB is a glycoprotein that consists of ten 
short tandem repeats known as GP1 structures, each containing ~60 amino acids joined together 
by two internal disulphide bonds (Ichinose, et al. 1990).  
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Pro-FXIII is activated during the late stages of the coagulation process by either Ca
2+
 or 
thrombin. Thrombin has been shown to cleave the activated peptide present on the NH2- 
terminus of FXIIIA, which results in the formation of the active truncated form of FXIIIA, 
FXIIIa (Muszbek, et al. 2011).  
Contractile and adhesive proteins as well as components of the fibrinolytic clotting system form 
protein substrates of FXIIIa. One of the main physiological functions of FXIII in the plasma is 
the cross linking and incorporation of plasminogen in activator into fibrin, so as to protect it 
from plasmin. Plasma FXIII is also involved in tissue repair and wound healing. Cellular FXIII, 
when present on the surface of the cells, can support and maintain homeostatic functions 
(Torocsik, et al. 2005).  
FXIIIa has also been demonstrated to limit bacterial infections in the wound and incorporates 
macromolecules to support cell survival and migration. The complex formed between α5β3 
integrin and VEGF receptor 2 is crucial for formation of granulation tissue and angiogenesis is 
mediated by FXIIIa. Reduced FXIII levels have been observed in plasma during chronic 
inflammatory conditions that involve blood loss and subsequent activation of the coagulation 
cascade (Soendergaard, et al. 2013).  
1.1.2 Keratinocyte transglutaminase 
Keratinocyte Transglutaminase (TG1) is also known as transglutaminase epidermal type 1 and 
expressed mainly in the stratified squamous epithelia of coverings, the lower female genital 
tract and the upper digestive tract. Three response elements similar to AP-2, approximately 0.5 
kb from the transcription initiation site are promoters of TG1. Proteolytic cleavage, TIG-3 
protein and Ca
2+
, activate the catalytic functions of TG1. Phorbol esters are known to induce the 
expression of TG1 while RA (Retinoic acid) down regulates the expression of TG1 (Mehta, 
2005). 
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Studies done on the time course of TG1 expression after incision on the dorsal skin of neonatal 
mice has provided great insights into the role of TG1 in cutaneous healing (Inada, et al. 2000). 
Using in situ hybridization, TG1 was found to be expressed in the suprabasal keratinocytes next 
to the wound edge, two hours post the wound and its expression increased in the subsequent 
hour near the edge of the injury. TG1 is also known to be expressed in the wound site much 
before the infiltration of leucocytes, which implied that TG1 is essential during very early 
stages of wound repair and also in preparation for the remodelling of stratum corneum. TG1 is 
found to be highly expressed in the leading edges of migrating keratinocytes, when re-
epithelialisation was completed. Within these migrating keratinocytes, the expression of TG1 
was seen to be concurrent to its cross linking substrate, involucrin on the plasma membrane 
(Inada, et al. 2000). 
The gene encoding TG1 is localized to chromosome 14 q11.2-13, and is reported to comprise of 
15 exons and 14 introns. At the tissue level, the localization of TG1 has been identified to the 
granular layer at the later stages of differentiation using immunochemical and 
immunohistological methods, while specific antibodies against the N-terminal fragments of 
TG1 showed that TG1 was also present in the spinous and suprabasal layers (Kim, et al. 1992; 
Steinert, et al. 1996). Mutations that include a C-to-T change in the binding site of the 
transcription factor Sp1 within the promoter region and the Gly143-to-Glu mutation in exon 3, 
Val382-to-Met mutation in exon 7 of the TGM1 gene result in autosomal recessive lamellar 
ichthyosis which is a rare keratinisation disorder of the skin. Patients of this disorder exhibit 
extremely decreased TG1 activity with an absence of any detectable TG1 polypeptide (Jessen, 
et al. 2000) 
1.1.3 Epidermal transglutaminase 
Epidermal transglutaminase or TG3, was first characterised by Buxman and Wuepper in 1975 
and purified in 1976, and still is one of the least understood members of the family of TGs 
(Buxman & Wuepper, 1976). The human TG3 gene is localized into chromosome 20q11-12 
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(Wang, et al. 1994). The sequences that are between the 128 and 91 base pairs upstream of the 
transcription initiation site represent the proximal promoter region of the TGM3 gene. The 
binding of the Ets and Sp1 motifs to their respective cognate binding factors is essential for the 
transcription of TGM3 (Mehta, 2005). 
The TG3 protein is an intact, latent pro-enzyme with low specific activity and of size, 77kDa. 
After the cleavage of TG3 into two 30kDa and 47kDa fragments, the enzyme becomes activated 
by the non-covalent interaction between the two fragments. A recent study done by Cheng et al. 
in 2006, cathepsin L was shown to cleave TG3 in vitro. The binding of Ca
2+
 to TG3 can 
increase the specific activity of the enzyme, similar to the other TGs (Cheng, et al. 2006) 
The use of polyclonal antibodies indicated that during the later stages of differentiation, TG3 
could be detected in the epidermis (Lee, et al. 1996) as well as in the small intestine, testis, 
brain and fore stomach (Hitomi, et al. 1999). Using a monoclonal antibody, the cytoplasmic 
distribution of TG3 in the cornified and granular layer was enumerated which implied that TG3 
played a role in the early phase of cornified cell envelope formation. Activated TG3 can cross 
link CE (cornified envelope) proteins such as trichohyalin, SPRs 1, 2 and 3 and loricrin which 
occurs during epidermal terminal differentiation (Hitomi, et al. 2003) 
TG3 cross links the keratin and trichohyalin intermediate filaments to harden the inner root 
sheath, which is very crucial for hair fibre morphogenesis. TG3 is also responsible for cell 
envelope formation during the latter stages of differentiation in the hair follicle and epidermis. 
The TG3
-/-
 mice embryos fail to get implanted which suggested that this gene plays a very 
pivotal role in the early developmental stages (John, et al. 2012). Other studies have also 
indicated that TG3
 -/- 
mice developed curled whiskers and fur as well as high protein 
extractability showing irregular structures in the cross linking of structural hair proteins 
(Thiebach, et al. 2007). TG3 along with TG1 is known to participate in the maturation of the 
epithelium by catalysing the specific cross linking of numerous structural proteins present in the 
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cell envelope (SRPs, involucrin, filaggrin, desmoplakin, keratins, loricrin and envoplakin) 
(Ahvazi, et al. 2002). 
1.1.4 Prostate transglutaminase (TG4) 
Prostate transglutaminase or TG4 was previously known as dorsal prostate protein 1 (DP1) or 
even androgen regulated major secretary protein because the main site of expression of this 
protein was in prostatic fluids, seminal plasma and the prostate. The regions between the 
positions of -113 and -61 base pairs upstream of the TGM4 gene promoter are very crucial for 
the core promoter activity. The transcriptional regulation of TGM4 promoter is the Sp1 binding 
motif at positions -96 to -87 base pairs upstream. The positions from -1276 to -563 harbour the 
promoter for a cyclophilin pseudo gene (Mehta, 2005).   
The rat homologue of TG4 has been shown to be responsible for the cross linking during the 
formation of the copulatory plug and also may be involved in sperm cell motility as well as 
immunogenicity to a certain degree (Davies, et al. 2007). Initial studies done showed that TG4 
expression was only confined to luminal epithelial cells. The function of this enzyme in prostate 
cancer cells has been linked to invasiveness and the regulation of the interactions between the 
endothelial cells and prostate cancer cells (Ablin, et al. 2011). Recently, variants of TG4 have 
also been reported in malignant and benign human prostate tissues (Cho, et al. 2010). This 
molecule has a diverse impact on prostate cancer cell growth, invasion, and migration and also 
involved in epithelial to mesenchymal transition and tumour-endothelial interaction. TG4 also 
interacts with other molecular complexes, thus implicating it as a biomarker of aggressive 
cancer as well as a therapeutic target (Jiang & Ablin, 2011). 
1.1.5 Transglutaminases 5, 6 and 7: 
Transglutaminase 5 (TGX), Transglutaminase 6 (TGY) and Transglutaminase 7 (TGZ) are the 
three recently discovered transglutaminases.  
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Transglutaminase 5 is encoded on human chromosome 15q15.1 (molecular weight 81kDa) and 
requires proteolytic processing for the activation of TG5 cross linking activity (Pietroni, et al. 
2008). In cultured keratinocytes, TG5 has been found to be co localized with vimentin during 
the formation of filament network, when undergoing EMT (Epithelial to Mesenchymal 
transition) (Candi, et al. 2001). Even though TG2 was found to be expressed in numerous adult 
and foetal tissues, the exact cells that express the proteins in tissues are unknown (Candi, et al. 
2004). However, the loss of function or mutated forms of TG5 has been reported to be the cause 
of developing acral peeling of skin syndrome, which implements its role in the formation of 
cornified cell envelops of keratinocytes (Cassidy, et al. 2005).  
Similar to TG5, TG6 is also activated by proteolytic processing and comprises of two 
polypeptide chains which are synthesized as a precursor form consisting of a single polypeptide. 
TG6 is mainly responsible for the late phases of formation of cell envelop in the hair follicle 
and epidermis. TG7 is expressed ubiquitously in testis and lung. The transcription level of TG7 
has been shown to be increased in breast cancer patients with a poor prognosis (Mehta, 2005).   
1.1.6 Erythrocyte band 4.2 
The human erythrocyte band 4.2 is a crucial membrane-associated protein present at 
approximately 200,000 copies per cell of 72 kDa in size. Band 4.2 is particularly important in 
normal erythrocyte function as patients who lack band 4.2, are anaemic due to the increased 
erythrocyte destruction with abnormally shaped and fragile erythrocytes. However, the exact 
function of band 4.2 in erythrocytes remains unclear. Even though the amino acid sequence 
homology between tissue transglutaminase and Factor XIIIA spans the regions containing the 
active sites, band 4.2 has no detectable cross linking activity when tested in vitro (Korsgren & 
Cohen, 1991).  
Erythrocyte band 4.2 is known to be one of the major components of the red blood cell member 
and is located on the interior surface of the cells, where, the protein binds to the cytoplasmic 
domain of the anion exchange protein, band 3, with high affinity. The gene of human 
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erythrocyte protein 4.2 maps to chromosome 15 q15-q21 and contains 13 exons (Najfeld, et al. 
1992).   
The interaction of band 4.2 with ankyrin and spectrin seems to suggest that this protein plays a 
functional role in stabilizing the links between the cytoskeleton and the over laying membrane. 
Studies (Mouro-Chanteloup, et al. 2003) have also shown that band 4.2 interacts with CD47 
which further contributes to the anchoring of the Rh molecule with the RBC skeleton (Dahl, et 
al. 2004). The interaction of band 4.2 with the remaining RBC proteins indicates its importance 
in maintaining the stability, integrity and flexibility of RBCs. Two isoforms of band 4.2 have 
been described, a protein fragment of 691 amino acids with a molecular weight of 72kDa 
encoded for by the short isoform cDNA and a protein of 721 amino acids with a molecular 
weight of 74kDa encoded for by the long isoform cDNA (Sung, et al. 1992 ; Zhu, et al. 1998)  
1.2 Tissue Transglutaminase 
Tissue transglutaminase or TG2 is the most ubiquitous member of the TG family. TG2 is a 
multifunctional protein that is involved in various cellular functions at different cellular 
locations. In contrast to the other transglutaminase family members, TG2 is involved in diverse 
roles in living and dying cells because of its different functions (Fesus & Piacentini, 2002).  
TG2 is a multifunctional protein and bi-functional enzyme that acts as a transglutaminase in the 
presence of Ca
2+
, but also as a GTPase/ ATPase, protein kinase and protein disulphide 
isomerase. It is involved in a vast array of cellular processes such as cell migration, survival, 
growth, adhesion, differentiation, ECM (Extracellular matrix) organization and apoptosis. Such 
an impact of TG2 in these functions suggests that this protein plays a crucial role in 
pathological states and physiological responses which contributes greatly toward inflammation, 
wound healing, tumour growth, metastasis, neurodegeneration, vascular remodelling and 
fibrosis (Nurminskaya & Belkin, 2012; Wang & Griffin, 2013; Wang & Griffin, 2012) 
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1.2.1 Structure of TG2 
The nature of the enzymatic activity of TG2 is reliant on the type and amount of binding ligands 
as well as structural status of the protein (Bergamini, 2007). TG2 has been shown to exist in 
both open and closed conformation and comprises four sequential domains: β-sandwich at the 
N-terminal, catalytic core domain and two β-barrels at the C-terminal. The active site is within 
the catalytic core, formed of Cys277, Asp358 and His 335, present at the base of a cavity and 
buried under two loops TG2 is a monomeric protein of 685-691 amino acids and has a 
molecular mass of 76-85kDa. TG2 also entails the same four structural domains as the other TG 
members. Domain 1 covers amino acids 1-139 and consists of a flexible loop, a short helix, an 
isolated β-strand, five tightly packed anti-parallel strands in β-sandwich conformation and a 
another short strand that covers the lower end of the β-sandwich. In the second domain, the 
peptide chain folds into two more β-strands that are directed downwards and upwards along the 
core domain. This domain spans amino acids 140-454 and contains Ser 171 and Lys 173 that 
are required for GTP binding. Four additional β-strands and α-helixes also span the domain. 
The first three α-helixes are arranged in a triangular fashion which contains the active site triad 
(Cis, His and Asp) whereas the last helix is close to the core domain and is involved in Ca
2+
 
binding activity. Amino acids 454-478 is the site that codes for the isoenzymes specialized 
function. Domains 3 and 4 are C-terminal domains and are crucial in regulating GTPase and 
transamidating activity (Griffin, et al. 2002; Nurminskaya & Belkin, 2012; Wang & Griffin, 
2013) (Figures 1.2 A & B)  
The four distinct domains of TG2 have unique properties. The N-terminal β-sandwich domain 
contains the binding site for FN and promotes the attachment of cells to the ECM. When 
induced by Ca
2+,
 the catalytic core domain extends and is responsible for cross-linking cellular 
proteins. The barrel 1 domain contains the GTP/ATP binding site that allows TG2-mediated 
signalling pathways to proceed. The C-terminal Barrel 2 domain in its GTP bound form  can 
recruit and activate phospholipase C (PLC) and contributes to the pro-inflammatory properties 
of TG2 (Mehta, et al. 2010). More recently, novel TG2 HS binding sites have been identified 
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which confirmed the interaction between syndecan 4 and matrix bound TG2. This binding site 
has also been demonstrated to be crucial for regulating the externalization of TG2 into the ECM 
via a method that involves the shedding of cell surface HS (Wang, et al. 2012) (Figure 1.2 C) 
 
(A)                                                                                  (B) 
  
(C) 
 
Figure 1.2: Structure of TG2: (A) TG2 structure in the absence of ligands bound to it. (B) 
Structure of TG2 (produced by using Rasmol) showing domains 1-4 coloured in Magenta, 
orange, blue and green respectively. Regulatory loop is coloured red (between Domain 2 and 3), 
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Active site amino acids forming the triad is in yellow, amino acids involved in Ca
2+
 binding in 
black and those interacting with GTP are in light grey (Chen & Mehta, 1999) (C) Structural and 
functional domains of TG2 (Mehta, et al. 2010) 
1.2.2 Cellular distribution of TG2: 
The possible reason that TG2 is engaged in various biological processes is due to its tissue wide 
distribution. Different cells and tissues constitutively express TG2, while in others, TG2 can be 
induced as a part of the maturation phase or induced by numerous external stimuli which induce 
cell stress or wound healing. TG2 is widely distributed in mammalian tissues with high levels 
found in smooth and vascular endothelial muscle cells (Thomazy & Fesus, 1989).  
At the cellular level, majority of the enzyme is present in cellular cytosolic compartments. 
However, detectable amounts of TG2 are also found associated with subcellular fractions such 
as the plasma membrane, nuclei, mitochondria and ECM. The mitochondrial location of TG2 is 
thought not to be related to TG2 activity but to its PDI (protein disulphide isomerase)  activity 
(Krasnikov, et al. 2005) 
1.2.2.1 Cytoplasm 
In theory, GTPase activity of TG2 should represent the main function of the enzyme as 
intracellular Ca
2+
 levels are low, but TG2 has also been reported  to act as a transamidating 
enzyme by catalysing the cross linking of intracellular proteins when Ca
2+
 rises (Nicholas, et al. 
2003). Furthermore, most of the potential substrates of TG2 are all primarily cytoplasmic 
proteins. TG2 transamidating function can be induced by numerous factors such as ROS, 
chemokines and growth factors which can increase intracellular Ca
2+
 by driving the release of 
Ca
2+
 from reserve sources (Facchiano & Facchiano, 2009).  
Using a FRET based technique; the conformational changes of TG2 in living cells have also 
been studied. Significant amounts of TG2 that was shown to be present in the perinuclear 
recycling compartment (PNRC) had a "closed” conformation. On the other hand, the TG2 
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located on the cell membrane had an "open" conformation, which is potentially active, 
catalytically. Moreover, results have also illustrated that when cell membrane TG2 gets 
internalized, the enzyme accumulates in the PNRC, rather than undergoing degradation. Once 
apoptosis is induced, the conformation of cytoplasmic TG2 changes and becomes activated, 
even so, the TG2 present within the endosomes was maintained in the inactive conformation 
even in the late stages of cell death (Pavlyukov, et al. 2012).  
Other small molecules can even interact with TG2 and alter the conformation of the protein 
(Nurminskaya & Belkin, 2012). Initial studies done by Singh & Cerione (1996) in HeLa cells 
revealed that TG2 was present latent in the cytoplasm as a part of a cytoplasmic complex multi-
protein that induced the GTPase function of TG2 (Singh & Cerione, 1996).  In the case of EGF  
induction, a similar result of TG2 shift from the cytoplasm to the cell membrane was observed 
(Antonyak, et al. 2009).Other than the GTPase and transamidating functions of TG2, the 
scaffolding functions of the protein have also been documented (Park, et al. 2010). TG2 
modulated Rho family of GTPases via a variety of unrelated but distinct mechanisms such as 
the activation of RhoA in a non-enzymatic manner by integrin cluster mediated by TG2 and the 
serotonylation of cytosolic Rac1 and RhoA induced by TG2 (Walther, et al. 2011). In addition 
to this, other cytosolic signalling proteins such as 14-3-3 and PKA/AKAP13 (Lewis, et al. 
2005), have been shown to interact with TG2 in the cytoplasm by binding to the PKA produced 
Ser 216 and pSer 212 residues on TG2 (Mishra & Murphy, 2004). Contradictory findings have 
also been reported as cytoplasmic TG2 was observed to decrease the activity of adenylyl 
cyclase activity in fibroblasts, but on the other hand was found to activate the adenylyl cyclase 
activity in neuroblastoma cells (Tucholski & Johnson, 2003) 
1.2.2.2 Nuclear 
TG2 can also be translocated into the nucleus with the help of importin-α-3 and studies have 
even shown that TG2 was localized to the mitochondrial membrane, which has been suggested 
to be vital in maintaining mitochondria function by regulating the activity of ANT1 activity. 
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Nuclear TG2 only represents about 5-7% of the total TG2 within a cell. Numerous stimuli such 
as increase in intracellular Ca
2+
 levels or cell stress can augment the TG2 concentration in the 
nucleus (Mehta, et al. 2006a/2006b). Increasing evidence is being provided to support the 
importance of nuclear TG2 in the function of regulating gene expression by either interacting 
with transcription factors or post translational modification of nuclear proteins such as histones 
(Mishra, et al. 2006), hypoxia-inducible factor 1 (Filiano, et al. 2008), Sp1 (Han & Park, 1999), 
Rb and E2F1 (Mishra, et al. 2007). Using these mechanisms, TG2 can control the survival, 
growth, apoptosis and differentiation that are involved in various physiological as well as 
pathological processes (Kuo, et al. 2011).  
1.2.2.3 Extracellular matrix (ECM)  
Ample evidence is available for the association of TG2 with the plasma membrane. The     
translocation of TG2 to the plasma membrane takes place by the binding of TG2 to the internal 
membrane surface, where it is not only adsorbed, but some of it is translocated to the external 
surface, by a process which is not well understood (Balklava, et al. 2002). TG2 lacks the classic 
hydrophobic leader sequence and so it cannot be secreted by the endoplasmic- Golgi dependent 
mechanism, even though it has been detected abundantly in the ECM and cell membrane 
fractions (Gaudry, et al. 1999; Stephens, et al. 2004). Extracellular TG2 is either retained on the 
cell surface or deposited into the ECM, which includes interaction with its high affinity binding 
partners such as FN (Fibronectin) and HS (Heparan sulphate) (Janiak, et al. 2006; Collighan & 
Griffin, 2009).   
TG2 has also been identified as an important enzyme involved in matrix turnover. At the cell 
surface as well as in the matrix, TG2 has been thought to be involved in cell adhesion on FN by 
acting as an integrin co-receptor (Akimov, et al. 2000). FN bound to TG2 via cell surface HS in 
a manner independent of transamidase activity promotes cell adhesion as well as survival 
mechanisms. The cell surface heparan sulphate proteoglycan syndecan-4 interacts with TG2 
which in turn activates its co-receptors, such as syndecan-2 and α5β1 integrins. The activation 
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of α5β1 involves the activation and binding of PKCα and phosphorylation of FAK and 
activation of ERK1/2 (Verderio et al. 1998) (Wang et al. 2010). 
1.2.3 Regulation of TG2 expression and activity 
Expression of TG2 is controlled by the TG2 promoter and encoded by TGM2 gene which 
comprises of 13 exons (Gentile, 1994). Classic CAAT and TATAA regions are present 
upstream of the open reading frame (ORF) where sequences are present to which Sp-1 and 
NFκB transcription factors bind (Ai, et al. 2012). Also, it has been reported that the TG2 
promoter may be highly methylated at the CpG islands, and this specific hyper methylation can 
silence the TGM2 gene with respect to tissue differentiation (Ai, et al. 2008).  Elevated 
expression of TG2 protein has been demonstrated in smooth muscle, and endothelial cells 
which are widely distributed throughout all organs (Thomazy & Fesus, 1989). Induction of 
increased TG2 expression in parenchymal and stromal cells  in organs may be due to 
inflammatory cytokines such as IL-1, IL-6, NFκB, TNF-α and TGF-β as well as retinoids and 
Vitamin D which induce expression due to a response element on the TGM2 gene promoter 
(Iismaa, et al. 2009). 
Numerous heterogeneous factors regulate the activity of TG2, once the protein is expressed. 
Acting as a G-coupled protein, TG2 binds to GTP and activates phospholipase C which allows 
transmission of signals from trans-membrane helix receptors (Iismaa, et al. 2000). In the 
presence of high levels of Ca
2+
, the GTP/ GDP molecules are released from the TG2 molecule, 
which inhibits signalling and promotes transamidating activity (Lorand & Graham, 2003). 
Interaction of TG2 with certain molecules like sphingosylphosphocholine (lyso-SM) can greatly 
reduce the calcium requirement. In the absence of molecules such as lyso-SM, almost 160μM of 
Ca
2+
 was required for TG2 activity which could be achieved at 10μM of Ca2+ in the presence of 
lyso-SM (Lesort, et al. 2000). In the extracellular environment, Ca
2+
 is present abundantly 
(approximately 1.2mM), whilst intracellularly, the levels of Ca
2+
 are very low (approximately 
100nM). Generally it was considered that under normal physiological conditions, TG2 is not 
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active intracellularly due to the low Ca
2+
 concentrations and high GTP. However, recent 
evidence has come to light which suggests that living cells can induce a decrease in their 
intracellular GTP levels by almost 20% and up regulate Ca
2+
 levels by almost 10 fold. 
Moreover, molecular interactions that take place between TG2 and other factors may render the 
enzyme sensitive to low concentrations of Ca
2+
 (Kiraly, et al. 2011) 
Another molecule that has a strong influence on the activity of TG2 is NO as almost 15 cysteine 
residues can be denitrosylated or nitrosylated in a manner dependent on Ca
2+
, which would 
activate and inhibit the enzyme respectively (Lai, et al. 2001; Telci, et al. 2009). Induction by 
RA can modify RhoA, which is a member of Rho GTPases family involved with 
rearrangements of the cytoskeleton (Singh, et al. 2003). TG2 also possesses nuclear localization 
sequence (NLS) and with the importin α3 can translocate into the nucleus (Peng, et al. 1999). 
Even in the nucleus, TG2 can act as a G-protein and transamidating enzyme. In the presence of 
nuclear Ca
2+
, TG2 can cross link transcriptional factors and histones (Ballestar, et al. 2001; 
Oliverio, et al. 1997). 
1.2.4 Role of TG2 in cell death: 
The multifunctional characteristic of TG2 complicates the role it plays in the complex circuitry 
of cell survival and death. TG2 can be activated by various apoptotic stimuli and has been 
reported to play numerous roles in cell death. Early studies reported that TG2 can regulate PCD 
(programmed cell death) in a caspase-dependent manner (Milakovic, et al. 2004; Tucholski & 
Johnson, 2002).  Also, there is evidence that points to the role of TG2 in modulating other 
modes of controlled cell death. The transamidating activity of TG2 can induce the release of 
AIF (apoptosis inducing factor) from the mitochondrial compartments of pancreatic ductal 
adenocarcinoma cells and activate apoptosis independent of caspase action (Fok & Mehta, 
2007). Similarly, in the same cell lines, TG2 was found to block autophagy (Akar, et al. 2007). 
Another report suggested that in the absence of TG2, autophagosomes could not mature and 
subsequent acidification does not happen (D'Eletto, et al. 2009). More recently, studies have 
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demonstrated that the transamidating activity of TG2 might be responsible for the final stages of 
maturation of the autophagosome and so is involved in autophagy (Rossin, et al. 2011).  
To support the pro apoptotic functions, inhibiting the expression of TG2 in U937 cells in 
response to apoptotic stimuli prevented death (Oliverio, et al. 1999). It has also been illustrated 
that in NIH 3T3 cells that have been treated with Calphostin C,  TG2 induced apoptosis was 
induced by TG2 by catalysing the cross linking of DLK (dual leucine zipper bearing kinase), 
which is a pro apoptosis kinase (Robitaille, et al. 2008). In the pancreatic cancer cell line, Panc- 
28, Fok & Mehta reported that Ca
2+
 induced apoptosis was facilitated by TG2 (Fok & Mehta, 
2007). Once a cell begins to undergo PCD, TG2 is activated within the cell to cross link 
intracellular proteins in order to prevent the leakage of the harmful contents of the cell 
(Nicholas, et al. 2003). This insoluble protein scaffold stabilizes the integrity of the apoptotic 
cells prior to being cleared by phagocytosis, thus preventing the non-specific release of any 
harmful intracellular components as well as subsequent inflammatory responses and scar 
formation in the nearby tissue (De Laurenzi & Melino, 2001). In the later phases of apoptosis, 
TG2 can be cleaved by caspase 3, which disable the cross linking function of TG2. This implies 
that there exists a functional relationship between the members of the apoptotic machinery and 
TG2 (Nanda, et al. 2001). TG2
-/-
 knockout mice also appear to have defective clearance of 
apoptotic cells (De Laurenzi & Melino, 2001). Peptides on the cell membrane derived from the 
TG2 sequence can cause conformational changes to Bax and result in its translocation into the 
mitochondria and subsequently release cytochrome c. The mutant of the active site of TG2 
(C277S) promoted cell death in U937 and HL-60 cancer cell lines, which suggests that the 
transamidating function of TG2 is not essentially responsible for the initiation of apoptosis. 
Instead, the BH3 domain of TG2 has been concerned in inducing apoptosis (Nardacci, et al. 
2003) TG2 and Bax have been shown to interact through their BH3 domains (Szondy, et al. 
2003). Due to this interaction, at the mitochondrial level, Bax serves as a substrate for TG2. 
During apoptosis, mitochondria with Bax polymerized by TG2, is clustered in specific 
cytoplasmic regions, with dense matrix and few cristae. A TG2- dependent shift of 
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mitochondria occurs to a high polarized state prior to the loss of mitochondrial transmembrane 
potential. Also, the induction of TG2 by RA in neuroblastoma and adenocarcinoma cell lines 
sensitized these cancer cell lines to apoptosis due to the hyper polarization of the mitochondria 
(Szondy, et al. 2003). Recently, it has been identified that a pro-apoptotic TG2 isoform, known 
as TGase-S, that lacks the 3'C-terminal end has been drawn into the cell death process. This 
isoform is inducible by TNF-α and can be detected in brain tissue derived from patients with 
Alzheimer disease, where in it promoted apoptosis via the formation of large size oligomers that 
are toxic to the cell (Antonyak, et al. 2006).  
In contradiction, TG2 expression has also been shown to protect cells from apoptosis. Rapidly 
dividing cancer cells are known to over express TG2. Cancer cells isolated from metastatic sites 
or that exhibit resistance to chemotherapeutic drugs have increased levels of TG2 expression 
(Chhabra, et al. 2009) TG2 is known to post-translationally modify the Rb protein, which is a 
vital suppressor of apoptosis (Oliverio, et al. 1997). The TG2/Rb interaction increases 
tremendously, parallel to a decrease in apoptosis, which is an important aspect of the anti-
apoptotic effects of TG2. Experiments in which Rb
-/-
 fibroblasts were used, demonstrated that 
Rb is essential for TG2 to reveal anti apoptotic activity in response to RA treatment (Milakovic, 
et al. 2004). It was also hypothesized that TG2 may protect the tumour cells from apoptosis by 
nuclear translocation. A controversy still prevails to whether TG2 activity in the nucleus is 
essential for binding and protecting Rb from degradation during apoptosis. Exposure of TG2 
expressing cells to LY29402, the PI3K inhibitor, decreases the ability of TG2 to bind to GTP. 
This suggests that PI3K regulates the switch between the GTP binding activity and 
transamidating activity of TG2. The Ras-ERK pathway greatly influences the switch between 
the pro-apoptotic transamidating activity and pro-survival TG2/GTPase activity (Antonyak, et 
al. 2003). The binding of GTP is known to convert the enzyme from an open conformation to a 
closed protein conformation which is able to provide protection against any apoptotic stimuli.  
The other hypothesis put forward  is that the expression of the full length form of TG2 in 
tumour cells confers protection against apoptosis whereas the expression of a shorter version of 
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TG2 which is truncated at the 3'end (TGase-S) and does not bind to GTP, is cytotoxic. The 
TGase-S shows no GTP binding capability, implying that the ability of TG2 to induce cell death 
is due to the inability of TG2 to bind to GTP (Antonyak, et al. 2006).  
Thus, the exact mechanisms by which TG2 modulates cell apoptosis or facilitates protection 
from cell death is specific to cell type and two widely described mechanisms exploited by TG2 
are (a) controlling transcription factors either directly or indirectly  promote apoptosis or 
survival and (b) mediating ECM contacts with the cell consequently promoting cell survival 
cues (Gundemir, et al. 2012).  
1.2.5 Pathological roles of TG2 
1.2.5.1 Coeliac disease: 
The post translational modification of proteins catalysed by TG2 can generate auto-antibodies, 
just as in auto immune disorders such as coeliac disease (CD) (Molberg, et al. 2000). Gluten 
sensitive enteropathy or coeliac disease is a multifactorial chronic disease which is caused by a 
permanent intolerance to ingested wheat gluten or similar proteins from barley and rye 
(Kagnoff, 2007). About 1% of the total population of children and adults are affected and the 
most conventional treatment is a gluten-free diet (GFD) (Kagnoff, 2007) 
One of the primary initiators of the inflammatory response to gluten in CD patients is a 33- 
amino acid peptide which is resistant to digestion by enzymes of the small intestinal mucosa of 
humans, both in vitro and in vivo (Shan, et al. 2002). As a result of abnormal CD4
+
 T-cell- 
initiated immune response to gluten chronic inflammation develops in the small intestine. This 
results in villous atrophy as well as flattening of the mucosa (Sollid, 2002).  Genes encoding for 
HLA-DQ2 and HLA-DQ8 are strongly associated with the pathology of CD (Sollid, 2000). 
Intestinal T cells recognize gluten peptides when glutamines are converted into glutamic acid. 
The deamination of gliadins by TG2, results in an epitope that binds very efficiently to the HLA 
receptors DQ2. This is recognized by T cells derived from the gut, thus starting the cascade of 
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inflammation that would consequently lead to mucosal damage (Molberg, 1998). TG2, itself, is 
an auto-antigen that is characteristic of CD. Patients of CD have high levels of serum antibodies 
to both gluten and TG2 (Dieterich, 1997). It has been speculated that TG2 can cross link itself 
to gliadin, resulting in the production of auto antibodies, apart from its deamidation of the 
gliadin peptide. The generation of anti-TG2 IgA antibodies could also depend on the gliadin 
specific T cells that are specific to TG2. IgG and IgA anti TG2 antibodies are found in the 
majority of patients with CD, which makes them a very powerful diagnostic tool (Tommasini, 
et al. 2004). Also, studies done by Myrsky et al. (2008) have demonstrated that the coeliac 
disease specific antibodies that target TG2 interrupted several stages in the angiogenesis 
cascade. Moreover, these auto antibodies can disorganize the actin cytoskeleton in capillary cell 
types. Such a disruption in angiogenesis could lead to disturbance of the mucosal vasculature 
which is observed in coeliac disease patients on a diet that contains gluten (Myrsky, et al. 2008) 
1.2.5.2 Neurodegeneration: 
Four transglutaminases have been shown to be expressed in brain: TG1, TG2, TG3 (Kim, 1999) 
and TG6 (Hadjivassiliou, 2008) and TG2 has been implicated in various processes in the 
peripheral and central nervous systems.  
The involvement of transglutaminase in the pathophysiology of Alzheimer's disease (AD), was 
initially suggested by Selkoe et al. in 1982 (Selkoe, et al. 1982). It was also hypothesized that 
TG2 facilitates the formation of insoluble aggregated amyloid beta (Ab) peptide, which are 
neurotoxic in an aggregated state (Selkoe, 2000). Studies have shown that TG2 can cross link 
Ab1-28 (Ikura, et al. 1993), Ab1-42 (Dudek & Johnson, 1994) and APP (Ho, et al. 1994). Tau 
protein has also been shown to be an excellent substrate for TG2 both in vitro and in vivo. 
Research conducted on human specimens indicates that TG2 could be involved in the cross 
linking of tau, as seen in AD pathology. TG2 activity was almost three fold greater in the 
prefrontal cortex of AD samples and recent findings seem to indicate that almost a fivefold 
increase is seen in TG2 in the brains of AD patients that is co-localized with neurofibrillary 
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tangles (Johnson, et al. 1997). These neurofibrillary tangles serve as the sites of γ-glutamyl-ε-
lysine cross links in AD patients (Citron, et al. 2001). It has also been reported that TG2 
undergoes alternative splicing in AD brains due to the intron- exon swapping of TG2 mRNA 
which results in a short and long isoforms (Citron, et al. 2002).  
Howard Green was the first to suggest that an increase in the number of glutamines beyond a 
threshold would result in a protein becoming a substrate for TG2 and hence contributed to 
aggregate formation in Huntington's disease (HD). Studies conducted in vitro confirmed that 
polyQ peptides were good substrates of TG2, as in the presence of TG2, it forms insoluble 
aggregates along with the proteins of brain extracts (Kahlem, et al. 1996). It was also 
demonstrated that Htt proteins with long polyamine expansions, formed cross linked polymers, 
when incubated in the presence of TG2 (Kahlem, et al. 1998). Even though, TG2 expression 
and activity levels are increased in HD brains, recent studies have shown that TG2 may not be 
essential for the formation of Huntington aggregates in the brain. Studies carried out on human 
neuroblastoma cell line, SH-SY5Y demonstrated that TG2 does not modify Htt, and that even in 
the absence of TG2, Htt aggregates are formed (Chun, et al. 2001). Experiments done on TG2
-/-
 
crossed with HD mice, suggests that the formation of the aggregates may not depend on TG2 
activity although cell survival may since TG2
-/-
 /HD mice showed a considerable delay in the 
initiation of death and motor dysfunction. It is therefore, currently unclear, if the enzymatic 
activity of TG2 plays a role in the formation of Htt aggregate formation, and if so, what role it 
plays in the pathogenesis of HD (Bailey & Johnson, 2005) 
1.2.5.3 Fibrosis  
The pathological process of fibrosis is usually characterized by the accumulation of ECM 
proteins and fibroblasts that destroy normal tissue function and structure. Numerous organs can 
be affected by this disease such as kidney, liver and lungs (Wynn, 2007) and TG2 has been 
implicated to play a regulatory role in most of the above. TG2 can promote fibrosis is several 
ways due to its multifunctional roles. TG2 has been reported to augment the production as well 
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as maturation of fibrillar FN in a transamidating-independent manner (Akimov & Belkin, 2001) 
and increase deposition of collagen both directly via cross linking and by activation of matrix 
bound TGF β. Moreover, studies done by Chau, et al.  in 2005, demonstrated that TG2 cross 
linked collagen had greater resistance to proteases secreted by the cell which results in 
protection from cell mediated degradation  (Chau, et al, 2005) 
In the rat and mouse models of liver and kidney fibrosis, TG2 enhances the process. Even in 
human kidney fibrosis, expression in TG2 is enhanced (Grenard, et al. 2001 ; Shweke, et al. 
2008). Initial studies done on mouse models of renal fibrosis demonstrated that the progress of 
the disease leads to profound changes in the cellular location, synthesis and subsequent activity 
of TG2. This causes both intracellular and extracellular changes wherein the enzyme can play a 
role in cell death as well as in matrix stabilization and deposition that can lead to the activation 
of TGF-β, thus effecting the progression of renal fibrosis. Due to this, TG2 has been implicated 
as a therapeutic target to control renal scarring and subsequent failure (Johnson, et al. 1999). 
Also, in patients that experienced nephropathies in the tubulointerstitium and glomeruli, an up 
regulation of insoluble and soluble TG2 was observed. The insoluble TG2 forms were detected 
extracellularly, while the soluble counterparts were mainly found inside the cell (Johnson, et al. 
2003). With the use of site directed and irreversible TG2 activity inhibitors, kidney function has 
been shown to improve and also prevent renal remodelling in rat models of kidney fibrosis and 
scarring. This further confirmed the role of TG2 as a potential target to prevent scarring of 
tissue (Johnson, et al. 2007).   
Using human lung biopsy sections of pulmonary fibrosis patients, cultured primary human lung 
fibroblasts and mouse models of fibrosis, TG2 has also been reported to play a major role in 
pulmonary fibroblast characteristics as well as pulmonary fibrosis regulated by TGF-β (Olsen, 
et al. 2011). Also, TG2
 -/-
 mice were protected from the progress of fibrotic lesions in models of 
obstructive nephropathy. This defence may result in decreased myofibroblast and macrophage 
infiltration. Reduce rates of collagen I synthesis were also observed due to low levels of TGF-β 
activation (Shweke, et al. 2008).   
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In the case of liver fibrosis, TG2 activity was found to be up regulated and the TG2 mRNA 
levels were in correlation to the expression of genes related to fibrosis. In knock out TG2 mouse 
models, hepatic TG2 activity was observed to be significantly low, but on administering TAA 
or CCl4, a pattern of liver fibrosis was revealed. This seems to imply that even though TG2 was 
increased during progression of hepatic fibrosis, it plays no role in stabilization of the collagen 
matrix or fibrogenesis (Popov, et al. 2011). Literature seems to clearly indicate that evidence 
provided for the role of TG2 in fibrosis is strong for kidney and lung models of fibrosis while 
on the other hand; involvement of TG2 in liver fibrosis remains under researched.  
1.2.5.4 Cancer progression: 
The progression of cancer is very similar to inflammatory responses (Mantovani, et al. 2008) 
and conflicting reports have indicated that TG2 may be down regulated or up regulated in the 
process (Mehta, 2008). In primary tumours, TG2 expression is usually reduced in the phases of 
tumour progression, while on the other hand, increased TG2 expression is observed in 
chemoresistant and secondary metastatic tumours (Kotsakis & Griffin, 2007). A recent study 
demonstrated that hyper methylation of CpG islands occurred. The CpG islands have been 
shown to overlap the transcriptional and translation promoter sites of the TGM2 gene (Ai, et al. 
2008). In a similar manner, in neuroblastoma cells, over expression of N-myc was illustrated to 
reduce TG2 expression by the recruitment of HDAC and Sp1 transcription factor to the 
respective binding sites of the TGM2 gene promoter (Liu, et al. 2007). Also, injecting TG2 into 
tumours of mice inhibited the growth of CT26 colon carcinoma (Jones, et al. 2006).  
Conversely, TG2 has been reported to be up regulated in numerous cancers such as ovarian, 
breast, colon and pancreatic cancers, increasing the invasive potential of tumours and promoting 
resistance against chemo therapeutic drugs (Wang, et al. 2012; Khanna, et al. 2011). 
Coherently, inhibiting TG2 with siRNA or specific TG2 activity inhibitors, reduced tumour cell 
migration as well as increased sensitivity to cell death induced by chemotherapy (Yuan, et al. 
2007). At a more molecular level, TG2 is known to be constitutively activated by several pro 
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survival factors such as FAK/Akt and NFκB (Mehta, 2005).  In drug resistant cancers, TG2 is 
up regulated in mRNA, protein as well as enzyme activity levels. In PC-14 lung cancer cells, 
Han and Park observed that TG2 expression increased after selection for doxorubicin resistance. 
Furthermore, inhibiting TG2 confers drug sensitivity to the PC-14 lung cancer cells, which 
clearly suggested that TG2 played a crucial role in cancer cells acquiring drug resistance (Han 
& Park, 1999).   
1.2.5.4.1 Regulation of cell survival in cancer cells by TG2 
Evidence has also been collected to show that intracellular TG2 can act as an anti- as well as 
pro-apoptotic factor in which the anti-apoptotic activity of TG2 can be attributed to NFκB 
activation (Mann, et al. 2006; Condello, et al. 2008). On the other hand, extracellular TG2 has 
an important role in cell survival because of its interaction with integrins (Kotsakis & Griffin, 
2007) or syndecans to enhance cell adhesion, thereby rescuing cells from anoikis (Verderio, et 
al. 1998). The role of TG2 has been known to vary depending on the stages of tumour 
progression as well as its metastatic ability. With regard to proliferation and apoptosis, 
intracellular TG2 has been related to transmitting anti-growth signals during the growth of the 
tumour (Birckbichler & Patterson, 1978) 
The link between TG2 and apoptosis has been well documented. Augmented expression of TG2 
results in rapid cell death or leaves the cell susceptible to agents that induce cell death (Mehta, 
et al. 2004). In contradiction, high TG2 expression can also lengthen cell survival by protecting 
it from apoptosis. To support this, various experiments have been conducted with drug resistant 
and metastatic cancer cell lines which have showed high expression of TG2. In fibroblasts, 
increased TG2 expression is known to protect the cells against apoptosis by retinoic acid. 
Additionally, TG2 links with the integrin family of proteins which prevents apoptosis 
(Antonyak, et al. 2001; Boehm, et al. 2002) 
In carcinomas such as breast, pancreatic and non-small cell lung cancer, TG2 is over expressed 
which in turn are thought to cause activation of NFκB by cross-linking its inhibitor IκBα. This 
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is however dependent on the intracellular enzymatic activity of TG2 through its activation  by 
Ca
2+
 which then  proceeds to constitutively activate NFκB. In HL60 leukaemia cells, TG2 
promotes cell survival by protecting the Rb gene product from caspase induced degradation by 
its transamidating activity. This results in cell survival. Also, in colon cancer cells, TG2 
suppresses apoptosis by cross-linking of caspase-3 which prevents its cleavage and activation. 
Moreover, this enzyme is involved in attaching epithelial cells to the ECM. This activates 
‘outside-in’ signalling which promotes cell survival (Cao, et al. 2008).  
1.2.5.4.2 Role of TG2 in invasion and adhesion of cancer cells: 
A huge amount of evidence has been reported to prove that increased TG2 expression causes 
enhanced cell attachment and spreading and under expression of TG2 can result in the 
disruption of these functions. Cell surface TG2 can act to either help or resist cell migration but 
this difference lies mainly on the composition of the extracellular matrix (Kotsakis & Griffin, 
2007). When cell surface TG2 undergoes proteolytic degradation by membrane type matrix 
metalloproteinases (MT-MMPs) in gliomas and fibrosarcomas, it causes decreased cell 
adhesion and movement of tumour cells on FN. However, it increases tumour cell motility on 
collagen matrices because cross-linking of collagen results in increased cell adhesion (Akimov, 
et al. 2000). Studies on NIH 3T3 cell lines have showed that when oncogenes (such as H-Ras 
and Raf-1) are activated, there is decreased TG2-mediated cell adhesion as TG2 biosynthesis 
and surface expression decreases (Akimov, et al. 2000). TG2 can act as a substrate for c-CAM 
which is a ubiquitously expressed cell adhesion molecule that slows down tumour growth 
(Hunter, et al. 1998) 
1.2.5.4.3 Role of TG2 in angiogenesis during cancer progression: 
Under normal physiological conditions, the TG2 cross linking activity within the cell is 
suppressed due to the low concentrations of Ca
2+
 and lack of nucleotides required for activation. 
Once TG2 is brought onto the surface it is activated by Ca
2+
 and via protein cross linking brings 
about a change in the ECM (Belkin, 2012). The ECM plays an important role in tumour 
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angiogenesis and tumour cell migration as its main role is to provide mechanical support to 
tumour cells (Kotsakis & Griffin, 2007). A stable ECM displays anti-angiogenic properties and 
can inhibit proliferation and spread of malignant cells mainly due to the collagen cross-linking 
caused by TG2 (Jones, et al. 2006).  Experiments have showed that over production of collagen 
due to TG2 stabilizes the ECM preventing tumour progression. It has also been reported that as 
primary tumours increase in size, TG2 activity and expression is down regulated. This is known 
to favour progression of the tumour as the decreased TG2 activity helps disrupt matrix stability 
aiding angiogenesis and increased spread of tumour cells (Kotsakis & Griffin, 2007). Increased 
expression of TG2 in the tissue surrounding tumours can therefore stabilize the ECM and cut 
off the tumour cells to the rest of the body by inducing fibrosis (Haroon, et al. 1999).  
Angiogenesis is a very important stage in tumour development as tumour cells require their own 
blood supply to grow and metastasize (Folkman, 1990). Inhibiting angiogenesis will result in 
lack of growth and endothelial cell migration. Most of the functions of TG2 seem to be similar 
to that of angiogenesis involving cell migration, adhesion and ECM stabilization. Even so, the 
exact role of TG2 in angiogenesis has still not been determined (Kotsakis & Griffin, 2007). In 
epithelial cells, the ECM proteins are cross linked by TG2 which is thought to play an important 
role in stabilization of the basement membrane. However, no vascular abnormalities have been 
observed in TG2 knockout mice. TG2 was shown to be down regulated in a gene array analysis 
study to check for gene expression during capillary morphogenesis (Bell, et al. 2001).This 
could mean that TG2 is not required for the initial stages of angiogenesis such as capillary 
formation. Since the migration of epithelial cells and formation of blood vessels is dependent on 
the composition of the endothelial basement membrane, TG2 activity might inhibit the 
endothelial mobilization process causing increased cell adhesion. TG2 is known to cause a 
change in the ECM which regulates capillary tube development. With the help of angiogenesis 
assays, it has been shown that administration of TG2 can stop angiogenesis without causing cell 
death. This is done by increasing the protein build up in the ECM (Jones, et al. 2006).With all 
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this evidence, it can be concluded that large amounts of TG2 activity is involved in suppressing 
angiogenesis in tumour cells.  
1.2.5.4.4 Role of TG2 in metastasis of cancer cells 
In pathologies such as cancer which is matrix associated, the transamidating and GTP-binding 
properties of TG2 aid in the proliferation and invasion of malignant cells into the surrounding 
tissue (Collighan & Griffin, 2009). Experiments undertaken on mutant malignant hamster 
fibrosarcoma cells have shown that reduced TG2 activity can be correlated to metastasis and 
growth of tumours (Knight, et al. 1991). The primary tumour undergoes a very rigid selection 
procedure due to which there is a higher expression in secondary tumours as compared to 
primary tumours (Kotsakis & Griffin, 2007).  This correlates with the metastasis studies done in 
human breast cancer, hemangioblastomas and in melanomas (Fok, et al. 2006 ; Mehta, et al. 
2012 ; Mizoguchi, et al. 1998). TG2 is known to be up regulated in cell lines with high 
metastatic ability as compared to those with low metastasizing ability (Jiang, et al. 2003).This 
may in part be attributed to the role TG2 plays in strengthening points of contact for the tumour 
cells on the sub-endothelial matrix (Kotsakis & Griffin, 2007). Integrin β1 and Syndecan-4 
present on the cell surface is known to form complexes with TG2 present on the cell surface. 
This interaction is known to facilitate adhesion, spreading and movement of cells (Verderio, et 
al. 1998). Also, TG2 when deposited in the matrix associates with FN through an RGD 
independent pathway and this interaction between TG2, integrins, syndecans and FN can cause 
a higher expression of TG2 in cancer cells resistant to drugs (Herman, et al. 2006). 
1.2.5.4.5 Role of TG2 in chemoresistance: 
A major obstacle in the successful treatment of cancer is the development of resistance to 
chemotherapeutic drugs and increased metastatic ability. High levels of TG2 are expressed in 
cancer cells selected for resistance or isolated from metastatic tumour sites. In breast cancer, 
TG2 promotes cell survival by associating with members of the integrin family (Herman, et al. 
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2006). All this gives a clear indication that TG2 is involved in promoting cancer progression 
and hence makes it of interest as a target for anti-cancer therapy. 
A number of studies have demonstrated that there was a key relationship between drug 
resistance against doxorubicin and expression of TG2. Epigenetic analysis and proteomic 
profiling studies conducted on breast cancer cells resistant to doxorubicin implicated TG2 as an 
important target protein that increases doxorubicin resistance (Chekhun, et al. 2007; Park, et al. 
2007). Activation of EGF signalling in breast cancer cells is another mechanism of TG2 
induction which contributes towards the oncogenic potential of these cells (Antonyak, et al. 
2004). Furthermore, in conditions of stress, several pathways and transcription factors can 
regulate the expression of TG2 (Jang, et al. 2010; Mehta, et al. 2010).  
1.2.5.4.6 Role of TG2 in EMT 
Recent studies show that Epithelial to Mesenchymal Transition (EMT) is important during 
progression of diseases such as inflammation, cancer and fibrosis (Sarkar, et al. 2009). EMT 
has been  shown to be vital in making cancer cells resistant to drugs and in helping early stage 
tumours to become more invasive (Thiery, et al. 2009). TG2 is also known to be up regulated in 
tumour cells and to play a crucial role in promoting inflammation and fibrosis. Links have been 
made between EMT and TG2 to suggest that TG2 participates in tumour progression by 
regulating EMT. Studies performed on ovarian cancer cells show that high TG2 expression 
regulates EMT and this increases invasiveness and metastasis of the cancer cells (Shao, et al. 
2009). TG2 is also responsible for promoting the autonomy of cancer cells from growth 
regulatory mechanisms and supporting anchorage-independent growth (Mehta, et al. 2010).  
1.3 Nuclear Factor- kappa B 
NFκB   is a cytoplasmic transcription factor that regulates over 200 genes. It is involved in 
many cellular and organismal processes including immune and inflammatory responses, 
developmental processes, cellular growth and apoptosis. It has also been implicated in a large 
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number of disease states such as cancer, arthritis, chronic inflammation, asthma, 
neurodegeneration and heart diseases (Beyaert, 2004). 
NFκB as a transcription factor has many diverse functions. At the cellular level, the activation 
of NFκB   inhibits programmed and elicited cell death. This protects the cell and allows it to 
survive. It also induces expression of crucial genes that encode for anti-apoptotic proteins such 
as Bcl-XL, c-FLIP, A1/Bfl etc. This upholds cell survival and also controls the expression of 
anti-oxidant genes such as ferritin heavy chain (Lin & Karin, 2003; Pham, et al. 2004) and 
superoxide dismutase 2 that add to its pro-survival functions (Kamata, et al. 2005).  
1.3.1 NFκB family members 
The NFκB   family is composed of five members: p65 or RelA, RelB, cRel, nfκb1 (p50/p105) 
which is a combination of p50 and its precursor p105, nfκb2 (p52/p100) which is a complex 
between p52 and its precursor 100. The inactive precursor, p100 and p105 are inhibitory 
proteins that maintain the NFκB   dimers in the cytosol of a resting cell (Pereira & Oakley, 
2008). They have been characterized as such due to the presence of an evolutionarily conserved 
300-amino acid Rel Homology Domain (RHD) positioned at their N-terminal ends (Hayden & 
Ghosh, 2004). Rel-A, Rel-B and c-Rel have transcriptional activation domains (TADs) in their 
C-terminal ends that allow them to activate target gene expression. On the other hand, nfκb1 
and nfκb2 do not contain TADs and so they repress transcription unless they are bound to a 
protein that has a TAD such as the other three NFκB   family members (Hoffmann, et al. 2006). 
The target genes coded for by NFκB   can be classified into four groups: immunoregulatory and 
inflammatory genes, anti-apoptotic genes, genes that positively regulate cell proliferation and 
genes that encode for negative regulators of NFκB. All of these groups contribute to 
tumourigenesis (Karin, et al. 2002). The NFκB   family members exist as either homodimers or 
heterodimers bound to the inhibitory family of proteins in an unstimulated cell. The IκB family 
restricts the translocation of NFκB   to the nucleus thereby maintaining it in its inactive state. 
Members of the IκB family have many copies of a sequence called the ankyrin repeat domains 
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that cover the nuclear localization sequence of the NFκB   members and prevent them from 
entering into the nucleus (Hayden & Ghosh, 2004) 
1.3.2 Activation of NFκB 
NFκB   is usually present in its latent, inactive form unless stimulated by an environmental 
response. Through the binding of NFκB   to T-cell receptors, B-cell receptors, TNFR, CD40, 
BAFFR, LTβR and Toll/IL-1R family, the function of various cytokines, growth factors and 
effector enzymes get regulated. It can also control the expression of genes and factors outside 
the immune system (Hayden & Ghosh, 2004). NFκB   activation is initiated by the signal 
induced degradation of IκB proteins by the activation of a kinase called the IκB kinase or IKK. 
The IKK proteins phosphorylated the IκB followed by quick ubiquitin-dependent degradation 
by the 26S proteosome (Karin & Ben-Neriah, 2001). The IKK is made up of IKKα and IKKβ 
which are two catalytic subunits as well as IKKγ or NEMO (NFκB essential modulator) which 
is a vital non-enzymatic regulatory subunit (Lin & Karin, 2003) 
When the cell receives any one of a multitude of external stimuli or certain receptors are 
recognized, NFκB   signalling can occur either by the classical pathway (canonical) or the 
alternate pathway (non-canonical) (Hayden & Ghosh, 2004; Karin, 1999). 
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(A)                                                                   (B) 
(Hayden & Ghosh, 2004) 
Figure 1.3 (A) Canonical & (B) Non-canonical pathway of NFκB activation 
The classical pathway gets activated by cytokines such as IL-1 and TNF-α or by bacterial 
products such as LPS or when a ligand binds to one of the TLR super family receptors. 
Activation of the receptor causes proteins like TRAF to get recruited to the cytoplasmic domain 
of the receptor. These adaptor proteins cause the activation of the IKK complex which in the 
canonical pathway consists of one molecule of IKKα, one molecule IKKβ and two molecules of 
NEMO. IKKβ phosphorylates IκBα at serine residues 32 and 36 resulting in poly-ubiquitination 
followed by degradation by the 26S proteosome. This releases NFκB which is predominantly 
p50:p65 from its inhibitor IκBα which then translocates into the nucleus and activates the target 
genes regulated by the κB sites (Hayden & Ghosh, 2004; Perkins, 2006). Dimers made up of 
RelA/p65, RelB, cRel and p50 are usually activated by the classical pathway. 
The non-canonical pathway activates NFκB complexes of p100/RelB and mainly occurs during 
the development of lymphoid organs responsible for the production of T and B lymphocytes. 
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Very few stimuli can activate NFκB through this pathway such as B cell activating factor, 
Lymphotoxin B and CD40. The IKK complex in this pathway is only made up of two subunits 
of IKKα. Activation by the ligand stimulates NFκB inducing kinase or NIK which in turn 
phosphorylates the IκB site of p100 which results in the processing and release of the p52/Rel-B 
active heterodimer. This active heterodimer translocates into the nucleus and causes target gene 
expression (Moynagh, 2005). 
1.3.3 Significance of NFκB in breast cancer progression 
Numerous studies have demonstrated that in both primary human breast cancer cells and 
mammary carcinoma cell lines, activation of NFκB is prominent (Cogswell, et al. 2000; Sovak, 
et al. 2000). Even so, the exact mechanism that underlies the activation of NFκB has yet to be 
understood. Almost a decade ago, NFκB was implicated to have an important role to play in 
driving the progression of breast cancer. The primary subunits of NFκB that are activated in 
breast cancer cells appears to be p50 and p65 homodimers and heterodimers (Karin, 2006). 
Studies also reported that breast cancer progression from a hormone-dependent non- metastatic 
grade to a higher hormone-independent metastatic form was reliant on the elevation of NFκB 
activity. Moreover, the constitutive activation of NFκB was demonstrated to occur frequently in 
ER (oestrogen receptor)- negative basal like breast cancer cells (Biswas, et al. 2000; Biswas, et 
al. 2004) 
In relation with these findings that indicated that NFκB was constitutively activated in 
metastatic breast cancer, several target genes of the oncogenic transcription factor were 
activated which would enhance the metastatic and invasive potential of breast cancer cells. For 
example, IL-8 was illustrated to increase in breast cancer cells in vivo and in vitro (Wu, et al. 
2008) and is also increased in the serum of patients who were experiencing breast cancer cell 
dissemination (Benoy, et al. 2004). Another well-known target of NFκB, TNF-α was exhibited 
to increase the invasiveness when used to treat breast cancer cell lines (Cho, et al. 2009; Kim, et 
al. 2008). Finally, IL-6 has also demonstrated to induce motility in breast cancer cells and 
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proposed to be a negative prognostic marker of metastasis (Knupfer & Preiss, 2007). The 
involvement of Rel A/ p65 in human carcinomas is still a major subject of debate. Previous 
studies conducted with antisense oligonucleotides that inhibited Rel A/p65 expression reported 
that Rel A/ p65 played a role in the neoplastic alteration of transformed cancer cell lines. These 
studies demonstrated decreased cancer cell adhesion, growth and progression (Rayet & Gelinas, 
1999). The over expression of Rel A/ p65 was noted in adenocarcinomas of stomach and breast 
as well as squamous carcinomas of the neck and head (Mantovani, 2010) 
1 .4 Relationship between tissue transglutaminase (TG2) and NFκB 
The over expression of TG2 in several cancer cells is often related to the constitutive activation 
of NFκB (Verma & Mehta, 2007a/2007b). Also, inhibiting the activity of TG2 using specific 
inhibitors resulted in the down regulation of NFκB activity (Cao, et al. 2008; Kim, et al. 2006). 
The ability of TG2 to promote activity of NFκB to induce chemoresistance against doxorubicin 
in breast cancer cells was observed both in EGFR negative and positive cell lines (Kim, et al. 
2006). In epithelial ovarian cancer cells, combination treatment of TG2 inhibitor, KCC009 and 
cisplatin, illustrated that TG2 enzymatic activity was responsible in modulating the activity of 
NFκB and promoting cell survival (Cao, et al. 2008).  
TG2 has been shown to form a direct complex with NFκB in the cytoplasmic fractions and 
subsequently modify the affinity of NFκB for IκBα (Verma & Mehta, 2007a/2007b). IκBα has 
also been described as a substrate for TG2 activity and this association could lead to the 
formation of an insoluble polymer in the cytosol that is unable to bind to NFκB (Lee, et al. 
2004). In the nucleus, TG2 can directly form a complex with Rel A/ p65 which is directed to 
target genes, including TGM2, which leads to a positive regulatory feedback loop in 
doxorubicin resistant breast cancer cell lines (Verma & Mehta, 2007a/2007b). Many hypotheses 
have been established with regard to interaction between the two proteins and efforts are being 
made to clearly define the mechanistic detail behind it. Cancer cells selected for being resistant 
to chemotherapy as well as cancer cells with high metastatic ability show high levels of TG2 
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expression (Herman, et al. 2006). This shows a direct link between TG2 activity, metastasis and 
drug resistance. This could be suggesting that the presence of TG2 constitutively activates 
NFκB to confer drug resistance, metastatic and apoptosis evading properties to the cancer cells. 
Active NFκB in cancer cells prevents the apoptotic response of cells to anti-cancer drugs and 
radiation. Anti-apoptotic genes are also regulated by NFκB. The process of metastasis involves 
the movement of cancer cells into, through and out of the blood vessels. Adhesion molecules 
required for this process are directly linked to NFκB (Karin & Lin, 2002).  
There is a high expression of TG2 in many drug-resistant and metastatic forms of cancer. NFκB 
is also constitutive in numerous hostile and metastatic tumours. With this theory, it could be 
implied that TG2 plays a role in constitutive activation of NFκB (Mann, et al. 2006). 
Experiments have been done where a calcium ionophore was used to increase Ca
2+
 levels in 
cancer cell lines with low and high levels of TG2 and where TG2 was absent. The increase in 
Ca
2+
 brought about increased activity of TG2 in the cell lines which had low and high basal 
levels of TG2 while the TG2 negative cell lines remained unaffected. When the in situ levels of 
TG2 were measured, there seemed to be a strong correlation with NFκB levels. Increasing the 
concentration of calcium ionophore seemed to increase NFκB activation. The TG2 negative cell 
lines had no noticeable NFκB activation. This goes to show that the transamidation activity and 
high expression of TG2 were crucial for activating NFκB (Mann, et al. 2006).  
There are various pathways by which NFκB can get activated without IKK activation. NFκB 
can get activated via the MKK3/6-p38 mitogen activated protein kinase. UV can bring about 
rapid degradation of IκBα and mutant IκBα. Reactive Oxygen intermediates can also activate 
the NFκB pathway. However, the major IKKα/β-independent pathway is the signal dependent 
lysosomal degradation of IκBα (Lee, et al. 2004). In human breast cancer cell lines, it has been 
shown that the presence of TG2 will increase their resistance to chemotherapeutic drugs such as 
doxorubicin. Also, a shift in the accumulation of NFκB from the cytosol to the nucleus was 
observed. Increasing TG2 in these cells also showed an increase in NFκB activation that co-
related with low levels of IκBα (Kim, et al. 2009). Analysis of IκBα and TG2 levels in breast 
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cancer cell lines showed that in the presence of TG2, IκBα expression was low and vice-versa. 
Such a low level of IκBα predominantly indicates the activation and release of NFκB. Western 
blot analysis conducted for pIκBα, illustrated no expression of this protein, which indicates that 
IκBα does not deplete because of phosphorylation (Kim, et al. 2006) 
Mobility shift assays done by Mann, et al. in 2006, illustrate that halting TG2 expression would 
stop the constitutive activation of NFκB. Immunoprecipitation studies done with anti-IκBα 
antibody on TG2 cells showed that IκBα formed dimeric forms. Further treating the cells with 
Ca
2+
 increased the formation of dimeric and polymeric IκBα. Similar results were obtained with 
TG2- specific inhibitors. This concludes that TG2 is closely associated with IκBα and that IκBα 
acts as a substrate for TG2 reactions (Mann, et al. 2006).  
Even nuclear localization of TG2 with Rel A/p65 has been reported with confocal microscopy. 
TG2 has properties to serve as a serine-threonine kinase and on the other hand Rel A/p65 
undergoes phosphorylation at its serine residues. These results could imply that Rel A/ p65 acts 
as a possible substrate for TG2 kinase activity (Mann, et al. 2006). TG2 transfection studies 
done by Lee et al. (2004) on microglial cells portray increase in NFκB activation. TG2 also 
seems to activate the NFκB pathway which in turn exacerbates inflammation. Finally, it can be 
hypothesized that TG2 polymerizes IκBα and reduces its binding capacity to NFκB.  Numerous 
stimuli that prompt NFκB activation have common characteristics with stimuli driven by TG2. 
This goes to show that NFκB and TG2 induce each other (Lee, et al. 2004).  
In liver cells, TNF-α induces the synthesis of TG2 via the activation of IκBα phosphorylation. 
This results in NFκB dissociating and becoming active to translocate into the nucleus. 
Following translocation, it binds to the TG2 promoter and induces its expression. In the similar 
way, TG2 can also cross link IκBα and cause NFκB activation (Kim, et al. 2010). Multiple 
cancer cell lines acquire resistance to drugs and metastatic ability due to the increased 
expression of TG2 and NFκB. The signalling of both these molecules is associated with 
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increased survival of cancer cells and invasiveness. TG2 expression activates FAK and Akt and 
NFκB down regulates tumour suppressor PTEN (Wang, et al. 2012). 
Due to the extensive role of TG2 in cancer progression, this protein has been hypothesized to 
also play a role in EMT. The NFκB, FAK and Akt pathways are known to be closely associated 
with the modulation of EMT, conferring drug resistance and promoting metastasis (Kalluri & 
Weinberg, 2009). NFκB has been shown to induce EMT through the expression of Zeb1 and 
Zeb2 (Chua, et al. 2007) as well as by stabilizing Snail and preventing its ubiquitination (Wu, et 
al. 2009). Based on the above observations, it has been reasoned that TG2 induced EMT is due 
to the constitutive activation of NFκB which has been supported along with increased in Snail, 
Zeb1 and Zeb2 expression (Shao, et al. 2009). 
All of the above studies seem to suggest that there is a deep molecular as well as mechanistic 
connection between NFκB, TG2 and the cancer progression cascade. Further research on this 
topic can help reveal valuable information on how to reverse the chemoresistance in breast 
cancer cells. 
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1.5 Aims of the project 
Previous work suggests that TG2 causes the constitutive activation of NFκB which allows 
breast cancer cells to exhibit a chemoresistant phenotype against drugs such as doxorubicin. 
However, the actual mechanism behind the interaction between TG2 and NFκB subunits to 
elicit a cell survival response and chemoresistance is still not fully understood. The aims of the 
project are as follows: 
(a)   To establish a relationship between TG2 and chemoresistance in breast cancer cells and to 
verify whether this phenotype can be reversed in the presence of TG2 activity inhibitors and 
specific siRNA.  
(b) To study the involvement of TG2 activity on the constitutive activation of NFκB and 
investigate whether this is an extracellular or intracellular phenomenon.  
(c) To characterize the pathway involved in the constitutive activation of NFκB induced by TG2 
(d) To determine the presence of NFκB subunits on the TGM2 gene promoter, which may 
contribute to a TG2-NFκB feedback loop in breast cancer cells  
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
The cell lines used in this study were breast cancer cell lines. The MDA MB 231 WT cells were 
a kind gift from Dr. Stephane Gross (Aston University, UK). The MDA MB 231 Clone 9 and 
MDA MB 231 Clone 16 cells were a kind gift from Dr. Kapil Mehta (Texas University, USA). 
The MCF7 cell lines was purchased from ATCC (American Type Culture condition). The 
SKBR3 and T47D cell lines were obtained from Birmingham University, Birmingham, UK. 
The doxorubicin resistant breast cancer cell lines, MCF7/RT, SKBR3/RT and T47D/RT used in 
this study were developed by selecting out surviving cells in the presence of increasing 
concentrations of doxorubicin, until the final cell lines were resistant and were able to survive in 
1μg/ml of doxorubicin. The complete growth  medium that the resistant cell lines were cultured 
in was always supplemented with doxorubicin, so that the cell lines can maintain their 
chemoresistant phenotypes.  
2.1.2 List of antibodies  
Neomarkers, Pierce, UK 
 Mouse monoclonal TG2 Antibody (Cub 7402) (1:1000) 
 Mouse monoclonal TG2 Antibody (TG100) (1:1000) 
Cell signalling, UK 
 Rabbit polyclonal Rel A/p65 antibody (1:1000) 
 Rabbit polyclonal Rel B antibody (1:1000) 
 Rabbit polyclonal c-Rel antibody (1:1000) 
 Rabbit polyclonal p100/p52 antibody (1:1000) 
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 Rabbit polyclonal E-Cadherin antibody (1:1000) 
 Mouse monoclonal N-Cadherin antibody (1:1000) 
 Rabbit polyclonal phospho-Serine 536-Rel A/p65 antibody (1:1000) 
Santa Cruz, UK 
 Rabbit polyclonal p105/p50 antibody (1:500) 
 Rabbit polyclonal IκBα antibody (1:1000) 
 Mouse α-Tubulin antibody (1:1000) 
Sigma Aldrich, UK 
 Rabbit polyclonal Lamin A antibody (1:1000) 
 Rabbit polyclonal Fibronectin antibody (1:2000) 
 Goat anti-mouse HRP conjugated secondary antibody (1:1000) 
Dako, Denmark 
 Swine anti- rabbit HRP conjugated secondary antibody (1:1000) 
 Rabbit anti-mouse FITC conjugated secondary antibody (1: 1000) 
2.1.3 Chemicals 
The cell culture media, RPMI-1640 and DMEM was purchased from PAA cell Culture 
Company. The distilled water (dH2O) used in the experiments was obtained from Milli Q water 
purifier (Millipore/Water, Watford, UK). The chemicals and reagents used in the experiments 
were obtained from the following companies: 
Zedira, Darmstadt, Germany 
 Purified guinea pig liver transglutaminase (gplTG) 
 Biotin-X-Cadaverine  
  Z-DON-Val-Pro-Leu-OMe (Z-DON) 
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Cleaver Scientific Ltd, Rugby, UK 
 BLUE Wide Range Pre-stained Protein Ladder 
Bio-Rad, Hemel Hempstead, UK 
 Bio-Rad protein assay kit 
Calbiochem (EMB Merck Millipore) , Nottingham, UK 
 Genecticin (G418 Sulphate) 
  Calpeptin (cell permeable Calpain inhibitor)  
 NFκB SN50 : {H-(AAVALLPAVLLALLAPVQRKRQKLMP)-OH} (cell permeable 
inhibitor peptide) 
Sigma-Aldrich, Poole, Dorset, UK 
 Tumour Necrosis Factor a  (TNF-α) 
  Geneticin (G418 Sulphate) 
 PS-1145 dihydrochloride  (N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-3-
pyridinecarboxamide dihydrochloride); IKK inhibitor 
Imgenex, San Diego, USA 
 NFκB/SEAPorter Assay kit  
 NFκB p65 (Ser 529/536) Inhibitory peptide set : (1mg of lyophilized peptide) 
 Inhibitor peptide (DRQIKIWFQNRRMKWKKNGLLSGDEDFSS); Rel A/p65 sequence is 
underlined 
 Control peptide (DRQIKIWFQNRRMKWKK) 
R&D Systems Europe Ltd., Abingdon, UK 
 Human RelA/NFκB p65 ExactaChIP Chromatin IP kit 
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Axon Medchem BV, Groningen, Netherlands 
 BX795  (Pyrrolidine-1-carboxylic acid [3-(5-iodo-4-{3-[(thiophene-2-carbonyl)-
amino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide); Potent and very specific 
inhibitor of IKKε 
Vector Laboratories, UK 
 Vectashield mounting medium 
Roche Applied Science, Burgess Hill, UK 
 Cell Proliferation Kit II (XTT) : Sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium-
bis (4-methoxy-6-nitor) benzene sulfonic acid hydrate reagents  
Life Technologies Ltd/ Invitrogen, Paisley, UK 
 Lipofectamine 2000 Transfection Reagent 
Qiagen 
 Human TG2 targeting siRNA 
 Human Rel A/p65 targeting siRNA. 
GE Healthcare 
 A and G-Sepharose bead slurry 
 ECL Chemiluminiscence development kit 
Aston university, Birmingham, UK 
 R283 : 1,3-dimethyl-2[(oxopropyl)thio]imidazolium derivative site directed TG2 
irreversible inhibitor which is cell permeable (Balklava, et al. 2002) 
 R294: non-permeable TG2 inhibitor which is known to block the cross linking activity 
of cell surface TG2 (Griffin, et al. 2008) 
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2.1.4   PCR primers 
Gene Primer sequences Annealing Temperature  
TGM2 
Forward 
5'-ATGAGAAATACCGTGACTGCCTTAC-3' 
63oC 
Reverse 
5'- CAGCTTGCGTTTCTGCTTGG-3' 
Rel A/p65 
Forward 
5'- ACGATCTGTTTCCCCTCATC-3' 
 
55oC 
Reverse 
5'-TGCTTCTCTCCCCAGGAATA-3' 
 
-κB site on TGM2 
gene promoter 
Forward 
5'-TACTTAGGTGGCTCCCTGTCTTC-3’ 
52oC 
Reverse 
5’-CCAGATGAAAGGATGGGTTTGG-3’ 
p21 
Forward 
5'-CCAGCCCTTGGATGGTTT-3' 
60oC 
Reverse 
5'-GCCTCCTTTCTGTGCCTGA-3' 
GAPDH 
Forward 
5'-TGCACCACCAACTTGCTTAGC-3' 
55-60oC Reverse 
5'- GGCATGGACTGTGGTCATGAG-3' 
 
 
Table 2.1: List of primers 
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2.1.5 Equipment 
Beckman Coulter Instruments Ltd, High Wycombe, UK 
 Spectrophotometer Model DU-7 
 Beckman Allegra X-15R centrifuge 
Bio-Rad, Hemel Hempstead, UK 
 Glass plates (1.5mm) 
 Protein III Minigel Vertical electrophoresis apparatus  
 Western blot wet transfer system 
Corning, Staffs, UK 
 pH meter 
Sanyo, UK 
 CO2 incubator Model IG150 
Nikon Inc, Badhoevedorp, Netherlands 
 Inverted Phase Microscope model TM-100 
Leica Microsystems Ltd, Milton Keynes, UK 
 SP5 TCS II MP Leica Laser Confocal Microscope 
 DMI4000 B Automated Inverted Leica Fluorescent Microscope 
IMPLEN GmbH, Munchen, Germany 
 NanoPhotometer Pearl 
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2.2   METHODS 
2.2.1   Cell culture techniques 
2.2.1.1 Culture conditions of cells 
The cells used in this project included MDA MB 231 Wild Type,  MDA MB 231 Clone 9, 
MDA MB 231 Clone 16, MCF7/Wild type, MCF7/ Doxorubicin Resistant (MCF7/RT), 
SKBR3/Wild Type, SKBR3/ Doxorubicin Resistant (SKBR3/RT), T47D/Wild Type , 
T47D/Doxorubicin Resistant (T47D/RT) breast cancer cell lines. All of the above mentioned 
breast cancer cell lines were cultured in a humidified atmosphere at 37
o
C and 5% (v/v) CO2. 
The MDA MB 231 Wild Type, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were 
cultured in complete  RPMI-1640 containing 10%  FBS, 25mM L-Glutamine and 
penicillin/streptomycin (100U/ml and 100μg/ml respectively) and used for experiments, unless 
otherwise indicated. The SKBR3/WT, SKBR3/RT, T47D/WT and T47D/RT cells were cultures 
in completed Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS, 1% (v/v) 
nonessential amino acids and penicillin/streptomycin (100U/ml and 100μg/ml respectively) and 
used for experiments.  
2.2.1. 2   Passaging of cell lines  
The complete cell culture medium (DMEM or RPMI-1640) and 0.25% (w/v) trypsin were pre 
warmed prior to use. The adherent confluent (at least 90% confluency) cells were washed once 
with serum free DMEM or RPMI-1640 to remove dead cells and debris. The cells were then 
treated with Trypsin for 5 min at 37
o
C for the cells to detach. The cells were then collected in 
complete medium (RPMI-1640 or DMEM) to inactivate the trypsin and centrifuged at 300xg 
for 5 min. The supernatant was then discarded and the cell pellet was resuspended in complete 
growth medium. Subsequently the cells were seeded into tissue culture flasks to obtain the 
desired confluency.   
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2.2.1.3   Cell counting using haemocytometer   
The cell lines were collected as described in detail in Section 2.2.1.2. To count the cells, 10μl of 
each cell line suspension was added into each side of the haemocytometer. Using a phase 
contrast microscopy on an inverted microscope, the cells were counted in four separate 
chambers, neglecting the cells present on the top and right corner lines. The cell numbers 
obtained after counting was multiplied with 10
4
 to determine the cell number present per ml of 
the cell suspension.    
2.2.1.4 Freezing and defrosting of cell lines  
The cell lines were trypsinized and counted as described above in Sections 2.2.1.2 and 2.2.1.3 
and subsequently re-suspended in freezing mixture which is composed of 10% (v/v) cell culture 
grade DMSO in heat inactivated FBS. The cells were then distributed as 1ml aliquots into 
cryogenic vials and kept at -20
o
C for 1 h. After this, the cryogenic vials were kept in -80
o
C for a 
few days, following which, the vials were transferred into a liquid nitrogen storage container for 
long term storage. 
To defrost the frozen cells, the cryogenic vials of the cell lines in liquid nitrogen were removed 
and placed in the cell culture incubator at 37
o
C until the freezing mixture and cells are 
completely thawed. The cell suspension was then carefully transferred into sterile Falcon tubes 
and 10 mls of complete growth medium (RPMI-1640 or DMEM) was added drop wise, with 
gentle mixing after every drop to make sure that the cells were diluted slowly. The cell and 
medium suspension was then transferred into a tissue culture flask. The medium was changed in 
the next 12- 24 h and the cell lines were passaged (Section 2.2.1.2) at least once prior to using 
them for an experiment.  
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2.2.1.5   SiRNA transfections 
In order to silence the expression of TG2 and Rel A/p65 in the breast cancer cell lines, different 
small interfering RNA (siRNA) sequences that target human TG2 and Rel A/p65 were obtained 
from Qiagen. The sequences for the siRNA are listed below: 
TG2 siRNA: 
TGM2-1   CCGCGTCGTGACCAACTACAA  
TGM2-6   CACAAGGGCGAACCACCTGAA    
Rel A/p65 siRNA:  
Hs_RELA_5    AAGATCAATGGCTACACAG   
Hs_RELA_7   CCGGATTGAGGAGAAACGT    
Hs_RELA_8    ATGGAGTACCCTGAGGCTA     
The universal negative control siRNA was purchased from Qiagen and used as control 
treatments. 1nmol of the lyophilized siRNA were dissolved in 100μl of sterile, RNase free 
water to obtain a 10μM solution which was stored at -20oC. The transfections were performed 
using Lipofectamine 2000 in accordance to the manufacturer's protocol. Prior to transfection, 
breast cancer cell lines were seeded (5x10
5
 cells into each well of a 6-well plate and 3000 cells 
into each well of a 96 well plate) for 24 h to reach 60-70% confluency. Before transfection, the 
cells were washed with serum free medium and replaced with pre-warmed fresh complete 
medium. Each siRNA was diluted with serum free medium to reach a final concentration of 
100nM. The siRNA and Lipofectamine 2000 transfection reagent was prepared as directed by 
the manufacturer by incubating the mixture at room temperature for 15-20 min to form the 
transfection complex. The complex was then added in a drop wise manner on to the seeded cells 
with gentle swirling of the plate to make sure that the transfection complex is uniformly 
distributed (in accordance to manufacturers' instructions). After 48 h of incubating the cells 
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with the siRNA at 37
o
C, the cells were used in western blotting, activity and cell viability 
assays.   
2.2.1.6   Cell transfection of TG2 and vector control plasmid  
2.2.1.6.1   Kill curves  
3000 cells of SKBR3 and MCF7 cell lines were seeded into per well of a 96-well plate and 
treated with increasing concentrations of G418 (250μg/ml, 500μg/ml, 750μg/ml, 1mg/ml and 
1.5 mg/ml). After 24, 48 and 72 h of incubation with the antibiotic, 30μl of XTT reagents 
(Section 2.2.13) mixture was added into each well and incubated with the cells for 4 h at 37
o
C. 
The absorbance was read at 490nm and 750 nm with a help of a Spectrafluor plate reader. The 
absorbances were expressed as absorbance of 490nm-750nm. The percentage of cell viability in 
the presence of increasing concentrations of the antibiotic was calculated.  
2.2.1.6.2 Transfection of the breast cancer cell lines with plasmids using 
Lipofectamine 2000 and selection using G418 
The cells were seeded into appropriate tissue culture flasks depending on the experiment to be 
conducted (5x10
5
 cells per well of a 6 well plate and 3000 cells per well of a 96 well plate) and 
allowed to adhere overnight and reach 70-80% confluency. The next day, the plasmids and 
Lipofectamine 2000, depending on the tissue culture flasks, were diluted into OptiMEM 
medium according to the manufacturer’s instructions. The diluted Lipofectamine 2000 and 
diluted plasmid DNA were combined and allowed to incubate at room temperature to for 15-20 
min to allow the formation of the transfection complex. The existing growth medium from the 
wells was aspirated and replaced with fresh pre-warmed complete medium. After the incubation 
time, the transfection complex was added drop wise on to the cells with gentle swirling. The 
cells were incubated along with the transfection complex for 48 h after which the clones were 
selected for further experiments using 500μg/ml of G418 for 48 h. Once transfected with the 
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plasmids, the cells were maintained in cell culture medium containing 250 μg/ml of G418 for 
further experiments. The sub cellular fractions of the transfected breast cancer cell lines were 
collected as detailed in Section 2.2.2 and the fractions were analysed for TG2 and NFκB 
expression as well as activity. 
2.2.2 Preparation of whole cell lysate, cytoplasmic and nuclear fractions of cells  
The cell lines were fractionated into the sub cellular fractions (whole cell lysate, cytoplasmic 
and nuclear fractions) as established previously (Suzuki, et al. 1999). The breast cancer cell 
lines were seeded and the cell monolayer was washed once with ice cold PBS after which the 
cells were collected using a cell scraper into 1 ml of PBS. The cells were then centrifuged at 
1500 x g  10 min and washed twice with ice cold PBS. The cells were again centrifuged at 2000 
x g for 5min at 4
o
C and the supernatant was discarded. The pellet was re-suspended in 200μl of 
ice cold Buffer A (1M Hepes/KOH, pH 7.9, 1M KCl, 2mM EDTA, 50mM EGTA, 0.1mM 
PMSF and 1% (v/v) Protease Inhibitor cocktail) and mixed well by pipetting. The cells in 
Buffer A were kept on ice for 15 min and then 100 μl of 10% NP-40 was added and vortexed 
vigorously until the cellular membrane is destroyed. A small amount of the cells and lysis 
buffer mixture was taken to be used as the whole cell lysate. The samples were then centrifuged 
at 2500 x g for 5mins at 4
o
C and  the supernatant was collected and used as the cytosolic 
fraction. The pellet was then re-suspended in 150μl of BL buffer (10mM potassium phosphate, 
10mM Tris-HCl, pH 8.0, 0.4M LiCl, 0.1% NP-40, 0.1mM PMSF and 1% (v/v) protease 
cocktail inhibitor) by pipetting and then vortexed for proper mixing after which the samples 
were left on ice for 15 min. The nuclear fraction is the supernatant collected by centrifugation 
of the samples at high speed (≥15,000x g) for 1 h at 4oC. The cytosolic and nuclear fractions 
were analysed for the expression of TG2 and Rel A/p65 by western blot. 
2.2.3 Protein Concentration  
The protein concentration of the sub cellular extracts were determined using the commercial kit 
available from Bio-Rad based on the Lowry protein concentration method (Lowry, et al. 1951). 
Chapter 2: Materials and Methods 
 
73 | 
 
Using BSA as a standard, 5µl of BSA at different concentrations (ranging from 0.1-1.5mg/ml) 
was added to a 96-well plate. 25µl of Reagent A was added to the wells followed by 200µl of 
Reagent B and incubated for 15min at room temperature. The absorbance was read at 750nm 
using a plate reader and the values were plotted as a standard graph to aid in determining the 
protein concentration of the cell samples.  
2.2.4 SDS-PAGE (Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis)  
After the protein concentration assay (Section 2.2.3), the protein extracts that contain the 
desired amount of protein was dissolved in a 1:1 ratio with 2x strength reducing Laemmli buffer 
(125mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (v/v) SDS, 10% (v/v) 2-β-mercaptoethanol 
and 0.004% bromophenol blue)  (Laemmli, et al. 1970) and boiled to denature for 5 min and 
then stored at -80
o
C until needed to be used or else resolved by the SDS-PAGE method. The 
gels consisted of a 10% (w/v) polyacrylamide separating gel which contained 0.75M Tris 0.2% 
(w/v) SDS stock solution, pH 8.8 and 3% (w/v) polyacrylamide stacking gel which consisted of 
0.2M Tris 0.2% (w/v) SDS stock solution, pH 6.8. The polymerization of the gels were initiated 
by the addition of freshly prepared 10% ammonium persulphate and N, N, N’, N’ -
Tetramethylethylenediamine (TEMED). 
The separating and stacking gels were prepared as indicated in the table below. The separating 
gels (80 x 60 x 1.5mm) were cast using the Atto-mini gel system and isopropanol was poured 
on top of the gel to fill the gel system and provide the gel with a flattened upper surface. The 
gels were then allowed to polymerise for 45 min to 1 h at room temperature.  
After polymerization of the separating gel, the upper surface was washed thoroughly using 
distilled water and the edge of the gels were blotted dry. The stacking gels were prepared and 
poured between the glass plates and either a 10-well comb or 15-well comb was used to form 
the sample wells. Following polymerization of the gel, the sample well comb was carefully 
removed and the wells were washed as well as filled with (25mM) Tris- (192mM) Glycine- 
(0.1% (w/v)) SDS electrode running buffer, pH 8.5. The desired protein concentration was 
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loaded into each well. Electrophoresis was conducted at 90V through the stacking gel and then 
120V through the separating gel until the bromophenol blue tracking dye is seen to reach the 
bottom of the separating gel. 
Running buffer (pH 8.5) 
 25mM Tris 
 192mM Glycine 
 0.1% (w/v) SDS 
Separating Gel 
 8% gel 10% gel 
30% Acrylamide 4.00 ml 5.00 ml 
4x Tris HCl/SDS, pH 8.8 3.75 ml 3.75 ml 
dH20 7.25 ml 6.25 ml 
10% Ammonium 
Persulphate 
0.05 ml 0.05 ml 
TEMED 0.01 ml 0.01 ml 
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Stacking Gel 
30% Acrylamide 0.65 ml 
Tris HCl/SDS, pH6.8 1.25 ml 
dH2O 3.05 ml 
10% Ammonium Persulphate 0.025 ml 
TEMED 0.005 ml 
 
Table 2.2 Composition of polyacrylamide gels 
2.2.5 Western Blotting of Proteins 
The proteins previously resolved by SDS-PAGE were electrophoretically transferred onto 
nitrocellulose membranes using a Bio-Rad wet blot system as per previously established 
protocols (Towbin, et al. 1979). The fibre pads, nitrocellulose sheets and electroblotting papers 
were soaked in ice cold transfer buffer. The gel holder cassette was placed open and the filter 
pads, pre-soaked in transfer buffer were placed on the black coloured surface of the cassette. 
The wet electrode paper was then placed on the filter pad, on top of which the gel was placed. 
The soaked nitrocellulose paper was then laid on top of the gel followed by wet electrode paper 
and finally the second pre-soaked filter pad. A glass roller was used to remove any trapped air 
bubbles in the set up. The cassettes were then assembled and inserted into the apparatus used 
for blotting in such a way that the membrane side of the set up faces the anode electrode. The 
apparatus was then filled with ice cold transfer buffer. The electro-transfer of the proteins in the 
gel was performed for 2 h at 200mA. The success of the transfer of proteins on to the 
nitrocellulose membrane was confirmed by the presence of high molecular weight markers on 
the membrane.   
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Transfer Buffer (pH 9.7) 
 48.8mM Tris 
 39mM glycine 
 20% (v/v) methanol 
2.2.6 Immunodevelopment of western blots 
After transferring the membranes were stained with Ponceau S stain to make sure that the 
proteins had been transferred correctly onto the membrane. The membrane is then destained 
using 1x TBS-Tween. After destaining, the membrane was blocked with 5% blocking buffer 
(5% Marvel in 1xTBS-Tween) probed with different primary antibodies overnight with shaking 
at 4
o
C. The next day, the membrane was washed 4 times for 15 min each and then probed with 
the suitable secondary antibody for 2 h with shaking at room temperature. The membrane is 
then washed again with 1x TBS-Tween, 4 times for 15 min each. Immuno-detection of the blots 
was completed using the Amersham enhanced Chemiluminescence (ECL) system kit in 
accordance to the manufacturers' protocol. The two reagents, A and B were mixed in an equal 
ratio and 1ml of the mixture was added onto each blot. After 1 min of incubation the 
membranes were wrapped in cling film and placed in an autoradiography cassette. The exposure 
of the blot was performed in a dark room using either Amersham Hyperfilm ECL (GE 
Healthcare, UK) or Kodak BioMax XAR film (Sigma-Aldrich, UK) exposed to the 
nitrocellulose membranes for varying time lengths depending on the intensity of the emitted 
signal The films were then developed using GBX developer and fixer (Sigma-Aldrich, UK), 
after which the films were extensively washed with water before air-drying.  
2.2.7 Stripping and re-probing of nitrocellulose membrane 
To make sure that the proteins loaded on the SDS-PAGE gel were equal, the primary and 
secondary antibodies were taken off from the blot using stripping buffer. The nitrocellulose 
membranes were immersed in stripping buffer and incubated between 50-60
o
C for 30min in an 
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oven, with occasional shaking. The stripping buffer was then discarded and the blots were 
washed four times (15 min each) with 1x TBS-Tween, pH 7.4 at room temperature with gentle 
agitation. The membrane was then blocked as described above and primary antibodies that will 
allow determination is equal protein loading (Anti-α-Tubulin and anti-Lamin-A) as well as the 
appropriate secondary antibodies were applied onto the membrane. The immunodetection of the 
blots was carried out as described in Section 2.2.6 using the ECL system.  
Stripping buffer 
 65 mM Tris HCl, pH 6.7 
 2% (w/v) SDS 
 100mM 2-mercaptoethanol 
2.2.8 Co-Immunoprecipitation 
The breast cancer cells were seeded into 60mm petridishes (1x 10
6
 cells/ dish), and left to 
become 60-70% confluent. The next day, the breast cancer cell lines were treated with the 
various inhibitors as per required. The subcellular fractions of the cell lines were collected as 
described in Section 2.2.2. 250μg of subcellular protein was then pre-cleared with 50μl of 
Protein A- or G- Sepharose bead slurries on a rocking platform by incubation for 2 h at 4
o
C. 
The precleared nuclear were then incubated with 0.5μg of the appropriate antibody for 90 min, 
with gentle shaking on a rocking platform at 4
o
C. The immune complexes were then 
precipitated with 50μl of Protein A or G-Sepharose bead slurries overnight at 4oC on a shaker. 
The next day, the beads were washed with the nuclear lysis buffer and extracted into 30μl of 2x 
Laemmli sample buffer by boiling for 5 min. Samples were resolved by SDS gel 
electrophoresis, transferred onto nitrocellulose membrane and then immunoprobed with the 
target antibodies (Sections 2.2.4-2.2.6).  
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2.2.9 Cellular localization of TG2 transamidating activity via incorporation of 
FITC-Cadaverine  
The in situ TG2 mediated cross links in the breast cancer cell lines were measured by 
incorporation of the fluorescent primary amine substrate, FITC-Cadaverine into cells and 
detected using fluorescent microscopy. The breast cancer cell lines (80,000 cells) were seeded 
into an 8-well chamber slide and incubated overnight. The next day, the cells were exposed to 
fresh complete medium that contains 0.5mM fluorescein Cadaverine and incubated for 16 h 
(Nicholas, et al. 2003). Following the incubation, the medium was removed and the cells were 
washed gently three times with PBS, pH 7.4 and then fixed with pre-chilled methanol (-20
o
C) 
and then incubated for 15 min at -20
o
C. The cells were then washed three times with PBS, pH 
7.4 and air dried. Drops of Vectashield mounting medium containing DAPI was added onto the 
cells and subsequently covered with a cover slip and sealed using nail varnish. The slides were 
then viewed by automated inverted microscope Leica DM1400B fluorescent microscopy and 
the resulting images were analysed using Leica LAS AF Image browser software. 
2.2.10 Detection of TG2 using confocal microscopy after immunocytochemistry 
The breast cancer cells were seeded into 8-well glass chamber slides (1x10
5
 cells per well) and 
allowed to attach and become confluent overnight. The next day, the cells were washed thrice 
(three min per wash) with PBS, pH 7.4. 100μl of 3.7% paraformaldehyde in PBS was added 
into each well and incubated at 37
o
C for 20 min to fix the cells. The breast cancer cell lines 
were then washed with PBS, pH 7.4 three times (three min per wash). 100μl of 0.5% Triton-X-
100 in PBS was added into each well and incubated for 15 min to permeablize the cells, after 
which the cells were washed with PBS, pH 7.4 as describe above. The wells were then blocked 
with 100μl of 10% horse serum (heat inactivated) in PBS for 2 h at 37oC after which the wells 
were washed again with PBS, pH 7.4. The mouse anti-human TG2 antibody Cub7402 (1:100 
dilution) in 1% horse serum in PBS, at a final volume of 100μl was added into each well and 
incubated for 45 min at 37
o
C. The wells were washed thrice with PBS, pH 7.4 (five min per 
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wash) and then incubated with the secondary anti-mouse FITC (1:200 dilution) in 1% goat 
serum in PBS for 45 min at 37
o
C. The cells were washed thrice with PBS. pH 7.4 (five min per 
wash) and then rinsed briefly in water. The samples were then air dried after which a drop of 
DAPI in Vectashield mounting medium was added onto the cells and sealed with a cover slip 
with the help of nail varnish. The slide was stored in the fridge (4
o
C) until different fields were 
captures using SP5 TCS II MP Laser confocal microscope made by Leica Microsystems and the 
resulting images were analysed using Leica LAS AF Image Browser software. 
2.2.11 Detection of the cell surface and whole cell lysate TG2 activity via Biotin 
Cadaverine incorporation into Fibronectin 
The transglutaminase activity of TG2 was measured via biotin-cadaverine incorporation into 
FN as described previously by Jones, et al. in 2006 (Jones, et al. 2006). 50μl of 5 μg/ml of FN 
in 50mM Tris-HCl, pH 7.4 was used to pre-coat the 96 well plates and left over night at 4
o
C. 
After washing the wells three times with 50mM Tris-HCl, pH 7.4, the wells were blocked with 
3% BSA in PBS, blocking buffer, pH 7.4 for 1 h at 37
o
C. To determine the cell surface TG2 
activity of the breast cancer cells, 2x10
4
 cells in 100μl of serum free medium was seeded into 
each well and incubated at 37
o
C with 5% (v/v) CO2 for 2 h in the presence of 0.1 mM biotin-X-
cadaverine, 1 mM DTT and 10mM CaCl2. To measure the whole cell lysate activity of TG2 
within the breast cancer cell lines, 50μg of whole cell lysate protein (obtained as described in 
Section 2.2.2) was diluted in serum free medium to a final volume of 100μl along with 0.1 mM 
biotin-X-cadaverine, 1mM DTT and 10mM CaCl2. 50 ng/well of guinea pig liver TG2 in serum 
free medium containing 1mM DTT, 0.1 mM biotin-X-cadaverine, 10mM EDTA (negative 
control) or 10mM CaCl2 (positive control) was used as the control samples. After incubation, 
for 2 h, the reaction was stopped by adding 100μl of 2 mM EDTA in PBS, pH 7.4 into each 
well and the cells were detached using 100μl of 0.1 % (w/v) deoxycholate in 2mM EDTA in 
PBS, pH 7.4 for 10 min at room temperature, with gentle shaking. the supernatant was 
discarded and the remaining fibronectin layer was washed with 50mM Tris-HCl pH 7.4, three 
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times and then blocked with blocking buffer for 30 min at 37
o
C. The biotin-X- cadaverine 
incorporated into FN was incubated with Extravidin-peroxidase conjugate (Sigma-Aldrich, UK) 
diluted in blocking buffer (1:1000) for 1 h at 37
o
C. The wells were again washed with 50mM 
Tris-HCl, pH 7.4, three times and the reaction was developed by the addition of 100μl of 
developing buffer containing SIGMAFAST OPD (o-Phenylenediamine dihydrochloride) tablets 
in 20mls of distilled water to yield a ready to use buffered solution that contains OPD and urea 
hydrogen peroxide.  The development of colour was terminated using 50μl 3N HCl and the 
absorbance was read at 490nm using a Spectrafluor plate reader. The results are expressed as 
percentage of TG2 activity with respect to the positive control samples.  
2.2.12 NFκB SEAPorter Assay Kit 
The NFκB SEAPorter assay kit has been designed to measure NFκB activation using the SEAP 
protein secreted into the culture medium as a read out. The concentration of SEAP found in the 
medium is directly proportional to the NFκB activity levels within the cell lines. The assay kit 
contains a pNFκB/SEAP plasmid which is known to express the SEAP protein, under the 
regulation of the NFκB promoter. The NFκB SEAPorter assay was performed as per the 
manufacturers' protocol (Cullen & Malim, 1992) 
2.2.12.1 Cell culture and transfection using the NFκB SEAPorter Assay Kit 
Approximately 5x10
5
 cells were seeded per well of a 6-well tissue culture plate containing 2ml 
DMEM supplemented with 10% FBS, non-essential amino acids. The cells were then incubated 
at 37
o
C in a CO2 cell culture incubator, overnight, so that the cells become 70-80% confluent. 
The next day, 4μg of plasmid DNA (pNFκB/SEAP plasmid) was diluted into 250μl of serum 
free medium that contained non-essential amino acids and for each transfection, 10μl of 
Lipofectamine 2000 was diluted into serum free medium. The two above solutions were mixed 
and then incubated at room temperature for 15-20 min. The existing medium in the plate was 
removed and replaced with 1.5ml DMEM with 10% FBS. 500μl of the plasmid-lipid mixture 
was added onto the plate drop by drop with gentle mixing. The cells were then incubated at 
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37
o
C in CO2 incubator for 48 h. After this incubation, the cells were treated with various 
inhibitors for the desired time course. Subsequent to the treatments, the cell supernatant was 
collected for the SEAP assay.  
2.2.12.2 Measurement of SEAP 
The standards of SEAP that were provided with the assay kit were used as the controls and 
allowed the quantitative measurement of SEAP protein in the 96-well micro titre plate. The 
supernatant of the transfected samples were diluted (1:10) using the dilution buffer provided 
along with the kit. 10μl of both the SEAP standards and the samples were added into each well 
in triplicates. Each well containing either a sample or a standard was supplemented with 10μl of 
water. The micro titre plate was then sealed and incubated at 65
o
C for 30 min to activate any 
endogenous alkaline phosphatase present in the supernatant. This allowed precise and accurate 
quantification of SEAP. The plate was then spun briefly to ensure that all of the liquid returned 
to the bottom of the well. 100μl of 1mg/ml PNPP substrate solution was added into each well 
and incubated at room temperature for 30 min, after which the absorbance reading was taken at 
405nm using the Spectafluor plate reader. The results have been represented with respect to the 
concentration of SEAP (standard) in ng/ml present in the media after accounting for  the 
dilution factor.  
2.2.13 Cell viability analysis using XTT Assay 
The XTT assay was used to measure the drug sensitivity of the breast cancer cell lines. The 
XTT assay quantifies the viable cell numbers in the presence of chemotherapeutic drugs such as 
doxorubicin. The XTT assay is based on the principle that the cleavage of the yellow 
tetrazolium salt, XTT to form an orange formazen dye only transpires in metabolically viable 
cells and was performed in accordance to the manufacturers' instructions (Roche Applied 
Sciences, UK). The formazen dye formed can be directly quantified using a Spectrafluor plate 
reader. The breast cancer cell lines were seeded into 96- well plates (3000 cells per well) at a 
volume of 100μl with complete medium and left over night in a humidified atmosphere at 37oC 
Chapter 2: Materials and Methods 
 
82 | 
 
and 5% CO2. The cells were incubated with the relevant treatments for a time course depending 
on the treatments and cell lines used. To perform the cell proliferation assay, 5 mls of XTT 
labelling agent was mixed with 0.1ml of electron coupling reagent. After the treatments were 
performed on the breast cancer cell lines, 30μl of the mixed XTT reagents, at a final 
concentration of 0.3mg/ml, were added into each well and incubated for 4 h in a humidified 
atmosphere at 37
o
C and 5% CO2. Following the incubation period, the formation of orange 
formazen dye was formed. The absorbance of the samples was measured using a Spectrafluor 
plate reader. The wavelength used to measure the formazen product is 450m, and the reference 
wavelength used was 750nm. The background wavelength of 750nm was subtracted from the 
absorbance values obtained from 450nm. The untreated cell lines were assumed to be 100% 
viable and the subsequent percentage of viable cells was determined.  
2.2.14 TGF-β1 Activity Assay 
The relative TGF-β1 activity of the breast cancer cell lines was detected using the Human/ 
Mouse TGF beta1 ELISA Ready-SET-Go (2nd generation) from eBiosciences. The assay was 
used to detect the endogenous human TGF beta 1 using the medium supernatant collected 
(Fantini, et al. 2006). A micro-titre 96 well plate was coated with 100μl/well of capture 
antibody diluted in coating buffer according to the instructions provided with the kit. The plate 
was then sealed and incubated overnight at 4
o
C. The next day, the wells were aspirated and 
washed five times with 1x wash buffer (approximately 250μl of wash buffer per well) and 
allowed to soak for at least 1 min during each wash and blotted to remove any residual buffer. 
The wells were then blocked with 200μl/well of 1x assay diluent and incubated at room 
temperature for 1 h. The wells were then aspirated and washed as per described above. Since 
animal serum that is used in the culture medium may contain very high levels of latent TGF 
beta 1, the latent TGF beta 1 was activated to the immunoreactive form by acidification and 
then neutralized subsequently. For every 100μl of the sample (medium supernatant), 20μl of 
HCl was added and incubated at room temperature for 10 min and then subsequently 
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neutralized with 20μl of 1N NaOH, which would dilute the sample to a factor of 1;1:4. 100μl of 
diluted acid activated sampled was added into wells in triplicates. The standards provided with 
the assay kit were also diluted using 1x assay diluent and 100μl of the standard was added into 
the wells. Following this, the plate was sealed and incubated overnight at 4
o
C to ensure 
maximum sensitivity of the assay. The next day, the wells were washed five times with 1x wash 
buffer and 100μl of detection antibody diluted in 1x assay diluent was added into each well and 
then incubated for 1 h at room temperature. The wells were washed as described previously 
after which 100μl of Avidin-HRP diluted in 1x Assay diluent was added to each well of the 
micro titre plate and incubated at room temperature for 30 min The wells were washed 7 times, 
with a soaking period of 2 min between washed. 100μl of substrate solution was added into 
each well and incubated at room temperature for 15 min and finally the reaction was stopped 
using 50μl of stop solution. The micro titre plate was then read at 450nm.  
2.2.15 Polymerase chain reaction 
2.2.15.1 Preparation of RNA 
TRIZOL Reagent was purchased from Invitrogen (Life Technologies) and used to rapidly 
isolate the total RNA from adherent cell monolayer as instructed in the manufacturers' protocol 
(Chomczynski & Mackey, 1995). Approximately, 5x10
6
 breast cancer cell lines were seeded 
per well into 6-well plates and allowed to become 80-90% confluent. Once the required 
confluency was attained, the cell monolayer was washed once with ice cold PBS. The cells 
were lysed directly in the tissue culture dish by adding 1 ml of TRIZOL reagent and scraped 
with the cell scraper. The cell solution in TRIZOL was passed several times through a pipette 
and vortexed thoroughly. To the cell lysate, 0.2 mls of chloroform was added and vortexed 
vigorously for 15 seconds after which the samples were incubated for 2 to 3 min at room 
temperature. The samples were then centrifuged at 12,000x g for 15 min using a refrigerated 
centrifuge (4
o
C). Subsequent to centrifugation, the lysate separates into a colourless upper 
aqueous phase, an interphase and the red phenol-chloroform phase which is the lower phase. 
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The RNA that needs to be extracted is present in the aqueous phase, exclusively. The upper 
aqueous phase was carefully separated and collected in a fresh tube. The volume of the aqueous 
phase was measured and mixed with 0.5 mls of isopropyl alcohol and used to precipitate the 
RNA. The samples were then incubated between 20-30
o
C for 10 min and then centrifuged at 
12,000x g for 10 min in a refrigerated centrifuge (4
o
C). The RNA precipitated is seen as a gel 
like pellet on the side of the tube. Following centrifugation, the supernatant was completely 
discarded and the RNA pellet was washed once with 1ml of 75% ethanol. The samples were 
vortexed and again centrifuged at 7,500x g for 5 min at 4
o
C. The supernatant was discarded and 
the ethanol wash step was repeated once more. The RNA pellet was then air dried for 15 min 
and then subsequently dissolved in DEPC-treated RNase free water by gentle pipetting. The 
dissolved RNA samples were analysed spectrophotometrically using a Nanophotometer 
(IMPLEN, Munchen, Germany) to determine the purity of the RNA (A260/A280) obtained as 
well as the concentration of RNA in the sample.  
2.2.15.2 Setting up of PCR 
 After the extraction of RNA from the breast cancer cell lines, the PCR reaction was performed 
using Taq PCR Core kit from Qiagen according to the manufacturer's instructions. The 
solutions were initially kept on ice after being thawed completely. The reaction mix for the PCR 
was made up as: 
 PCR buffer - 5μl  (1x) 
 Forward Primer - 0.5μM 
 Reverse Primer - 0.5μM 
 dNTP mix - 1μl  (200μM) 
 Taq DNA polymerase - 0.25μl   (2.5 units/ reaction) 
 Template DNA - 100ng 
 Distilled water to make the final reaction volume 50μl 
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All of the solutions, with exception of the template DNA was mixed depending on the number 
of PCR reactions that need to be conducted. The master mix was mixed thoroughly by pipetting 
and then distributed among pre-chilled PCR tubes. The template DNA was then added into the 
individual PCR tubes that contained the master mix. A typical PCR thermal cycler program was 
set up as described in the table below: 
Denaturation 15 min 95oC 
Annealing 1 min 
Depending on the primers 
used (Table 2.2) 
Extension 1 min 72oC 
Number of cycles 40 cycles 
Final extension 10 min 72oC 
Hold Infinite time 4oC 
Table 2.3 Typical PCR program set up 
The samples were always analysed in triplicate. After the PCR reaction was performed, the 
PCR samples were mixed with the loading dye and run on a 1.5% agarose gel in TAE buffer 
and analysed by gel electrophoresis.  
2.2.16 Human Rel A Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP assay) is a very useful technique to identify target genes 
of specific transcription factors, study mechanisms of gene expression and categorize proteins 
that regulate transcription as well as genetic networks. This assay will allow determination if a 
particular DNA-protein interaction is present at a certain location, time point and treatment 
conditions. According to the manufacturers' instructions the DNA-protein complexes were fixed 
using formaldehyde cross linking, the chromatin was sheared by sonication and the protein-
DNA complex of interest was immunoprecipitated using specific antibodies. The DNA bound 
to protein fragments were then identified by PCR (Solomon & Varshavsky, 1985) 
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2.2.16.1 Assay procedure 
The ChIP assay was performed to determine the interaction between the dimeric Rel A/p65 
forms and DNA. The breast cancer cells were seeded into 60mm petridishes and left to become 
80-90% confluent. Once the cells reached the desired confluency, the cells were fixed by adding 
37% (w/v) formaldehyde to a 1% (w/v) final concentration (40μl of formaldehyde for 1ml of 
complete media) and the samples were kept on the shaker for 15 min at room temperature. The 
formaldehyde was quenched by adding 1 M glycine to a final concentration of 125 mM (141μl 
of glycine for 1 ml of complete media). The samples were kept on the shaker for 5 min at room 
temperature, pelleted and the media was removed. The cell pellet was resuspended in 500 μl of 
Lysis Buffer, resuspended by pipetting and then incubated on ice for 10 min. The samples were 
then sonicated to shear chromatin (Output 3, 10 cycles, and 30 seconds "ON", samples on ice 
for 2 min before next cycle). The lysates were then centrifuged for 10 min at 12,000 x g at 4
o
C. 
The supernatant was collected and the pellet was discarded. The supernatant by diluted adding 1 
mL of Dilution Buffer and 5 μl of the Anti-RelA Antibody or Normal Sheep IgG (control) to 
the samples and incubated overnight at 4
oC on the shaker. The next day 50μl Protein A- 
Sepharose bead slurry was added to the samples and incubated for 30 min at 4
o
C with gentle 
shaking. The beads were then collected by centrifugation at 12,000 x g for 1 min. A series of 
washes were then performed with the four wash buffers provided with the assay kit by adding 
1ml of the wash buffer into the beads and pipetting up and down between each wash. The beads 
were then collected by centrifugation at 12,000xg for 1 min. After the last wash, 100μl of 
Chelating Resin Solution was added directly to the beads and boiled for 10 min in a water bath. 
The samples were then centrifuged at 12,000xg for 1 min at room temperature and the 
supernatant was transferred into a clean tube. The final volume of the samples collected was 
approximately 60-80μl. To clean up and concentrate the obtained DNA, 0.1 volumes of 3M 
sodium acetate buffer solution, pH5.2 and 0.7 volumes of isopropanol was added to collected 
samples. The samples were mixed well and centrifuged at 15,000xg for 30 min after which the 
supernatant was discarded. The DNA pellet was then rinsed in 1.5ml of 70% ethanol and 
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centrifuged as previously for 10 min. The supernatant was discarded and the pellet was air dried 
until it was free of ethanol. The DNA pellet was then resuspended in 100μl of endotoxin free 
water and the concentration and purity of the ChIP samples was determined using a Nano 
Photometer.  
2.2.16.2 PCR analysis of ChIP samples 
The protein-DNA complexes obtained from chromatin immunoprecipitation were used in 
subsequent PCR reactions with appropriately designed primers. The p21 promoter primers 
provided along with the kit was used as the positive control.  The PCR was carried out for the -
κB site on the TGM2 gene promoter and GAPDH as specified in Section 2.2.15.2.  
2.2.17 Statistical analysis 
Any statistically significant differences between data sets in experiments were calculated using 
ANOVA and post hoc tests were performed on the significant data
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3. Relationship between TG2 and 
chemoresistance in breast cancer cells 
3.1 INTRODUCTION 
Metastasis and chemoresistance are known to be the major hurdles in the successful treatment 
of breast cancer. A very common feature in metastatic and drug resistant tumour cells is that 
they display amplified resistance to apoptosis. Chemotherapy is a crucial component in the 
treatment regime for breast cancers. Despite a rapid reduction in tumour mass subsequent to 
chemotherapeutic cycles, cancers may persist and develop distal metastasis afterwards (Gong, 
et al. 2010). Data exists supporting the hypothesis that the expression of particular oncogenes or 
aberrant expression of tumour suppressor genes encourages aggressiveness, tumour cell growth 
and also relative expression of drug resistance. In addition, metastatic cancers demonstrate 
elevated resistance to radiation and drug therapies than their primary tumour counterparts 
(Fesik, 2005). Understanding the molecular factors responsible for chemoresistance and 
metastasis of breast cancer cells is therefore essential for the development of successful and 
novel therapeutic approaches.  
It is very reasonable to contemplate that the over expression of TG2 signifies a link between 
metastatic and chemoresistant tumour cells. Many cancer cell lines, such as malignant 
melanoma, glioma, lung adenocarcinoma, breast carcinoma, pancreatic ductal adenocarcinoma, 
prostate carcinoma, ovarian carcinoma and prostate carcinoma, chosen for drug resistance, 
express high levels of TG2 (Verma & Mehta, 2007a).  In the same way, metastatic cancer cells 
derived from patients with malignant melanoma (Fok, et al. 2006), breast cancer (Mehta, et al. 
2004) and ovarian cancer (Hwang, et al. 2008); demonstrate a considerable increase in TG2 
levels over their primary tumour cells. Reduction of or inhibiting TG2 in cancer cells has been 
demonstrated to be concurrent with susceptibility to cell death induced by chemotherapeutic 
drugs and also inhibit invasion (Yuan, et al. 2007). In parallel with these results, increased 
expression of TG2 in ovarian carcinoma enhanced cell adhesion to FN and promoted cell 
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migration (Satpathy, et al. 2007). In ovarian cancer patients, increased TG2 expression in 
tumour cell samples was associated with considerably worse prognosis in both multivariate and 
univariate analysis (Hwang, et al. 2008). Increased expression of TG2 in pancreatic tumour 
cells has been related to lymphovascular invasion and nodal metastasis (Verma, et al. 2006). All 
of the above findings indicated that presence of TG2 in cancer cells was abnormal and 
concerned with promoting a metastatic and a chemoresistant phenotype.  
Previous studies undertaken have shown that drug resistance and metastatic breast cancer cells, 
expressed very high levels of TG2 which may imply that TG2 contributes to the development of 
a chemoresistant phenotype. A further understanding of TG2 mediated cellular interactions with 
the ECM and the signalling pathways induced in response to any such interaction may provide 
new targets for the treatment and intervention of metastatic and chemoresistant breast cancers 
(Mangala, et al. 2007) 
Ai et al. in 2008 hypothesized that the epigenetic silencing of the TGM2 gene in breast cancer 
cells could serve as a marker for chemotherapeutic drug sensitivity (Ai, et al. 2008). The down 
regulation of TG2 using siRNA or antisense resulted in the reversal of chemoresistance, while 
the ectopic expression conferred resistance to drugs in melanoma, glioblastoma, ovarian and 
breast cancer cells (Verma & Mehta, 2007a).  TG2 expression can protect cancer cells from 
both apoptosis and autophagy. Inhibiting TG2 expression using siRNA could also result in the 
induction of autophagy in cancer cell lines and eventually cell death. Inhibiting the PKCδ 
activity by siRNA or rottlerin has been associated with a parallel decrease in the expression of 
TG2 and induction of autophagy in pancreatic cancer cells (Akar, et al. 2007) 
The aim of the work contained in this chapter was to identify the potential involvement of TG2 
expression and activity in chemoresistance against doxorubicin in breast cancer cells. Further 
studies were conducted to find out whether supplementing chemotherapeutic agents with TG2 
cross linking inhibitors or silencing TG2 expression could decrease the chemoresistance 
phenotype.  
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3.2   METHODS: 
3.2.1 TG2 whole cell lysate and cell surface activity assay 
Cells (2x10
4
 cells/ml and add 100μl/well) or 50μg of whole cell lysate protein, along with 
0.1mM Biotin-X- Cadaverine, 10mM CaCl2 or 10mM EDTA and 1mM DTT was seeded into 
96-well plates pre-coated with 5μg/ml of Fibronectin and allowed to incubate for 2 h at 37oC. 
The TG2 whole cell lysate and cell surface activity of the breast cancer cells in the presence of 
inhibitors was measured as detailed above (Section 2.2.11).  
3.2.2   In situ TG2 activity using FITC-Cadaverine incorporation: 
To investigate the in situ TG2 activity within the breast cancer cells with varying expressions of 
TG2, FITC Cadaverine was incorporated into the breast cancer cell lines and then subsequently 
analysed using Fluorescence microscopy (Section 2.2.9) 
3.2.3   Immunostaining of TG2: 
The breast cancer cells were stained using anti-TG2 Cub 7402 antibody (1:100) and anti-mouse 
FITC (1:200) secondary antibody was used. The cells were then subsequently analysed using 
confocal microscope (Section 2.2.10)  
3.2.4   Cell viability analysis: 
Breast cancer cell lines treated with TG2 inhibitors (R283, R294 and Z-DON) or TG2 siRNA 
and doxorubicin for time points of 24, 48 and 72 h culture periods were incubated with XTT 
reagents (Roche, UK) and the signals were detected using plate reader at 490 and 750 nm 
(background reading, which was erased from the absorbance 490nm) as described in detail in 
Section 2.2.13. 
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3.2.5   SiRNA transfection: 
TG2 specific targeting siRNA was used to inhibit the expression of TG2 in breast cancer cells 
using Lipofectamine 2000 (Invitrogen) as the transfection reagent. Two different siRNA 
sequences that targeted human TG2 was obtained from Qiagen. The sequences are listed below: 
TGM2-1   CCGCGTCGTGACCAACTACAA (denoted as (i)) 
TGM2-6   CACAAGGGCGAACCACCTGAA   (denoted as (ii)) 
A stock of lyophilized siRNA was dissolved in 100μl of sterile RNase-free water to obtain a 
10μM solution and then stored at -20oC. The transfections were performed according to the 
manufacturer’s protocol. Prior to transfection, breast cancer cells, were seeded into plates 
overnight to reach a confluency of 70-80%. The next day, the cells were washed with serum 
free medium and replaced with pre- warmed fresh complete growth medium. The siRNA were 
diluted in serum free medium to reach a final concentration of 100nM. After pre-incubation 
with Lipofectamine 2000 (Invitrogen) for 10-15 min, the transfection complex containing 
Lipofectamine 2000 and TG2 siRNA was added drop wise onto the cells seeded in the plates, 
along with gentle swirling to make sure that the transfection complex is uniformly distributed. 
48 h after transfection, further experiments were performed on the cell lines.  
3.2. 6   Detection of siRNA transfection efficiency: 
After 48 h of incubation with TG2 targeting siRNA or negative control siRNA with breast 
cancer cells, the whole cell lysate, cytoplasmic and nuclear fractions were collected and the 
protein concentration was detected as described in Sections 2.2.2-2.2.3. Western blotting was 
conducted to detect the presence of TG2 using mouse anti-TG2 monoclonal antibody (Cub 
7402) (1:1000) and anti-mouse secondary antibody (1:1000) dilution (Sections 2.2.4-2.2.6). 
Signals were detected using ECL system kit.  
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3.3    RESULTS: 
3.3.1    Development of doxorubicin resistant cell lines  
3.3.1.1     Cell viability analysis of TG2 null breast cancer cell lines in the presence 
of doxorubicin 
The TG2-null MCF7/WT, SKBR3/WT and T47D/WT breast cancer cell lines were treated with 
increasing concentrations of doxorubicin (0.25, 0.5, 0.75 and 1μg/ml) in 96-well plates for time 
points of 24, 48 and 72 h. The XTT assay which is designed to spectrophotometrically quantify 
viable cell numbers on treating the cells with cytotoxic agents was applied as described 
previously in Section 2.2.13. 
Earlier studies have shown that low or null- TG2 breast cancer cell lines were more chemo 
susceptible to even very low concentrations of doxorubicin (Verma & Mehta, 2007a/2007b).In 
agreement, the MCF7/WT, SKBR3/WT and T47D/WT breast cancer cell lines were 
demonstrated to be chemosusceptible to doxorubicin which might be attributed to the absence 
of endogenous TG2 in these breast cancer cell lines. 
Treating the MCF7 cells with increasing concentrations of doxorubicin, demonstrated an initial 
decrease in the viability of the cells over the treatment time period (Figure 3.1 A).  Initially, the 
susceptibility of the T47D to 0.25μg/ml of doxorubicin was less compared to the SKBR3 cells; 
however successive increases in the concentration of doxorubicin to 0.5μg/ml of doxorubicin 
rendered both the T47D and SKBR3 breast cancer cell lines equally susceptible to the 
chemotherapeutic agent (Figure 3.1 B & C).  
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(C)
Figure 3.1 Cell viability analysis of MCF7/WT (A), SKBR3/WT (B) and T47D/WT (C) 
cells in the presence of increasing concentrations of doxorubicin. 
The MCF7/WT, SKBR3/WT and T47D/WT cells (3000 cells/ well of a 96 well plate) were 
treated with increasing concentrations of doxorubicin (0.25, 0.5, 0.75 and 1μg/ml). After 4, 48 
and 272 h of incubation with doxorubicin, the XTT assay was performed and the absorbance 
was read at 490nm as well as 750nm using a Spectrafluor plate reader (as introduced in 
Section 2.2.13). The data shown above is mean percentage of viable cells + SEM with respect 
to the untreated cells (taken as 100% viability) of independent experiments (n=3).  
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3.3.1.2    Western Blot analysis of TG2 in the presence of increasing concentration 
of doxorubicin 
The MCF7/WT, SKBR3/WT and T47D/WT were cultured initially in the lowest concentration 
(0.25μg/ml) of doxorubicin and half of the surviving cells were lysed and separated into their 
cytoplasmic and nuclear fractions and the rest of the cells were grown in the next increasing 
concentration of doxorubicin (0.5μg/ml). This was repeated until the final cells obtained were 
resistant and able to survive in 1μg/ml of doxorubicin. The surviving cells in 1μg/ml of 
doxorubicin were termed MCF7/RT, SKBR3/RT and T47D/RT. The cellular fractions collected 
were analysed by Western Blotting using anti-TG2 antibody (Cub 7402; TG100) (1:1000) as 
described in Section 2.2.4-2.2.6. The MDA MB 231 Clone 16 cells that are known to express 
high levels of TG2 were used as the positive control for the western blot experiments.   
The western blot data indicated a clear gradual increase in the TG2 expression observed in the 
MCF- cells (Figure 3.2 A). The cytoplasmic fractions of the MCF7 cells treated with the initial 
concentrations of (0.25µg/ml) doxorubicin demonstrated no detectable TG2 expression, which 
was similar to the parental MCF7 cell line. From concentrations of 0.5μg/ml onwards, the 
expression of TG2 was observed. The MCF7 cells resistant to 1μg/ml of doxorubicin 
(MCF7/RT), showed significant TG2 expression. This seems to suggest that in the presence of 
escalating concentrations of doxorubicin, chemoresistance of the breast cancer cell lines 
increased in the MCF7 breast cancer cell line concurrent with increase in TG2 levels. These 
results suggest that TG2 may be responsible for rendering MCF7 cells resistant to 
chemotherapeutic agents such as doxorubicin.  
With the SKBR3 cells, no detectable TG2 expression was observed in the cell lines obtained 
when resistant up to 0.75μg/ml of doxorubicin. The SKBR3/RT cells that are resistant to 
1μg/ml of doxorubicin (Figure 3.2 B), demonstrated a slight expression of TG2 in their 
cytoplasmic fractions. On the other hand, the T47D cells that are resistant to 1μg/ml of 
doxorubicin showed no increase in their TG2 expression (Figure 3.2 C). This could suggest that 
the mechanism of chemoresistance within the T47D/RT cell line functions via a pathway that is 
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independent of TG2 activity and expression. The above findings seem to indicate the 
mechanism of chemoresistance inculcated by TG2 in breast cancer cell lines may be dependent 
on numerous other cell characteristics and could be specific to cell type. Also, since TG2 
expression in the SKBR3 cells was only observed at 1μg/ml but the MCF7 cells increased their 
TG2 expression at lower concentrations (0.5μg/ml) of doxorubicin, other survival pathways 
might also be at play in these SKBR3 cells cultured in low concentrations of doxorubicin.  
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(A) 
 
(B) 
 
(C) 
 
Figure 3.2   Detection of TG2 expression in MCF7, SKBR3 and T47D cells cultured in the 
presence of increasing concentrations of doxorubicin using western blot 
The MCF7 (A), SKBR3 (B) and T47D (C) (2x10
6
 cells/ 100mm petridish) were cultured from 
the lowest to the highest concentration of doxorubicin, where the surviving cells from the lower 
doxorubicin concentrations were subsequently cultured in higher concentrations, until the final 
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surviving wild type breast cancer cells were resistant to 1μg/ml of doxorubicin (Section 3.3.1). 
The cells were then fractionated into the whole cell lysate fractions (Section 2.2.2) and analysed 
by western blotting and detected using anti-TG2 antibody (Cub 7402; TG100) (1:1000) and 
anti-α-Tubulin for equal loading. The positive control used in the experiments was MDA MB 
231 Clone16 cells, which are known to express very high levels of TG2 protein (Mehta, et al. 
2004).  
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3.3.2   Chemoresistant breast cancer cell lines have high TG2 expression and 
activity 
3.3.2.1   Detection of cell surface and whole cell lysate TG2 activity in the presence 
of TG2 activity inhibitors 
Cells surface and whole cell lysate TG2 activity was measured using the Biotin-X- Cadaverine 
incorporation assay as described in Section 2.2.11. The MDA MB 231 WT, MCF7/WT, 
SKBR3/WT, T47D/WT and T47D/RT lack TG2 activity in their whole cell lysates. The MDA 
MB 231 Clone 9 (Mehta, et al. 2004) and SKBR3/RT cells illustrated very low whole cell 
lysate TG2 activity, while the MDA MB 231 Clone 16 (Mehta et al. 2004) and MCF7/RT cells 
demonstrated fairly high WCL TG2 activity. Treating the TG2-null breast cancer cell lines with 
TG2 activity cell permeable inhibitors, R283 and Z-DON as well as cell impermeable inhibitor, 
R294, did not show any change in the TG2 activity status in these cells. The SKBR3/RT, MDA 
MB 231 Clone 9, MDA MB 231 Clone 16 and MCF7/RT cells, on being treated with the above 
TG2 inhibitors, displayed a decrease in TG2 whole cell lysate activity (Figure 3.3). 
With respect to the cell surface TG2 activity of these breast cancer cell lines, the MDA MB 231 
WT, MDA MB 231 Clone 9, MCF7/WT, SKBR3/WT, SKBR3/RT, T47D/WT and T47D/RT 
illustrate no detectable TG2 activity on their cell surface, which is concurrent with the TG2 
whole cell lysate activity data obtained (Figure 3.4) 
 The MDA MB 231 Clone 16 cells that demonstrated high TG2 whole cell lysate activity also 
had cell surface TG2 activity. As depicted in Figure 3.4, treating the MDA MB 231 Clone 16 
cells with R283, R294 and Z-DON, led to a significant decrease, in the cell surface TG2 activity 
of the Clone 16 cells. On the other hand, no detectable cell surface TG2 activity was observed 
in the MCF7/RT cells (Figure 3.4)  
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Figure 3.3 Detection of TG2 activity in whole cell lysates of breast cancer cell lines in the 
presence of TG2 activity inhibitors. 
The levels of TG2 activity was analysed by Biotin-X- Cadaverine incorporation into fibronectin. 
The breast cancer cell lines were treated with the TG2 inhibitors, R283 (500μM), R294 
(500μM) and Z-DON (50μM) for 72h and analysed as described in Section 2.2.11. The positive 
control (50 ng/ml gplTG + 10mM  CaCl2) was taken as 100% TG2 activity (1.1893 ± 0.12739). 
Data shown is the mean percentage of TG2 activity + SEM from 3 independent experiments, 
with respect to the positive control (n=3).  Statistical analysis was performed using ANOVA 
with Dunnett’s post-hoc test. * p<0.05; ** p<0.01 between untreated and inhibitor treated 
cells. # p<0.01 between cell groups.  
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Figure 3.4 Detection of cell surface TG2 activity in breast cancer cell lines. 
The breast cancer cell lines were analysed for the cell surface TG2 activity in the presence of 
TG2 activity inhibitors as described in Section 2.2.11. Positive control (50 ng/ml gplTG + 
10mM  CaCl2) was taken to be 100% TG2 activity (1.21874±0.19475). Data shown is the mean 
percentage of TG2 activity + SEM from 3 independent experiments, with respect to the positive 
control (n=3).  Statistical analysis was performed using ANOVA with Dunnett’s post-hoc test. * 
p<0.05; ** p<0.01 between untreated and inhibitor treated cells.  
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3.3.2.2   Detection of TG2 expression in breast cancer cells after exposure toTG2 
activity inhibitors 
The breast cancer cell lines were treated with TG2 inhibitors, R283, R294 and Z-DON, after 
which the whole cell lysate, cytoplasmic and nuclear fractions of the cells were collected as 
described in Section 2.2.2. 50μg of protein of each fraction was collected using Lowry protein 
concentration (Section 2.2.3) and analysed by Western Blot using anti-TG2 antibody (Cub 
7402; TG100) to determine TG2 expression levels with the breast cancer cells. The MDA MB 
231 WT, MCF7/WT, SKBR3/WT and T47D/WT cells did not exhibit any TG2 protein 
expression in their whole cell lysate fractions (Figures 3.5). The MDA MB 231 Clone 9 and 
MDA MB 231 Clone 16 illustrate low and high expression of TG2 respectively in their whole 
cell lysate fractions (Figure 3.5). On treating the TG2 expressing cells with the cell permeable 
activity inhibitors, R283 and Z-DON, a significant decrease was observed in the cytoplasmic 
TG2 expression of these breast cancer cells (Figure 3.6). The cell impermeable inhibitor, R294, 
failed to change the expression of TG2 in the TG2 expressing breast cancer cells lines. The 
MCF7/RT cell lines (that were derived as explained in Section 3.3.1), also illustrated TG2 
expression, which on being treated with cell permeable TG2 activity inhibitors (R283 and Z-
DON) decreased significantly, while the cell impermeable inhibitor, R294, did not affect the 
expression of TG2. The SKBR3/RT and MDA MB 231 Clone 9 cells that demonstrated low 
TG2 expression, also showed a decrease in TG2 expression levels, on being treated with R283 
and Z-DON (Figure 3.6). A time course dependent treatment of the MDA MB 231 Clone 16 
cells with R283 and Z-DON exhibited a decrease in TG2 expression, following 48 h of 
treatment. This pattern continues onto the 72 h treated samples (Figure 3.7). These results may 
suggest that the decrease in TG2 expression in the high TG2 breast cancer cells, on being 
treated with TG2 cell permeable inhibitors, could be as a result of inhibiting TG2 activity within 
the cells.  
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Figure 3.5 Western blot detection of TG2 expression in breast cancer cell lines. 
The MDA MB 231 WT, Clone 9 and Clone 16 (A), MCF7/WT (C), SKBR3/WT (E) and 
T47D/WT (G) cells were seeded into 60mm petridishes (1x10
6
 cells/ plate) and allowed to 
become confluent after which the whole cell lysate, cytoplasmic and nuclear fractions were 
collected (Section 2.2.2) and analysed for TG2 expression using Cub 7402 (1:1000) and TG100 
(1:1000) (A, C, E & G) The western blot data shown is a  representation of three independent 
experiments (n=3). (B, D, F & H) Densitometry analysis was performed using image J and is 
represented as the mean densitometry of three blots + SEM. * p<0.05. 
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Figure 3.6 Treatment of TG2 expressing breast cancer cells with TG2 activity inhibitors 
The MDA MB 231 Clone 16 (A), MCF7/RT (C), SKBR3/RT (E) and MDA MB 231 Clone 9 (G) 
cells were treated with R283, Z-DON and R294 for a time course of 72 h after which the whole 
cell lysate, cytoplasmic and nuclear fractions of the breast cancer cells were collected (Section 
2.2.2) and  analysed for the TG2 expression levels by western blotting using anti-TG2 antibody 
(Cub 7402; TG100) (1:1000). Anti-α-Tubulin was used as the equal loading marker. (A, C, E & 
G) The western blot data shown is a representation of three independent experiments (n=3). (B, 
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D, F & H) Densitometry analysis was performed using image J and is represented as the mean 
densitometry of three blots + SEM, * p<0.05 
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Figure 3.7 Detection of TG2 expressions in MDA MB 231 Clone 16 cells on treatment with 
TG2 inhibitors over a time course  
The MDA MB 231 Clone 16 cells (1x10
6
 wells/ dish of 60mm petridish) were treated with R283 
(500μM) and Z-DON (50μM) and after time points of 12, 24, 48 and 72 h, the whole cell lysate 
fractions of the Clone 16 cells were collected as introduced in Section 2.2.2 for the protein 
expression of TG2 using Cub 7402 (1:1000). Lane 1 represents Untreated cells, Lane 2 
represents cells treated with TG2 inhibitor for 12 h, Lane 3 represents treatment time course of 
24 h, Lane 4 represents treatment time course of 48 h and Lane 5 represents treatment time 
course of 72 h. The membranes were subsequently analysed using anti-α-Tubulin to ensure 
equal loading of protein.  (A&C) The western blot data shown is a representation of three 
individual experiments (n=3). (B&D) Densitometry analysis was performed using image J and 
is represented as the mean densitometry of three blots + SEM. * p<0.05. 
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3.3.2.3    Detection of TG2 in situ activity by FITC-Cadaverine Incorporation and 
Fluorescent microscopy.  
In order to investigate the location of the TG2 activity within these breast cancer cell lines, the 
MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were incubated 
with 0.5mM FITC-Cadaverine for 16 h in 8-well chamber slides. The fluorescent signals were 
detected using the fluorescence microscope as described in Section 2.2.9. As shown in Figure 
3.8, the MDA MB 231 Clone 16 and MCF7/RT cells showed high TG2 activity. The MDA MB 
231 WT and MCF7/WT illustrated no measurable fluorescent signal.  
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Figure 3.8 Cellular localization of TG2 activity in breast cancer cell lines using fluorescent 
microscopy 
The cellular localization of TG2 in MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and 
MCF7/RT cells was analysed by FITC- Cadaverine incorporation into cells. The live cells were 
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incubated with FITC- Cadaverine for 16 h and subsequently analysed by fluorescence 
microscopy (Section 2.2.9) (n=3) 
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3.3.2.4 Detection of TG2 using Immunocytochemistry and confocal microscopy 
The cellular localization of TG2 within the breast cancer cell lines were further investigated 
using anti-TG2 (Cub7402) and secondary anti-mouse FITC conjugated antibody as described in 
detail previously in Section 2.2.10. The distribution of TG2 protein with the MDA MB 231 
WT, MDA MB 231 Clone 16, MCF7/WT and MCF/RT was detected using confocal 
microscopy. No fluorescence signal was detected in the MDA MB 231 WT and MCF7/WT 
cells and an equal distribution of TG2 antigen was illustrated in the cytoplasmic fraction of the 
MDA MB 231 Clone 16 and MCF7/RT cell lines with no detectable TG2 seen in the nucleus 
(Figure 3.9)  
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Figure 3.9 Cellular localization of TG2 protein expression in breast cancer cells using 
confocal microscopy 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were stained as 
described in Section 2.2.10. 1x10
5
 cells were seeded into 8-well chamber slides overnight. The 
next day the cells were fixed and blocked, subsequently after which the cells were incubated 
with primary anti-TG2 (Cub7402) (1:100) for 45 min and secondary mouse anti-FITC (1:200) 
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for 45 min at 37
o
C. The slides were then mounted with Vectashield mounting medium 
containing DAPI after which the fluorescent signals were detected using laser confocal 
microscopy (n= 3).  
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3.3.2.5    Cell viability analysis of breast cancer cell lines in the presence of 
doxorubicin 
To decipher the relationship between TG2 activity and chemoresistance in breast cancer cell 
lines, the MDA MB 231 WT, MDA MB 231 Clone 9, MDA MB 231 Clone 16, MCF7/WT, 
SKBR3/WT, T47D/WT and their respective resistant cell lines, MCF7/RT, SKBR3/RT, and 
T47D/RT that were derived as described in detail in Section 3.3.1 were cultured in the presence 
of increasing concentrations of doxorubicin (0.25- 1μg/ml) and then with 1μg/ml of doxorubicin 
along with the TG2 cell permeable inhibitors, R283 and Z-DON as well as the cell 
impermeable, R294 for a time course of 72 h. A dose-dependent decrease was observed in the 
cell viability of all the breast cancer cells, however, the TG2 expressing breast cancer cell lines 
clearly seemed to be more chemoresistant to doxorubicin than the low TG2 expressing and TG2 
null breast cancer cell lines (Figure 3.10). 
The susceptibility of these breast cancer cell lines varied according to their relative expressions 
of TG2. The MDA MB 231 WT, MCF7/WT, SKBR3/WT, T47D/WT and MDA MB 231 Clone 
9 cells demonstrated low cell viability in the presence of doxorubicin due to the lack of or low 
TG2 expression and activity (Figure 3.10). On the other hand, the MDA MB 231 Clone 16, 
MCF7/RT cells that expressed high TG2 activity, showed higher cell viability as compared to 
the MDA MB 231 WT and MCF7/RT cells, on being treated with 1μg/ml of doxorubicin. 
Treatment of the MDA MB 231 Clone 16 and MCF7/RT cells with R283 and Z-DON caused a 
significant decrease in the cell viabilities of the high TG2 expressing cell lines. R294, the cell 
impermeable inhibitor did not show any considerable decrease in the cell viability of the Clone 
16 and MCF7/RT cells as compared to the cell permeable inhibitors (Figure 3.11).  
The SKBR3/RT cells showed very low TG2 expression in the presence of 1μg/ml of 
doxorubicin and subsequent treatment of the cells surviving in 1μg/ml doxorubicin in 
combination with cell permeable TG2 inhibitors did however show a significant decrease in cell 
viability. The T47D/RT cells did not show any TG2 expression even in the presence of 
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doxorubicin and, combination treatments of the cells with TG2 inhibitors and doxorubicin, did 
not show any decrease in the cell viability of T47D/RT cells (Figure 3.11) 
This could imply that TG2 activity caused the MDA MB 231 Clone 16, MCF7/RT and 
SKBR3/RT cells to become more resistant to doxorubicin. Using cell permeable TG2 inhibitors 
that targeted the activity of TG2, the chemoresistance of these breast cancer cell lines against 
doxorubicin could be reduced. High TG2 activity causes these breast cancer cells to become 
more resistance to chemotherapeutic drugs such as doxorubicin. This also shows a positive 
correlation between chemoresistance and TG2 activity/ expression levels. 
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Figure 3.10 Cell viability analyses of breast cancer cell lines in the presence of increasing 
concentrations of doxorubicin 
The breast cancer cells were seeded (3000 cells per well) into 96 well plates and treated over a 
time course of 72 h and treated with increasing concentrations of doxorubicin (0.25, 0.5, 0.75 
and 1μg/ml). After the treatment time course, the cells were analysed by using XTT reagents 
and the relative absorbance was detected as 490nm and 750nm. Untreated cells were taken as 
100% viable.  Data shown above is mean percentage of cell viability + SEM from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA with 
Bonferroni post-hoc test. * p<0.05; **p<0.01.  
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(A) 
 
(B) 
Figure 3.11 (A & B) Detection of cell viability in breast cancer cell lines in the presence of 
doxorubicin and TG2 inhibitors 
The breast cancer cells (3000 cells per well of 96 well plate) were treated with doxorubicin 
(1μg/ml) as well as TG2 inhibitors (R283 {500μM}, R294 {500μM} and Z-DON {50μM}). After 
72 h of treatment, the cell viability of the breast cancer cells were detected by XTT analysis and 
the absorbance was measured at 490 nm and 750 nm. Untreated cells were taken as 100% 
viable.  Data shown above is mean percentage of cell viability + SEM from 3 independent 
experiments (n=3). Statistical analysis was performed using ANOVA with Dunnett’s post-hoc 
test. * p<0.01 between untreated and treated cells; # p<0.01 between cell groups.  
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3.3.2.6     Cell viability analysis of breast cancer cell lines in the presence of 
cisplatin 
The MDA MB 231 Clone 16 and MCF7/RT cells have been shown to be resistant to 
doxorubicin, as depicted in Figure 3.10. To verify whether the increased TG2 activity and 
expression within these cells would confer chemoresistance to other chemotherapeutic agents, 
the cell viability of these breast cancer cell lines in the presence of cisplatin was tested .  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT were treated with 
increasing concentrations (0.25μg/ml, 0.5μg/ml and 1μg/ml) of cisplatin for time courses of 24 
and 48 h. The cell viability of the breast cancer cells was detected as described previously in 
Section 2.2.13.  
Even though the MDA MB 231 Clone 16 and MCF7/RT cells were shown to have resistance 
against doxorubicin, treatment with only 0.25μg/ml of cisplatin for a time period of 24 h 
showed extremely low cell survival rates. The TG2-null MCF7/WT and MDA MB 231 WT 
cells were also very susceptible to treatment with low concentrations of cisplatin. As the results 
indicated, the high TG2 and TG2-null cells illustrated similar susceptibility to cisplatin, 
suggesting that chemoresistance against cisplatin in these breast cancer cell lines may be 
independent of TG2 expression and activity (Figure 3.12). 
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(A)
 
(B) 
Figure 3.12  Cell viability analysis of breast cancer cell lines in the presence of increasing 
concentrations of cisplatin over a time course 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells (3000 cells / 
well in a 96 well plate) were treated with increasing concentrations of cisplatin (0.25, 0.5, 
1μg/ml) over a time course. After 24 h and 48 h, the cell viability of the breast cancer cells were 
analysed by XTT analysis as introduced in Section 2.2.13. Untreated cells were taken as 100% 
viable.  Data shown above is mean percentage of cell viability + SEM from 3 independent 
experiments (n=3).  
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3.3.3    Inhibition of TG2 using TG2 specific siRNA  
3.3.3.1   Susceptibility of breast cancer cell lines treated with TG2 specific siRNA 
in the presence of doxorubicin  
To verify whether decreasing the expression of TG2 in breast cancer cell lines conferred them 
more susceptible to doxorubicin, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT 
and MCF7/RT cells were treated with doxorubicin (1μg/ml) after transfection with TG2 specific 
siRNA. The viable cells were determined using the XTT assay as detailed above in Section 
2.2.13. As illustrated in Figure 3.13, the MDA MB 231 Clone 16 and MCF7/RT cells 
demonstrated a significant decrease in their cell viable numbers, on being treated with a 
combination of doxorubicin and TG2 specific siRNA, TGM2-6 (ii), as compared to the cells 
treated only with doxorubicin. Decreasing the expression of TG2 using TG2 specific siRNA, 
resulted in the decrease of the chemoresistance against doxorubicin in the high TG2 expressing 
cell lines.  
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Figure 3.13   Cell viability of breast cancer cells after treatment with doxorubicin and 
TG2-specific siRNA 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT (3000 cells per well 
of 96 well plate) cells were treated with TG2 specific siRNA for 48 h (final concentration of 
100nm) and doxorubicin (1μg/ml) for a time course of 72 h after which the viable cells were 
detected using XTT analysis. Global negative siRNA control was used as the negative control. 
Untreated cells were taken as 100% viable.  Data shown above is mean percentage of cell 
viability + SEM from 3 independent experiments (n=3). Statistical analysis was performed 
using ANOVA with Dunnett’s post-hoc test. * p<0.01 between cells transfected and non-
transfected with siRNA in the presence of doxorubicin. # p<0.05 between cell groups.  
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3.3.3.2    TG2 expression and activity decreases on treating the breast cancer cell 
lines with TG2 siRNA2  
3.3.3.2.1 The inhibitory effect of TG2 targeting siRNA on TG2 expression  
TG2 specific targeting siRNA were used to inhibit the expression of TG2 in the MDA MB 231 
WT, MDA MB 231 Clone 16, and MCF7/WT and MCF7/RT cell lines as introduced in Section 
3.2.5. After 48 h of incubation with the siRNA (final concentration of 100nM), the cytoplasmic 
and nuclear fractions were collected and Western blotting was performed to detect the presence 
of TG2 antigen in the cellular fractions (Sections 2.2.2-2.2.6). As shown, no effect of the 
control global negative siRNA was found on the expression of TG2. Treating the TG2 
expressing MDA MB 231 Clone 16 and MCF7/RT cell lines with TGM2-6 (ii) and TGM2-1 (i) 
exhibited significant reduction in the endogenous TG2 expression of these breast cancer cell 
lines (Figure 3.14).   
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Figure 3.14 Analysis of the expression of TG2 in MDA MB 231 Clone 16 and MCF7/RT 
cells in the presence of different TG2 specific siRNA. 
The MDA MB 231 Clone 16 and MCF7/RT cells were (5x10
5
 cells/well) seeded into 6- well 
plates and treated with TG2 specific siRNA (final concentration of 100nM) for 48 h, after which 
the cytoplasmic fractions of the MDA MB 231 Clone 16 and MCF7/RT cells were analysed for 
the relative TG2 expression. Global negative siRNA was used as the negative control. Anti-α-
Tubulin was used as the marker for equal loading of protein. (A&C) The western blot data 
shown is representative of three independent experiments (n=3). (B&D)  Densitometry analysis 
was performed using image J and is the mean densitometry of three blots + SEM. * p<0.05.  
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3.3.3.2.2 The inhibitory effect of TG2 targeting siRNA on TG2 whole cell lysate 
activity.  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were 
analysed for differences in the TG2 activity in their whole cell lysate on being treated for 48 h 
with various TG2 specific siRNA as described previously in Section 3.2.5. The TGM2-6 (iii) 
demonstrated the most significant decrease in the whole cell lysate TG2 activity of the MDA 
MB 231 Clone 16 and MCF7/RT cells, followed by TGM2-1 (i), which seems to be consistent 
with the decrease in the TG2 expression within these cells as showed in the western blot (Figure 
3.15). These results suggest that inhibiting the expression of TG2 using TG2 specific siRNA 
consequently reduces the whole cell lysate TG2 activity of the MDA MB 231 Clone 16 and 
MCF7/RT breast cancer cell lines.  
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Figure 3.15 Investigation of TG2 whole cell lysate activity in the presence of TG2-specific 
siRNA 
The whole cell lysates of MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
after treatment with 100nM of TG2 specific siRNA for 48 h were collected and analysed for the 
TG2 activity as described in Section 2.2.11  by Biotin-X- Cadaverine incorporation into 
fibronectin. Positive control (50 ng/ml gplTG + 10mM  CaCl2) was taken to be 100% TG2 
activity (1.29574±0.199473). Data shown above is mean percentage TG2 activity + SEM from 
3 independent experiments (n=3). Statistical analysis was performed using ANOVA with 
Dunnett’s post-hoc test. * p<0.05 between cells transfected and non-transfected with siRNA. # 
p<0.05 between cell groups.   
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3.3.4     Transfection of TG2 plasmid into TG2-null breast cancer cell lines  
3.3.4.1   Susceptibility of MCF7/WT and SKBR3/WT cells to G418 
Previous studies have shown that when TG2-null cell lines were transfected with TG2, their 
chemoresistance against chemotherapeutic drugs increased significantly (Verma A, 2006) To 
verify this, the TG2 null MCF7/WT and SKBR3/WT breast cancer cell lines were transiently 
transfected with TG2 plasmid and a Vector control plasmid.  For the establishment of the 
transiently transfected cell lines, MCF7/WT and SKBR3/WT cell lines were cultured in a range 
of G418 concentrations (250μg/ml, 500μg/ml,750μg/ml, 1mg/ml and1.5mg/ml) and used to 
identify the lowest possible concentration that would induce at least about 80% of cell death 
within 48-72 h as introduced in Section 2.2.1.6. The resulting killing curve suggested that the 
concentration of 500μg/ml of G418 was the optimal concentration for the selection of MCF7 
and SKBR3 TG2 containing clones (Figure 3.16) 
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Figure 3.16 The effect of G418 on TG2 null MCF7 and SKBR3 cell proliferation 
illustrated via XTT assay. 
The TG2-null MCF7/WT and SKBR3/WT cells (3000 cells per well of 96 well plate) were 
cultured with increasing concentrations of G418 (250μg/ml, 500μg/ml, 750μg/ml, 1mg/ml and 
1.5 mg/ml). After 24 h, 48 h and 72 h of incubation with G418,  XTT assay was conducted and 
absorbance was measured at 490nm and 750nm using a plate reader. Untreated cells were 
taken as 100% viable.  Data shown above is mean percentage of cell viability + SEM from 3 
independent experiments (n=3).  
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3.3.4.2   Transfecting breast cancer cell lines with TG2 plasmid increased TG2 
activity and expression.  
The MCF7 and SKBR3 cells were transiently transfected with TG2 and empty vector control as 
introduced in Section 2.2.1.6 and grown in cell medium supplemented with 500μg/ml of G418 
to select the transfected cells. For all subsequent experiments performed, the transfected cells 
were maintained with 250μg/ml of G418 in the cell culture medium. The effect of the 
transfection was studied by detecting the levels of TG2 expression via Western Blotting. In the 
MCF7/WT, SKBR3/WT, MCF7 and SKBR3 cells transfected with empty vector plasmid, TG2 
antigen was not detected by Western Blot in the cytoplasmic fractions as demonstrated in 
Figure 3.17.  After transfecting the cells with TG2 carrying plasmid, high levels of TG2 antigen 
was detected using a TG2 specific (TG100) monoclonal antibody against TG2. These results 
prove the successful establishment of the TG2 transfected MCF7 and SKBR3 cell lines, which 
provide an ideal model to investigate the role of endogenous TG2 in the chemoresistant process 
against doxorubicin, since the potential influence of exogenous TG2 was ruled out in the 
previous Section. The SKBR3 cells transfected with the TG2 plasmid were also treated with 
cell permeable inhibitors, R283 and Z-DON. Both the cell permeable inhibitors knocked down 
TG2 expression significantly in these cell lines (Figure 3.18) 
In order to confirm the results from the Western blotting of the presence of the TG2 antigen 
within the TG2 transfected MCF7 and SKBR3, whole cell lysate TG2 activity was measured 
via the biotinylated  cadaverine incorporation assay as described in Section 2.2.11. As 
illustrated in Figure 3.19, the whole cell lysate TG2 activity was only detected in the TG2 
transfected MCF7 and SKBR3 cells but not in the MCF7/WT and SKBR3/WT cells, which 
further confirmed the presence of TG2 activity due to the expression of TG2 plasmid in the 
MCF7 and SKBR3 breast cancer cell lines. Moreover, treating the TG2 transfected MCF7 and 
SKBR3 cells with TG2 inhibitors, R283 and Z-DON, showed a significant decrease in the TG2 
expression as well as TG2 activity within these breast cancer cell lines. These results clearly 
suggest that the transfection of TG2 plasmid into TG2-null MCF7 and SKBR3 cells resulted in 
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the endogenous expression and activity of TG2 in the cytoplasmic fractions of the breast cancer 
cell lines.  
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Figure 3.17 Detection of TG2 in TG2 transfected MCF7 (A) and SKBR3 (C) cells by 
western blot 
Western blotting was conducted with the cytoplasmic (C) and nuclear (N) fractions to confirm 
the presence of TG2 in the TG2 and empty vector transfected MCF7 and SKBR3 cells using 
Lipofectamine as described in Section 2.2.1.6. The membranes were reprobed with anti-α-
Tubulin antibody to check for equal loading of protein. (A&C) The western blot data shown is a 
representation of three independent experiments (n=3). (B&D) Densitometry analysis was 
performed using Image J and is represented as the mean densitometry of three blots + SEM.                      
* p< 0.05.  
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Figure 3.18 Detection of TG2 in the TG2 transfected SKBR3 cells on being treated with 
TG2 inhibitors by Western blot 
Western blotting was conducted on the cytoplasmic and nuclear fractions of the TG2 and 
Vector plasmid transfected cells, treated with TG2 inhibitors, R283 (500μM) and Z-DON 
(50μM) for 72 h. The membranes were reprobed with anti-α-Tubulin antibody to check for 
equal loading of protein. (A) The western blot data shown is a representation of three 
independent experiments (n=3). (B) Densitometry analysis was performed using image J and is 
represented as the mean densitometry of three blots ± SE. * p<0.05.  
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Figure 3.19 Detection of whole cell lysate TG2 activity in MCF7 and SKBR3 transfected 
breast cancer cell lines. 
The establishment of the TG2 transfected MCF7 and SKBR3 cells was accomplished as 
mentioned in Section 2.2.1.6. The whole cell lysate TG2 activity of these breast cancer cells was 
measured via Biotin-X-Cadaverine incorporation into fibronectin. Positive control (50 ng/ml 
gplTG + 10mM  CaCl2) was taken to be 100% TG2 activity (1.38136±0.23753). Data shown 
above is mean percentage TG2 activity + SEM from 3 independent experiments (n=3). 
Statistical analysis was performed using ANOVA with Dunnett’s post-hoc test. * p<0.01 
between TG2 plasmid transfected cells untreated and treated with TG2 inhibitors. # p<0.01 
between non transfected and TG2 plasmid transfected cells.   
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3.3.4.3    TG2 transfected breast cancer cell lines are more resistant to doxorubicin 
The effect of TG2 expression and activity on the chemoresistant nature of breast cancer cell 
lines was investigated using TG2 transfected SKBR3 cells lines, while the empty vector 
transfected cells were used as the control group. As shown in Figure 3.20, transfecting TG2 into 
SKBR3 cell lines seems to increase the chemoresistance against increasing concentrations of 
doxorubicin. Treating the TG2 transfected SKBR3 with the TG2 activity inhibitors, R283 and 
Z-DON, demonstrated significant decrease in the viable cells in the presence of 1μg/ml of 
doxorubicin (Figure 3.20). These results indicate that the presence of endogenous TG2 
expression is sufficient to confer chemoresistance to breast cancer cell lines and that treating 
these transfected cell lines with TG2 cell permeable inhibitors, facilitates the cell lines 
susceptible to chemotherapeutic drugs such as doxorubicin. This further suggests that the 
presence of TG2 confers chemoresistance to these breast cancer cell lines against doxorubicin. 
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Figure 3.20 Detection of cell viability of TG2-null SKBR3 and MCF7 cells after 
transfection with TG2  
The SKBR3 cells (3000 cells / well in a 96 well plate) that were transfected as previously 
described (Section 2.2.1.6) were analysed by XTT in the presence of doxorubicin (1μg/ml) along 
with the cell permeable TG2 inhibitors, R283 (250μM) and Z-DON (25μM) to check for 
chemoresistant nature of the TG2 transfected cells. These transfected cells were then 
subsequently analysed by the XTT assay. Untreated cells were taken as 100% viable.  Data 
shown above is mean percentage of cell viability + SEM from 3 independent experiments (n=3). 
Statistical analysis was performed using ANOVA with Bonferroni post-hoc test. * p<0.01 
between TG2 plasmid transfected cells treated with and without inhibitors in the presence of 
doxorubicin.  
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3.4   DISCUSSION 
Tumour progression and drug resistance creates a key clinical obstacle in the treatment of breast 
cancer. Understanding the molecular mechanisms that underlie the development of the 
metastatic phenotype and drug resistance is crucial for the development of effective therapies 
against breast cancer treatment (Mehta, et al. 2004). The above findings provide evidence that 
TG2 expression and activity is up-regulated in drug resistant breast cancer cells. Therefore, 
increased expression and activity of TG2 may serve as a prognostic marker for drug resistant 
tumours and play an important role in the establishment of these phenotypes. 
The MDA MB 231 Clone 9 and MDA MB 231 Clone 16 cells were derived from the parental 
MDA MB 231 as described previously by Mehta et al. (2004). The MDA MB 231 WT cells did 
not express any TG2 while the clones, MDA MB 231 Clone 9 and MDA MB 231 Clone 16, 
isolated from the metastatic parent cell line MDA MB 231, display low and high TG2 
expression respectively . It should be noted that the MDA MB 231 WT cells obtained from 
Aston University did not express any endogenous TG2 which was contradictory to the results 
published by Mehta et al. in 2004 (Mehta, et al. 2004). However, the chemosensitive nature of 
these MDA MB 231 WT cells in the presence of doxorubicin was similar to what was observed 
by Mehta et al. (Mehta, et al. 2004). Following treatment with the TG2 cell permeable 
inhibitors (R283 and Z-DON), a clear and significant decrease was observed in the endogenous 
TG2 expression, of the high TG2 and chemoresistant breast cancer cell line. This is agreement 
with the data obtained from the Biotin -X- Cadaverine Incorporation assay, where the 
inhibitors, R283 and Z-DON, illustrated significant reduction in the TG2 whole cell lysate and 
cell surface activity of MDA MB 231 Clone 16. 
The MCF7/RT cell line was derived from the parental MCF7/WT cells by culturing the TG2-
null cell line in the presence of increasing concentrations of doxorubicin (0.25, 0.5, 0.75 and 
1μg/ml). The MCF7 cells illustrate an increase in TG2 expression, as the cells begin to gain 
resistance to 0.75 μg/ml of doxorubicin. The TG2 expression further increases when the 
doxorubicin concentration was increased to 1μg/ml, thus ensuring that the MCF7/RT cell lines 
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derived did express significant levels of TG2 protein expression as well as TG2 whole cell 
lysate activity. Similar to the MDA MB 231 Clone 16 cells, the MCF7/RT cells also, became 
more susceptible to doxorubicin treatment, on being treated with the cell permeable TG2 
activity inhibitors. This chemosusceptible nature of the MCF7/RT cells could be attributed to 
the decrease observed in the endogenous TG2 expression and activity levels. 
MDA MB231 and MCF7 breast cancer cell lines are adenocarcinomas that are cancers of the 
epithelial tissue that originated from the mammary gland. The MDA MB 231 breast cancer cell 
line was derived from a metastatic carcinoma, while the MCF7 cell line was derived from an in 
situ carcinoma, which has not yet invaded surrounding tissue (Alkhalaf & El-Mowafy, 2003). 
Clinically, studies have shown that cancers of the MDA MB 231 cell line is much harder to 
treat as compared to the MCF7 cell line as the MDA MB 231 cells are more resistant to 
chemotherapy and even grow exponentially faster. Also, the MCF7 cell line expresses both 
oestrogen as well as progesterone receptors, which is absent in the MDA MB 231 breast cancer 
cells (Sorlie, et al. 2009). Similar to the MDA MB 231 and MCF7 breast cancer cell lines, the 
SKBR3 breast cancer cell line is also an adenocarcinoma derived from metastatic sites.  
Contrary to the above three breast cancer cells, the T47D cell line is of ductal carcinoma origin 
(Trempe, 1976). This could account for the difference in chemoresistance patterns as well as 
TG2 expression between the T47D and the other three breast cancer cell lines.  
It should be further noted that the expression of endogenous TG2 protein and activity in the 
chemoresistant breast cancer cells, was confined to the cytoplasmic fraction of these cells. This 
was verified using in situ FITC-cadaverine incorporation and immunocytochemistry for TG2 
antigen respectively. The majority of the TG2 activity and expression observed in the MDA 
MB 231 Clone 16 and MCF7/RT cells, was localized to the cytoplasmic fractions with no TG2 
activity or expression detected in the nuclear fractions  
The SKBR3/RT and T47D/RT breast cancer cell lines were derived from the parent 
SKBR3/WT and T47D/WT using the same method as the MCF7/RT cell lines were obtained. 
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The SKBR3 cell line does not express any TG2, till the cell lines show resistance to1μg/ml of 
doxorubicin. The SKBR3 cells resistant to doxorubicin concentrations lower than 1μg/ml do not 
demonstrate any TG2 expression. Conversely, the T47D cells derived that are known to be 
resistant to 1μg/ml of doxorubicin, do not express any TG2 protein. This could suggest that the 
mechanism of chemoresistance in the T47D breast cancer cell lines could be independent of 
TG2 function. These results were supported by previous studies that have demonstrated  that, 
independent of their type and source, cancer cells selected out for resistance against chemo 
therapeutic drugs display only a  moderate increase in TG2 levels (Budillon, et al. 2013) 
Based on previous observations and current data that breast cancer cells, resistant to 
chemotherapeutic drugs, express high levels of TG2, it can be speculated that TG2 may be 
protecting cancer cells from chemically or drug induced apoptosis. A reduction in the levels of 
TG2, by transfection with TG2-specific siRNA was shown to reduce chemoresistance in MDA 
MB 231 Clone 16 and MCF7/RT cell lines.  Conversely, transfecting  TG2  plasmid into TG2-
null MCF7 and SKBR3 breast cancer cell lines, increased chemoresistance against doxorubicin, 
which can be reversed by treatment with TG2 cell permeable inhibitors (R283 and Z-DON),  
which clearly suggests that TG2 plays a major role in the acquisition of chemoresistance. This 
has been shown in PC-14/ADR lung cancer cells as well, where the reduction in TG2 levels due 
to transfection with TG2 specific antisense can reverse the drug resistance (Han & Park, 1999) 
In a study conducted by Jiang et al. in 2003, to identify the metastasis-associated proteins using 
proteomic analysis, TG2 was observed to be one of the eleven proteins that were amplified 
selectively in metastatic human lung cancer (Jiang, et al. 2003a). Comparable, to these findings, 
comprehensive research of more than 30,000 genes using three different methods suggested that 
TG2 was one of the most prominently expressed genes in pancreatic tumours (Iacobuzio-
Donahue, et al. 2003).Treating cancer cells with EGF induced the expression of TG2 and 
subsequently subverted apoptosis induced by doxorubicin (Antonyak, et al. 2004). These above 
studies clearly implicate TG2 to be playing a major role in the acquisition of chemoresistance 
by cancer cells. 
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Founded on the information and results attained this chapter, it can be speculated that TG2 is a 
very promising therapeutic target to reverse chemoresistance in breast cancer cells. With respect 
to this, the use of TG2 specific siRNA and TG2 cell permeable activity inhibitors, to silence the 
endogenous TG2 expression and activity holds great promise in developing new therapeutics 
required to overcome drug resistant in metastatic cancer cells.  
These findings of increased TG2 levels in drug resistant breast cancer cells have amplified 
interest towards understanding the contributions of TG2 in the development of chemoresistance. 
TG2 is reputed to cause the constitutive activation of the NFκB and FAK/PI3K/AKT cell 
survival signalling pathways (Mehta, et al. 2004) the next chapter will concentrate on 
elucidating the mechanisms behind the conferment of drug resistant phenotype by TG2 in breast 
cancer cell lines. Individually or collectively, these pathways have been known to confer 
resistance to chemotherapy by avoiding autophagic or apoptotic death (Mehta, et al. 2010). This 
increased threshold of cancer cells to undergo apoptosis, allows them to display resistance 
against numerous anticancer drugs as well as to survive and proliferate successfully in the 
stressful microenvironment following metastasis to foreign tissues. TG2 thus represents a 
crucial target for further investigation in order overcome chemoresistance in breast cancer cells.  
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4. TG2 activity results in aberrant 
NFκB activation through an 
intracellular mechanism 
4. 1 INTRODUCTION: 
The previous chapter provides evidence that the increased expression and activity of TG2 can 
promote survival, growth and chemoresistance of breast tumour cells and as such TG2 could 
represent a potential therapeutic target to provide improved results for patient outcomes. 
Deciphering the molecular mechanisms that supports the development of metastasis and drug 
resistance in cancer cells can offer new targets for the treatment of disease.   
The transcription factor, nuclear factor-kappaB (NFκB) is known to play a crucial role in the 
regulation of apoptosis, cell growth and metastatic functions. Even though the constitutive 
activation of NFκB has been observed in various cancers, the molecular mechanisms that result 
in such an activation remain unknown (Nakanish & Toi, 2005). On the basis of previous studies 
done, metastatic and drug resistant cancers express very high levels of TG2 which can confer 
chemoresistance to cancer cells (Antonyak, et al. 2004; Mangala & Mehta, 2005). It could 
therefore be hypothesized that TG2 may contribute to the constitutive activation of NFκB. 
Many reports suggest that the over expression of TG2 is linked to the constitutive activation of 
NFκB (Mann, et al. 2006). Over expression of TG2 is concurrent with constitutive NFκB 
activity in tumour cell lines. Activation of TG2 results in the activation of NFκB and 
conversely, the down regulation of TG2 using small interfering RNA decreases the activation of 
NFκB. This may point to TG2 inhibition as an alternate therapy to prevent the constitutive 
activation of NFκB and leave cancer cells sensitized to effective anti-cancer therapy (Mehta, et 
al. 2010).  
In pancreatic and breast cancer cells, TG2 is known to activate NFκB by the cross linking of the 
IκBα subunit, which leads to the polymerization of IκBα and the subsequent translocation of the 
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NFκB subunit to the nucleus. This polymerization of IκBα is dependent on the enzymatic 
activity of TG2 which leads to the activation of NFκB that is sustained and constitutive (Kim, et 
al. 2006 ; Mann, et al. 2006). EMSA and Western blot studies conducted on cancer cell lines 
with varying TG2 expressions demonstrated that in the presence of increased levels of TG2, 
there was a parallel increase in the activation as well as enzymatic activity of NFκB. With these 
results, it was hypothesized that there could be a direct correlation between the expression 
levels of TG2 and the activation of NFκB in numerous cancer cells (Mann, et al. 2006).   
In spite of the noteworthy advances in primary treatment of breast cancer, prevention and 
prediction of metastasis and drug resistance remains a discouraging clinical problem. To 
improve progress in the field of chemotherapy, it is necessary to understand the basic molecular 
mechanism that is known to regulate the progression of a primary tumour to a metastatic 
disease. Several reports as well as results from Chapter III have clearly suggested that tissue 
transglutaminase (TG2) plays an important role in the development of metastatic and drug 
resistant cancer phenotype (Cao, et al. 2008 ; Grigoriev & al., 2001  ; Kim & al., 2006) 
 Mehta et al. (2004) isolated two clones, MDA MB 231 Clone 9 and Clone 16 from a metastatic 
parental breast cancer cell line, MDA MB 231 Wild Type based on their different TG2 
expression levels and sensitivity to doxorubicin  (Mehta, et al. 2004). The highly drug resistant 
clone, MDA MB 231 Clone 16 demonstrated almost a 12-15 fold increased expression of TG2 
as compared to the drug sensitive MDA MB 231 Clone 9. Results obtained in the previous 
chapter (Chapter III),  have illustrated that the parental MDA MB 231 WT obtained from Aston 
University did not show any detectable endogenous TG2 expression and activity. The MDA 
MB 231 Clone 9 demonstrated very low TG2 expression and activity while the MDA MB 231 
Clone 16 cells illustrated the highest TG2 expression and activity of all the breast cancer cell 
lines.  Prior evidence has suggested that without any relation to the type and source, the cancer 
cells that have been selected out for the chemoresistance exhibited an immoderate increase in 
the levels of TG2 (Verma, et al. 2006 ; Chhabra, et al. 2009). On the basis of the current 
observations made and the previous published results, chemoresistant breast cancer cells 
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express high levels of TG2 protein, which may imply that TG2 can protect breast cancer cell 
lines from apoptosis induced by stress as well as chemotherapy (Mehta, et al. 2004).  
The molecular details behind the regulation of TG2 by NFκB (Rel A/p65) has been initially 
elucidated in Raw cells (with and without LPS treatment) using a ChIP based promoter. The 
ChIP promoter using Rel A/p65 specific antibody showed that Rel A/p65 was recruited to the -
630 and -839 region of the TGM2 gene promoter which is enhanced further in the presence of 
LPS. Parthenolide effectively blocked the binding of the Rel A/p65 to this region of the TGM2 
promoter (Ghanta, et al. 2011). 
Increased TG2 activity was also known to trigger NFκB activation by causing the 
polymerization of the NFκB inhibitor, IκBα, as opposed to the stimulation of IKK (Kim, 2006). 
This polymerization of the IκBα subunit causes the consecutive activation of NFκB, which 
would result in the activation of target genes which are involved in inflammatory process 
(Falasca, et al. 2008 ; Kim, 2006). The lack of TG2 is an actual advantage, during the endotoxic 
shock as this deficiency seems to be related with the activation of NFκB which will allow the 
restoration of the immunological equilibrium (Ghanta, et al. 2011) 
In view of the above observations, studies in this chapter will attempt to determine how the 
cross linking activity of TG2 may be responsible to promote oncogenic and drug resistant 
mechanisms in breast cancer cell lines. Evidence will be provided to understand the mechanistic 
detail behind the constitutive activation of NFκB by TG2 in breast cancer cells and how this 
aberrant activity of NFκB will lead to a chemoresistant phenotype. Studies will also be done to 
comprehend whether inhibiting TG2 cross linking activity using cell permeable and cell 
impermeable inhibitors and inhibition of mRNA TG2 expression will down regulate the 
constitutively activated NFκB and consequently decrease chemoresistance in breast cancer cell 
lines.  
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4.2    METHODS 
4.2.1    Sub-cellular fractionation of breast cancer cell lines: 
The whole cell lysate, cytoplasmic and nuclear fractions of the breast cancer cell lines were 
collected as described in detail in Section 2.2.2.  
4.2.2   Western Blot analysis: 
The subcellular components of the breast cancer cells were analysed for their protein 
concentration and 50μg of protein from each fraction was loaded onto an SDS-Page gel and 
then transferred onto a nitrocellulose membrane. The various primary antibodies and the 
complementary secondary antibodies were used to immuno probe the nitrocellulose membrane 
after appropriately blocking the membrane. The membranes were then developed using ECL 
from GE Healthcare and then subsequently exposing them to film (Sections 2.2.3-2.2.6). To 
ensure that the changes observed were significant, the results described in this study have been 
obtained from at least three independent experiments. Using anti-α-Tubulin as a loading marker 
for the cytoplasmic fractions and anti-Lamin-A as a loading marker for the nuclear fractions, 
equal loading of proteins was ensured. With the help of Image J software, the reported increase/ 
decrease in protein band densities were statistically assessed after densitometry analysis.  
4.2.3   NFκB Activity Assay: 
The NFκB activity assay was performed using the NFκB SEAPorter assay kit from IMGENEX. 
The assay kit includes pNFκB/SEAP plasmid that expresses the SEAP protein under the control 
of the NFκB promoter.  
The protocol used was in accordance with the manufacturer’s protocol (Section 2.2.12) .  
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4.2.4   Detection of the interaction between Rel A/ p65 and TG2 in the nucleus via 
co-immunoprecipitation 
Co-immunoprecipitation assays were performed to detect the interaction between Rel A/ p65 
and TG2 in the nucleus of high and no TG2 expressing breast cancer cell lines as introduced in 
Section 2.2.8. The rabbit anti-Rel A/ p65 polyclonal antibody and protein A beads were used to 
pull down the Rel A/ p65 immuno-complex in the pre-cleared (with Protein A beads) nuclear 
fraction samples. Western blotting (Section 2.2.3-2.2.6) was used to detect the presence of Rel 
A/ p65 dimers and monomers in the nucleus as well as the presence of TG2 in the immune 
complex using anti-TG2 monoclonal antibody (Cub 7402) (1:1000).  
4.2.5   SiRNA transfection: 
Rel A/p65 specific targeting siRNA was used to inhibit the expression of Rel A/p65 in the 
breast cancer cell lines using Lipofectamine 2000 transfection method, according to the 
manufacturers' instructions (Invitrogen). Three different siRNA sequences that target human 
Rel A/p65 were obtained from Qiagen. The sequences are listed as below: 
Hs_RELA_5    AAGATCAATGGCTACACAG (denoted as (i))  
Hs_RELA_7   CCGGATTGAGGAGAAACGT   (denoted as (ii))  
Hs_RELA_8    ATGGAGTACCCTGAGGCTA (denoted as (iii))   
Universal negative control siRNA was also used to treat the cells as a control, to ensure that any 
changes observed were due to the action of the siRNA and no other factors relating to 
transfection procedure. The lyophilized siRNA was dissolved in 100 μl of sterile DNase / 
RNase free water to obtain a 10μM stock solution which was then stored at -20oC. Prior to 
transfection, the breast cancer cell lines were seeded in plates and allowed to become 60-70% 
confluent, overnight. The cells were then washed with PBS, pH 7.4 and the medium was 
replaced with pre-warmed fresh complete growth medium. The siRNA were diluted in serum 
free growth medium for the siRNA to reach a final concentration of 100nM. The siRNA were 
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then pre-incubated with Lipofectamine 2000 in serum-free medium at room temperature for 15-
20 min for the transfection complex to form. The complex was then added drop wise onto the 
cells while gently swirling the plate to make sure that the transfection complex was uniformly 
distributed. 48 h after transfection, the breast cancer cells were analysed for the Rel A/p65 
expression in the subcellular fractions, relative NFκB activity levels and TG2 activity and 
expression levels in the cells.  
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4.3    RESULTS: 
4.3.1 Aberrant Rel A/p65 expression and activity in the nuclear fractions of breast 
cancer cell lines that exhibit high levels of TG2. 
4.3.1.1 Decreased NFκB activity in breast cancer cell lines in the presence of TG2 
inhibitors 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT, MCF7/RT, SKBR3 and MCF7 
cells transfected with TG2 plasmid and empty vector control plasmid were analysed for the 
relative NFκB activity levels in the presence of various TG2 inhibitors.  
The NFκB SEAPorter Assay is designed to measure the level of NFκB activation using secreted 
alkaline phosphatase in the medium as a read out. The NFκB/SEAP plasmid expresses SEAP 
protein under the control of the NFκB promoter. Ligands and inhibitors added to the cells that 
alter NFκB activity can be screened for by measuring the SEAP present in the cell culture 
medium (Section 2.2.12).  
The TG2 expressing MDA MB 231 Clone 16, MCF7/RT and TG2 transfected SKBR3 and 
MCF7 illustrated a higher activation of NFκB as compared to the MDA MB 231 WT, 
MCF7/WT and empty vector transfected SKBR3 and MCF7 cells. On treating the MDA MB 
231 Clone 16, MCF7/RT and TG2 transfected SKBR3 and MCF7 cells with the TG2 cell 
permeable inhibitor, Z-DON, maximum inhibition of NFκB activity was observed, followed by 
R283. The cell impermeable TG2 specific inhibitor, R294 did not show any significant decrease 
in NFκB activity compared to the cell permeable inhibitors (Figures 4.1). This could imply that 
the activation of NFκB in these MDA MB 231 Clone 16, MCF7/RT and TG2 transfected 
SKBR3 and MCF7 cells could be due to the role of intracellular activity of TG2. These cell 
permeable TG2 inhibitors illustrated a significant difference in both the TG2 activity, TG2 
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expression and subsequently the basal NFκB activity levels measured in these breast cancer cell 
lines.  
The low and no TG2 expressing breast cancer cell lines (MDA MB 231 WT, MCF7/WT, 
SKBR3/WT, SKBR3/RT, T47D/WT, T47D/RT and empty vector transfected SKBR3 and 
MCF7  cells) that have been treated with the TG2 inhibitors, did not show any significant 
change in the NFκB activity (Figures 4.1). This could be attributed to the lack of TG2 
expression as well as TG2 activity within these breast cancer cell lines. 
Also, on treating the high TG2 and TG2-null breast cancer cell lines with TNF-α, the NFκB 
activity increased significantly. Furthermore, a considerable decrease was seen in the NFκB 
activity of these breast cancer cells on being treated with SN50 which is an NFκB inhibitor that 
inhibits the translocation of NFκB into the nucleus. TNF-α and SN50 were used as the positive 
and negative controls respectively to determine the efficiency of the assay. 
These results strongly indicate that the constitutive activation of NFκB in breast cancer cell 
lines can be attributed to the transamidating activity of TG2. In the absence of TG2, the SKBR3 
and MCF7 cells illustrate low levels of NFκB activity while transfecting these cell lines with 
the TG2 plasmid demonstrated an increase in NFκB activity levels, which could be 
constitutively induced due to the presence of TG2. This increased NFκB activity in the high 
TG2 breast cancer cell lines could be reduced significantly in the presence of cell permeable 
TG2 activity inhibitors.  
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(C) 
Figures 4.1 (A, B and C) Analysis of NFκB activity levels in breast cancer cell lines in the 
presence of TG2 activity inhibitors 
The NFκB activity of the breast cancer cell lines were analysed using the NFκB/SEAP Reporter 
Assay. 5x10
5
 cells of each breast cancer cell line was seeded into 6-well plates and left 
overnight. The next day the cells were transfected with NFκB/SEAP plasmid.  48 h after 
transfection, the breast cancer cell lines were treated with TG2 inhibitors, R283 (500μM), R294 
(500μM) and Z-DON (50μM). The supernatant was then collected for the SEAP assay as 
described in detail in Section 2.2.12. Data shown is mean concentration of SEAP + SEM from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA with 
Dunnett’s post-hoc test. * p< 0.05 between untreated and TG2 inhibitor treated cells. # p<0.05 
between cell groups.  
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4.3.1.2 Detection of Rel A/p65 expression in the cytoplasmic and nuclear fractions 
of breast cancer cell lines in the presence of TG2 inhibitors. 
The decrease observed in the expression of TG2 within the breast cancer cells on treating them 
with TG2 activity inhibitors indicated that another factor may be involved in regulating TG2 
expression within these cells. Also, previous data has shown that TG2 is responsible for the 
constitutive activation of NFκB within these cells (Mann, et al. 2006). The breast cancer cell 
lines were seeded and allowed to become confluent (70-80%) overnight.  After treating the cells 
for 72 h with TG2 inhibitors, the samples were collected and fractionated into their cytoplasmic 
and nuclear fractions as described in Section 2.2.2 and analysed by Western blotting.  
In the western blot data obtained, monomeric Rel A/p65 in the cytoplasm of the breast cancer 
cells at 65kDa was observed.  However, in the nucleus of TG2 expressing MDA MB 231 Clone 
16 and MCF7/RT cell lines as well as TG2 transfected MCF7 and SKBR3 cells, the Rel A/p65 
band was observed at a higher molecular higher weight. The Rel A/p65 in the nucleus appears 
to be approximately 130kDa in size which may indicate that this could be a high molecular 
weight form of Rel A/p65. Also, this high molecular weight Rel A/p65 observed in the nuclear 
fractions could be representative of a cross linked form of RelA/p65 (Figure 4.2) as a result of 
TG2 activity within these high TG2 breast cancer cell lines. Treating the MDA MB 231 Clone 
16, MCF7/RT and TG2 transfected SKBR3 and MCF7 breast cancer cell lines with cell 
permeable TG2 activity inhibitors (R283 and Z-DON) demonstrated a considerable decrease in 
the high molecular weight Rel A/p65, which was not observed on treatment with R294 (cell 
impermeable TG2 activity inhibitor). The decrease observed in the high molecular weight Rel 
A/p65 form in the nucleus is concurrent with the decrease in the TG2 expression in the 
cytoplasmic fraction of MDA MB 231 Clone 16, MCF7/RT and TG2 transfected SKBR3 and 
MCF7 cell lines. Also, as demonstrated in Chapter 3, the TG2 activity of the MDA MB 231 
Clone 16, MCF7/RT and TG2 transfected SKBR3 and MCF7 cells also decreased on treatment 
with cell permeable TG2 activity inhibitors, R283 and Z-DON. This could imply that 
intracellular TG2 activity is responsible for the constitutive activation of NFκB in these breast 
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cancer cell lines as both the TG2 cell permeable activity inhibitors seem to reduce the 
constitutive activation of NFκB more significantly than the cell impermeable TG2 activity 
inhibitor, R294.   
 The TG2 null MDA MB 231 WT, MCF7/WT and SKBR3/WT cells did not illustrate any high 
molecular weight Rel A/p65 in the nucleus and only a monomeric Rel A/p65 was observed in 
the cytoplasmic and nuclear fractions. Treating these no or low expressing TG2 breast cancer 
cell lines with TG2 inhibitors, does not cause any change in the Rel A/p65 expression within 
these cells. On transfecting the MCF7 and SKBR3 cells with TG2 as introduced in Section 
2.2.1.6, the Rel A/p65 high molecular weight form was observed in the nuclear fractions which 
can be attributed to the expression and activity of TG2 observed within these breast cancer 
cells. The empty vector control plasmid does not induce the expression and activity of TG2 and 
in these cells no high molecular weight Rel A/p65 form was observed (Figure 4.2).  
Even though the MDA MB 231 Clone 9 and SKBR3/RT cells do illustrate low TG2 expression 
and activity, no high molecular weight Rel A/p65 forms were observed in the nuclear fraction. 
Also, treatment with the TG2 inhibitors (R283 and Z-DON) did not demonstrate any difference 
in the cytoplasmic and nuclear expression of Rel A/p65, even though there was a clear decrease 
observed in the TG2 expression in the MDA MB 231 Clone 9 and SKBR3/RT cells. This may 
imply that the amount of TG2 expression levels and activity within breast cancer cell lines was 
crucial to determine if the Rel A/p5 high molecular weight form will be observed in the nuclear 
fraction. Also, these results indicate that high expression and activity of TG2 was essential for 
the formation of the Rel A/p65 high molecular weights in the nucleus.  The breast cancer cell 
lines that have previously been shown to be resistant to doxorubicin, demonstrate high 
expression and activity of TG2 as well as a high molecular weight Rel A/p65 form in the 
nuclear fractions. This aberrant form of Rel A/p65 could therefore be responsible for rendering 
these breast cancer cell lines resistant to doxorubicin as Rel A/p65 has been shown previously 
to confer drug resistance (Kim, et al. 2006) 
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Figure 4.2 (A-R) Analysis of the expression of Rel A/p65 in the cytoplasmic and nuclear 
fractions of breast cancer after treatment with TG2 activity inhibitors using western blot. 
The MDA MB 231 WT (A), MDA MB 231 Clone 16 (C),MDA MB 231 Clone 9 (E), SKBR3/WT 
(G), SKBR3/RT (I), MCF7/WT (K), MCF7/RT (M) and TG2 and vector plasmid transfected 
MCF7 (O) and SKBR3 (Q)  cancer cell lines (1x10
6
 cells per well) were seeded into 60mm 
petridishes and left overnight to become confluent. The next day, the cells were treated with 
R283 (500μM), R294 (500μM) and Z-DON (50μM) for a time course of 72 h. After treatment, 
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the cells were fractionated into the cytoplasmic and nuclear fractions as described in detail in 
Section 2.2.2. The sub cellular fractions were then analysed by western blotting  for the 
expression of Rel A/p65 using rabbit polyclonal anti-Rel A/p65 antibody (1:1000) and anti-TG2 
antibody (Cub 7402; TG100) (1:1000). The membranes were reprobed with anti- Lamin A and 
anti-α-Tubulin antibody to check for equal loading of protein. The breast cancer cells were 
treated with 10ng/ml of TNFα for 24 h and the sub cellular fractions were collected and used as 
the positive control. (A, C, E, G, I, K, M, O & Q) The data shown above is taken from three 
independent experiments (n=3). Differences in expression (B, D, F, H, J, L, N & P) as 
calculated by Image J analysis is representative of the mean densitometry reading obtained 
from three independent experiments + SEM. * p<0.05 
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4.3.1.3 Co-immunoprecipitation of Rel A/p65 and TG2 in the nuclear fraction of 
breast cancer cell lines after treatment with TG2 inhibitors. 
To determine the association between Rel A/ p65 high molecular weights and TG2 in the 
nucleus, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were 
treated with TG2 activity inhibitors R283, R294 and Z-DON. 72 h after treatment, the nuclear 
fractions of these cells were collected as described in Section 2.2.2. Using anti- Rel A/p65 
antibody and Protein A beads, the Rel A/p65 complex was immunoprecipitated out as described 
in Section 2.2.8. 
In the nuclear fractions of the MDA MB 231 WT and MCF7/WT cells, only a monomeric form 
of Rel A/p65 (~ 65kDa) was observed with no significant change in the nuclear Rel A/ p65 in 
the presence of TG2 inhibitors. This can clearly be attributed to the absence of TG2 expression 
and activity within these breast cancer cell lines (Figures 4.3). 
On the other hand, in the nuclear fractions of the MDA MB 231 Clone 16 and MCF7/RT cells, 
it was observed that two Rel A/ p65 bands were pulled down using the rabbit polyclonal anti-
Rel A/p65 antibody, a monomeric Rel A/p65 (~65kDa) and a high molecular weight Rel A/p65 
(~130kDa). On treating these breast cancer cells with cell permeable, TG2 inhibitors, the high 
molecular weight Rel A/p65 form decreased significantly, with no change observed in the 
monomeric Rel A/p65 (Figures 4.3). Also, on reprobing the membrane with anti-TG2 antibody, 
no nuclear TG2 expression was observed. This was in correlation to the localization studies 
done in Chapter III, which demonstrated that the expression and activity of TG2 within the TG2 
expressing breast cancer cell lines was primarily concentrated in the cytosol. The cell 
impermeable TG2 inhibitor, R294, failed to show any significant decrease in both the 
monomeric and high molecular weight form of Rel A/p65. These results  suggest that the high 
molecular weight form of Rel A/p65 observed in the nucleus fractions was as a result of 
cytosolic TG2 cross linking activity, as TG2 expression is completely absent in the nucleus of 
these breast cancer cell lines.  
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Figure 4.3 (A-H) Detection of the interaction between TG2 and Rel A/p65 in the nuclear 
fractions of breast cancer cell lines 
The MDA MB 231 WT (A), MDA MB 231 Clone 16 (C), MCF7/WT (E) and MCF7/RT (G) cells 
(1x10
6
 cells/ well) were seeded into 60 mm petridishes and left overnight. The next day these 
breast cancer cell lines were treated with R283 (500μM), R294 (500μM) and Z-DON (50μM) 
over a time course of 72 h. After treatment, the breast cancer cells were fractionated into the 
cytoplasmic and nuclear fractions as described in Section 2.2.2. The nuclear fractions of the 
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breast cancer cell lines were used in co-immunoprecipitation experiments as introduced in 
Section 2.2.8. After collection of the nuclear fraction and pre-clearing using protein A beads, 
rabbit anti-Rel A/p65 polyclonal antibody (0.5μg/sample) and protein A beads were used to pull 
down the Rel A/ p65 immunocomplex and (A, C, E, &G) western blotting was then used to 
detect the presence of Rel A/p65 (1:1000) and TG2 (1:1000) within the immunocomplex 
collected from the various cell samples (n=3). (B, D, F &H) Differences in expression as 
calculated by Image J analysis is representative of the mean densitometry reading obtained 
from three independent experiments + SEM. * p<0.05 
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4.3.2 Expression of NFκB family members in breast cancer cell lines 
4.3.2.1    Western blot detection of p105/p50 in breast cancer cell lines in the 
presence of TG2 inhibitors. 
In order to determine if the expression and activity of TG2 in breast cancer cell lines affected 
the status of the other NFκB family members in these breast cancer cell lines, the MDA MB 
231 Wild Type and MDA MB 231 Clone 16 were analysed by western blot (introduced in 
Sections 2.2.4-2.2.6) to examine the relative expression of p105/p50 in the cytoplasmic and 
nuclear fractions of the breast cancer cell lines. After 72 h of treating these breast cancer cell 
lines with TG2 activity inhibitors, R283, R294 and Z-DON, the cells were fractionated into the 
cytoplasmic and nuclear fractions (Section 2.2.2).  On analysis of the sub cellular fractions by 
western blotting using anti- p105/p50 antibody (1:500), no difference was observed between the 
TG2 null MDA MB 231 WT and high TG2 expressing MDA MB 231 Clone 16 cells. 
Subsequent treatment of the breast cancer cell lines with the various TG2 inhibitors (R283, 
R294 and Z-DON), failed to demonstrate any significant change in the expression levels of 
p105/p50, both in the cytoplasmic as well as nuclear fraction of the cell lines (Figures 4.4). 
These results clearly indicate that the activity and expression of TG2 within the breast cancer 
cell lines did not have any effect on the expression of p105/p50. Also, this could be indicative 
that the constitutive activation of NFκB members by TG2 did not involve p105/ p50.  
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Figure  4.4   Analysis of p105/p50 in the cytoplasmic and nuclear fractions of breast 
cancer cell lines in the presence of TG2 activity inhibitors by western blot 
The MDA MB 231 WT (A) and MDA MB 231 Clone 16 (C) (1x10
6
 cells/ well) were seeded into 
60 mm petridishes and left overnight. The next day, the cells were treated with R283 (500μM), 
R294 (500μM) and Z-DON (50μM) for a time course of 72 h. After treatment, the cells were 
fractionated into the cytoplasmic and nuclear fractions as described in detail in Section 2.2.2. 
TNF-α and SN50 treated cells were taken as the positive and negative controls respectively. 
(A&C) The sub cellular fractions were then analysed by western blot (Section 2.2.4- 2.2.6) for 
the expression of p105/ p50 using rabbit polyclonal anti-p105/p50 antibody (1:500). The 
membranes were reprobed with anti-α-Tubulin and Lamin A antibody to check for equal 
loading of protein. The data shown is a representation of three independent experiments (n=3). 
(B&D) Differences in expression as calculated by Image J analysis is representative of the 
mean densitometry reading obtained from three independent experiments + SEM.  
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4.3.2.2   Expression of Rel B and c-Rel in the presence of TG2 inhibitors. 
To effectively determine whether TG2 expression and activity had any significant effect on the 
expression of the other NFκB family members, the relative levels of Rel B, c-Rel and p52/p100 
were determined in the whole cell lysate fractions of the MDA MB 231 WT and MDA MB 231 
Clone 16 cells. The WCL fractions of the breast cancer cell lines were collected as described in 
Section 2.2.2 and 50μg of whole cell lysate protein was analysed by western blot using anti-Rel 
B, anti-c-Rel and anti-p52/p100 antibodies (Figure 4.5). The MDA MB 231 WT and MDA MB 
231 Clone 16 cells did not demonstrate any difference in the expression levels of Rel B and c-
Rel. Also, treating these breast cancer cell lines with R283, R294 and Z-DON, did not alter the 
protein levels of Rel B or c-Rel. The MDA MB 231 WT and MDA MB 231 Clone 16 cells did 
not express any p100/p52, which remained unchanged, in the presence of TG2 inhibitors. This 
could signify that the expression and activity of TG2 within breast cancer cell lines only caused 
the constitutive activation of the Rel A/p65 member of the NFκB family and had no effect at all 
on the other family members. 
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Figure 4.5   Analysis of Rel B, c-Rel and p100/p52 in the whole cell lysate fractions of 
breast cancer cell lines in the presence of TG2 activity inhibitors by western blot 
The MDA MB 231 WT and MDA MB 231 Clone 16 (1x10
6
 cells/ well) were seeded into 60 mm 
petridishes and left overnight. The next day, the cells were treated with R283 (500μM), R294 
(500μM) and Z-DON (50μM) for a time course of 72 h. After treatment, the whole cell lysate 
fractions of the breast cancer cells were collected as described in detail in Section 2.2.2. The 
whole cell lysate fractions(50μg protein) were then analysed by (A) western blot (Section 2.2.4- 
2.2.6) for the expression of Rel B, c-Rel and p100/p52 using rabbit polyclonal anti-Rel B 
antibody (1:1000), rabbit polyclonal anti-c-Rel antibody (1:1000) and rabbit polyclonal anti-
p100/p52 antibody (1:1000). The membranes were reprobed with anti-α-Tubulin antibody to 
check for equal loading of protein (n=3). (B) The data shown is a representation of three 
independent experiments. Differences in expression as calculated by Image J analysis is 
representative of the mean densitometry reading obtained from three independent experiments 
+ SEM. 
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4.3.3 Constitutive activation of Rel A/p65 decreased in the presence of TG2 specific 
siRNA 
4.3.3.1 Decreased Rel A/p65 high molecular weight in the presence of TG2 siRNA 
To determine if inhibiting the mRNA expression of TG2 would cause an effect on the formation 
of Rel A/ p65 high molecular weights, the MDA MB 231 Clone 16 and MCF7/RT cells were 
transfected with 100nm of TG2 specific siRNA as well as global negative control siRNA for a 
time course of 48 h as described previously using Lipofectamine (Section 2.2.1.5) After the 
treatment, these cells were collected and fractionated into the cytoplasmic and nuclear fractions 
as explained in Section 2.2.2. Subsequently, western blot was used to detect the presence of Rel 
A/p65 high molecular weights in the nucleus as well as TG2 expression in the cytosolic fraction 
The MDA MB 231 Clone 16 and MCF7/RT cells that have been known previously to express 
high levels of TG2, illustrated a significant decrease in the TG2 expression levels on being 
treated with the two TG2 specific siRNA. Consequently, the Rel A/p65 high molecular weight 
observed in the nuclei of untreated and global negative siRNA treated samples, decreased and a 
monomeric form of Rel A/p65 in the nuclei was seen, on treating the breast cancer cell lines 
with TG2 specific siRNA (Figures 4.6).  
With these results, it may be concluded, that the Rel A/ p65 high molecular weights seen in the 
MDA MB 231 Clone 16  and MCF7/RT  nuclei is an effect of TG2 transamidating activity 
within these cells. Treating these cells with TG2 siRNA shows a decrease in the high molecular 
weight Rel A/ p65 form seen in the nuclei of these cells. There is also a subsequent increase in 
the expression of Rel A/p65 monomers in the nucleus which was previously not observed in the 
MDA MB 231 Clone 16 and MCF7/RT cells on being treated with cell permeable TG2 activity 
inhibitors.  
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Figure 4.6  Analysis of the expression of Rel A/p65 in the cytoplasmic and nuclear 
fractions of breast cancer after transfection with TG2 specific siRNA using western blot.  
TG2 siRNA targeting human TG2 were used to inhibit the mRNA expression of TG2 in the MDA 
MB 231 Clone 16 (A) and MCF7/RT(C) cell lines. 5x10
5
cells (per well) were seeded into 6 well 
plates and left overnight. The next day, the cells were transfected with two TG2 specific siRNA 
(final concentration of 100nm) for a time course of 48 h (Section 2.2.1.5). Global negative 
control siRNA was used as the negative control. After treatment, the cells were fractionated into 
the cytoplasmic and nuclear fractions as described in detail in Section 2.2.2. (A &C) The sub 
cellular fractions were then analysed by western blot for the expression of Rel A/p65 using 
rabbit polyclonal anti-Rel A/p65 antibody (1:1000). The membranes were reprobed with anti- 
Lamin A and anti-α-Tubulin antibody to check for equal loading of protein. The data shown are 
representative westerns from three independent experiments (n=3).  (B&D) Differences in 
expression as calculated by Image J analysis is taken from the mean densitometry reading 
obtained from three independent experiments + SEM. * p<0.05 
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4.3.3.2   NFκB activity decreases in breast cancer cell lines in the presence of TG2 
siRNA 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were assayed 
for the respective NFκB activity levels as described previously in Section 2.2.12. The NFκB 
reporter assay showed that on treating the high TG2 breast cancer cell lines with TG2 siRNA, 
the NFκB activity within these cells decreased considerably. This correlated with the cell 
viability assay in the presence of doxorubicin, wherein the breast cancer cells lost 
chemoresistance to doxorubicin on being treated with TG2 siRNA. These results could indicate 
that the presence of TG2 in these breast cancer cell lines constitutively activates the Rel A/ p65 
subunit of the NFκB family members in an aberrant manner, which decreases on being treated 
with the TG2 specific siRNA. The MDA MB 231 WT and MCF7/WT cells demonstrated very 
low levels of NFκB activity, which remained unchanged on being treated with TG2 specific 
siRNA. This could imply that the aberrant and constitutive activation of Rel A/ p65 observed in 
the MDA MB 231 Clone 16 and MCF7/RT cells was as a result of TG2 expression and activity 
within these breast cancer cell lines. Treatment with TG2 specific siRNA clearly shows a 
significant decrease in the NFκB activity levels in  these breast cancer cells, which is similar to 
the basal levels of NFκB activity observed in the chemosusceptible parent cell lines (Figure 
4.7). 
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Figure 4.7 Analysis of NFκB activity levels in breast cancer cell lines in the presence of 
TG2 specific siRNA. 
The NFκB activity of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cell lines were analysed using the NFκB/SEAP Reporter Assay. 5x105 cells of each breast 
cancer cell line were seeded into 6-well plates. The next day, the cells were transfected with 
NFκB/SEAP plasmid. 48 h after transfection, the breast cancer cell lines were treated with 
TG2specific siRNA (at a final concentration of 100nM). The supernatant was then collected for 
the SEAP assay as described in detail in Section 2.2.12.  Data shown is mean concentration of 
SEAP + SEM from 3 independent experiments (n=3). Statistical analysis was performed using 
ANOVA with Dunnett’s post-hoc test. * p< 0.05 between cells transfected and non-transfected 
with siRNA.  
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4.3.4   Treatment of breast cancer cells with Rel A/p65 specific siRNA 
4.3.4.1   Decreased expression of Rel A/p65 and TG2 in the cytoplasmic and nuclear 
fractions of breast cancer cell lines on being treated with Rel A/p65 specific siRNA  
The MDA MB 231 WT and MDA MB 231 Clone 16 cells were transfected with Rel A/p65 
specific siRNA as described in Section 2.2.1.5 and subsequently fractionated into the 
cytoplasmic and nuclear fractions (Section 2.2.2).  The fractions were then analysed by western 
blotting to detect the presence of Rel A/p65 and TG2. The MDA MB 231 WT  cells 
demonstrated a clear decrease in the Rel A/p65 expression in both the cytoplasmic and nuclear 
fractions on being treated with Rel A/p65 specific siRNA for 48 h. The MDA MB 231 WT cells 
did not express any TG2, which does not change on to transfection with Rel A/p65 specific 
siRNA (Figure 4.8). The MDA MB 231 Clone 16 cells demonstrated a significant decrease in 
the monomeric and high molecular weight Rel A/p65 in the cytoplasm and nucleus respectively 
on being transfected with Rel A/p65 specific siRNA (Figure 4.8).  The TG2 levels in the 
cytoplasm of the MDA MB 231 Clone 16 cells also decreases, subsequent to Rel A/p65 siRNA 
transfection, with the most significant decrease observed with Hs_RELA_5 (i), followed by  
Hs_RELA_7 (ii) and the least decrease was demonstrated by Hs_RELA_8 (iii) (Figure 4.8). 
The global negative control siRNA does not show any difference in the Rel A/p65 expression 
levels in the TG2 expressing and TG2 null breast cancer cell lines. These results seem to imply 
that the expression of TG2 in the MDA MB 231 Clone 16 was dependent on transcriptional 
activity of Rel A/p65. Inhibiting the mRNA expression of Rel A/p65 in the MDA MB 231 
Clone 16 cells resulted in the decrease of TG2 expression within these high TG2 expressing 
breast cancer cells. The membranes were then reprobed with anti-α-Tubulin and anti-Lamin A 
to determine equal loading of protein.  
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Figure 4.8 Analysis of the expression of Rel A/p65 and TG2 in the cytoplasmic and 
nuclear fractions of breast cancer after transfection with Rel A/ p65 specific siRNA using 
western blot.  
Rel A/p65 siRNA targeting human p65 were used to inhibit the expression of Rel A/p65 in the 
MDA MB 231 WT (A) and MDA MB 231 Clone 16 (C) cell lines. 5x10
5
cells (per well) were 
seeded into 6 well plates and left overnight. The next day, the cells were transfected with three 
different Rel A/p65 specific siRNA (final concentration of 100nM) for a time course of 48 h 
(Section 2.2.1.5). Global negative control siRNA was used as the negative control. After 
treatment, the cells were fractionated into the cytoplasmic and nuclear fractions as described in 
detail in Section 2.2.2. The sub cellular fractions were then analysed by western blot for the 
expression of Rel A/p65 using rabbit polyclonal anti-Rel A/p65 antibody (1:1000) as well as 
mouse monoclonal anti-TG2 antibody (1:1000). The membranes were reprobed with anti- 
Lamin A and anti-α-Tubulin antibody to check for equal loading of protein. (A &C)The western 
blot data shown is a representative of three independent experiments (n=3). (B &D) 
Differences in expression as calculated by Image J analysis is representative of the average 
densitometry readings obtained from three independent experiments + SEM. * p<0.05 
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4.3.4.2   Decreased NFκB activity of breast cancer cell lines in the presence of Rel 
A/p65 specific siRNA 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were 
transfected with Rel A/p65 specific siRNA and then analysed for the NFκB activity levels using 
the NFκB/SEAP reporter assay as described previously in Section 2.2.12.  The SEAP reporter 
assay demonstrated a considerable decrease in the NFκB activity levels of the breast cancer cell 
lines on being transfected with the Rel A/p65 specific siRNA (Figure 4.9), which is in 
comparison to the data obtained by western blot analysis (Figure 4.8). The Hs_RELA_5 (i) 
demonstrated the most significant decrease in NFκB activity, followed by Hs_RELA_7 (ii) and 
finally Hs_RELA_8 (iii) in all of the breast cancer cell lines.  The remaining NFκB activity 
observed in these breast cancer cell lines could be representative of the activity of the other 
NFκB family members in the breast cancer cell lines. These results seem to imply that the 
majority of the NFκB activity observed in the MDA MB 231 Clone 16 and MCF7/RT cells is as 
a result of constitutive activation of the Rel A/p65 member of the NFκB family due to the cross 
linking activity of TG2. Also, treating the MDA MB 231 Clone 16 and MCF7/RT cells with 
Rel A/p65 specific siRNA reduces the NFκB activity levels within these breast cancer cells to 
similar levels observed in the untreated MDA MB 231 WT and MCF7/WT cells. This clearly 
suggests that the aberrant activation of NFκB within the MDA MB 231 Clone 16 and MCF7/RT 
from the basal levels could be attributed to the endogenous transamidating activity of TG2 
within these breast cancer cell lines.  
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Figure 4.9 Analysis of NFκB activity levels in breast cancer cell lines in the presence of Rel 
A/p65 specific siRNA. 
The NFκB activity of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cell lines were analysed using the NFκB/SEAP Reporter Assay. 5x105 cells of each breast 
cancer cell line was seeded into 6-well plates and left overnight. The next day, the cells were 
transfected with NFκB/SEAP plasmid. 48 h after transfection, the breast cancer cell lines were 
treated with three different Rel A/p65 specific siRNA as well as global negative control siRNA 
(at a final concentration of 100nM). The supernatant was then collected for the SEAP assay as 
described in detail in Section 2.2.12. Data shown is mean concentration of SEAP ± SE from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA with 
Dunnett’s post-hoc test. * p< 0.05 between cells transfected and non-transfected with siRNA. 
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4.3.4.3 Detection of TG2 activity of breast cancer cell lines on treatment with Rel 
A/ p65 targeting siRNA 
As described in Section 2.2.1.5, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT 
and MCF7/RT cells were treated with Rel A/p65 specific siRNA and the whole cell lysates of 
these breast cancer cell lines were collected (Section 2.2.2). The whole cell lysate fractions of 
the breast cancer cell lines treated with Rel A/p65 specific siRNA and global negative control 
siRNA were analysed for   TG2 activity (Section 2.2.11). The MDA MB 231 WT and 
MCF7/WT cells do not express any TG2 activity in the whole cell lysate fractions, which 
remains unchanged on transfection with Rel A/p65 specific siRNA.  On the other hand, the 
MDA MB 231 Clone 16 and MCF7/RT cells that are known to exhibit TG2 activity show a 
significant decrease in the TG2 activity levels on being transfected with Rel A/p65 specific 
siRNA. The Hs_RELA_5 (i) shows the most significant decrease, followed by Hs_RELA_7 (ii) 
and finally Hs_RELA_8 (iii) (Figure 4.10). These results are in correlation with the decrease 
observed in the NFκB activity (Figure 4.9) and expression levels as well as TG2 expression 
within the MDA MB 231 Clone 16 and MCF7/RT cell lines (Figure 4.8) . The global negative 
control siRNA does not demonstrate any change in the TG2 activity levels within the above 
mentioned breast cancer cell lines. These results seem to indicate that inhibiting the mRNA 
expression of Rel A/p65 using Rel A/p65 targeting siRNA in the high TG2 expressing breast 
cancer cell lines could lead to a significant decrease in both the TG2 activity (Figure 4.10) as 
well as TG2 expression of the MDA MB 231 Clone 16 and MCF7/RT cell lines (Figure 
4.8).With this, it is possible to speculate that Rel A/p65 has a response element on the TGM2 
gene promoter which would allow  control of the expression and subsequent activity of TG2 
within these cells.  
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Figure 4.10 Investigation of TG2 whole cell lysate activity in the presence of Rel A/p65 -
specific siRNA 
The whole cell lysate fractions of the  MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT 
and MCF7/RT after treatment with three different Rel A/p65  specific siRNA over a time course 
of 48 h were collected and analysed for the TG2 activity as described in Section 2.2.11  by 
biotinylated cadaverine incorporation into fibronectin. Positive control (50 ng/ml gplTG + 
10mM  CaCl2) was taken to be 100% TG2 activity (1.13258±0.20936). Data shown above is 
mean percentage TG2 activity + SEM from 3 independent experiments (n=3). Statistical 
analysis was performed using ANOVA with Dunnett’s post-hoc test. * p<0.05 between cells 
transfected and non-transfected with siRNA.  
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4.3.4.4 Increased susceptibility of chemoresistant breast cancer cell lines to 
doxorubicin on treatment with Rel A/p65 specific siRNA 
To determine the effect of inhibiting mRNA expression of Rel A/p65 using Rel A/p65 specific 
siRNA on the chemoresistance of the breast cancer cell lines, the MDA MB 231 WT, MDA MB 
231 Clone 16, MCF7/WT and MCF7/RT cell lines were transfected with Rel A/p65 specific 
siRNA in the presence of doxorubicin. The viability of the breast cancer cell lines was then 
determined using the XTT assay as described in detail in Section 2.2.13. The MDA MB 231 
WT and MCF7/WT cells were chemosusceptible to doxorubicin and subsequent transfection 
with Rel A/p65 siRNA and global negative control siRNA maintains the chemosensitive 
phenotype of the TG2 null breast cancer cell lines. On the other hand, the untreated and global 
negative control siRNA transfected MDA MB 231 Clone 16 and MCF7/RT cell lines have been 
shown to be chemoresistant against doxorubicin. Transfecting these breast cancer cell lines with 
Rel A/p65 siRNA demonstrated a significant decrease in the cell viability of the high TG2 
breast cancer cell lines, in the presence of doxorubicin. It was also noted that transfecting the 
high TG2 breast cancer cells with Rel A/ p65 siRNA induced toxicity in the cells (Figure 4.11).  
Previous studies have shown that the activation of NFκB can attenuate the apoptotic response of 
breast cancer cells against chemotherapeutic drugs and subsequently inhibiting the constitutive 
activation of NFκB can greatly sensitize tumour cells to chemotherapy (Karin, et al. 2002).  
Also, one of the major drivers of constitutive NFκB activity in cancer cell lines has been 
identified as TG2 (Mangala & Mehta, 2005). Correlating these findings with the results 
obtained in the current study, it can be hypothesized that in the high TG2 breast cancer cell 
lines, MDA MB 231 Clone 16 and MCF7/RT, the chemoresistant phenotype against 
doxorubicin can be a feature of constitutively activated Rel A/p65 induced by TG2 
transamidating activity.  
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Figure 4.11 The effect of transfecting breast cancer cell lines with Rel A/p65 specific 
siRNAs in the presence of doxorubicin as illustrated via XTT assay. 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells (3000 cells per 
well) were seeded into 96-well plates and left overnight. The next day the cells were treated 
with three different Rel A/p65 specific siRNA for 48 h (final concentration of 100nM) and 
doxorubicin (1μg/ml) for a time course of 72 h after which the viable cells were detected using 
XTT analysis. Untreated cells were taken as 100% viable.  Data shown above is mean 
percentage of cell viability + SEM from 3 independent experiments (n=3). Statistical analysis 
was performed using ANOVA with Dunnett’s post-hoc test. * p<0.05 between cells transfected 
and non-transfected with siRNA in the presence of doxorubicin.  
 
Chapter 4: TG2 activity results in aberrant NFκB activation through an intracellular 
mechanism 
 
174 | 
 
4.3.5   Aberrant Rel A/p65 is not altered on treatment with various TG2 
inactivating antibodies. 
4.3.5.1 Detection of TG2 cell surface and whole cell lysate activity on treatment 
with different TG2 antibodies. 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were 
analysed for the whole cell lysate and cell surface TG2 activity assay as described in Section 
2.2.11, subsequent to treatment with TG2 antibodies. The three TG2 antibodies used include 
mouse monoclonal ID10, mouse monoclonal, transglutaminase-inactivating antibody (TG2 In 
Ac Ab) and mouse monoclonal Cub 7402. Mouse monoclonal IgG isotype was used as the 
negative control for the experiment.  
With respect to the cell surface TG2 activity in the breast cancer cell lines, the MDA MB 231 
Clone 16 cell line are the only breast cancer cells that express cell surface TG2 activity. On 
being treated with the three different TG2 antibodies and the mouse IgG isotype, the MDA MB 
231 Clone 16 cells demonstrated a significant decrease in the cell surface TG2 activity. The 
most significant decrease was observed when the MDA MB 231 Clone 16 cells were treated 
with mouse monoclonal transglutaminase-inactivating antibody (TG2 In Ac Ab), followed by 
mouse monoclonal ID10 antibody and finally mouse monoclonal Cub 7402 antibody.  The 
mouse IgG isotype did not cause any change in the cell surface TG2 activity of the MDA MB 
231 Clone 16 cells. The MDA MB 231 WT, MCF7/WT and MCF7/RT cells did not express 
any cell surface TG2 activity and so, there was no change on being treated with the TG2 
antibodies and the mouse IgG isotype (Figure 4.12).  
To determine the whole cell lysate activity of TG2 in the breast cancer cell lines on being 
treated with the various TG2 antibodies as well as mouse IgG isotype, the MDA MB 231 WT, 
MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were seeded into 6-well plates (5x10
5
 
cells/ well), and subsequently treated with 25ng/ml of the TG2 antibodies as well as Mouse IgG 
isotype for a time course of 24 h. After treatment, the whole cell lysate fractions of the breast 
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cancer cell lines were obtained as described in Section 2.2.2.  50μg of whole cell lysate protein 
of each treated cell line was used to determine the whole cell lysate TG2 activity as described in 
detail in Section 2.2.11.  
The MDA MB 231 WT and MCF7/WT cell lines did not demonstrate any TG2 whole cell 
lysate activity and so remain unaffected by the treatment with TG2 antibodies as well as mouse 
IgG isotype (Figure 4.13). The TG2 expressing MDA MB 231 Clone 16 and MCF7/RT cells 
illustrated no significant change in the whole cell lysate TG2 activity on being treated with the 
various TG2 antibodies. The mouse IgG was used as the negative control for the TG2 
antibodies. 
These results signified that the TG2 antibodies used were cell impermeable and so only affected 
the cell surface TG2 activity of the MDA MB 231 Clone 16 cells. Also, the whole cell lysate 
activity of the high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT cells remain 
unaltered on treatment with the TG2 antibodies. 
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Figure 4.12 Investigation of TG2 cell surface activity in the presence of TG2 antibodies 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT (2X 10
4
 per 100μl of 
medium) were seeded into 96-well plates and analysed for the cell surface TG2 activity by 
biotinylated cadaverine incorporation into fibronectin as introduced in Section 2.2.11. Positive 
control (50 ng/ml gplTG + 10mM  CaCl2) was taken to be 100% TG2 activity (1.2947 ± 
0.199364). Data shown above is mean percentage TG2 activity + SEM from 3 independent 
experiments (n=3). Statistical analysis was performed using ANOVA with Dunnett’s post-hoc 
test. * p<0.05 between untreated and TG2 antibody treated cells. 
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Figure 4.13 Investigation of TG2 whole cell lysate activity in the presence of TG2 
antibodies 
The whole cell lysates of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and 
MCF7/RT after treatment of cells with TG2 antibodies, ID10 (25ng/ml),  transglutaminase-
inactivating antibody (TG2 In Ac Ab)  (25ng/ml), Cub 7402(25ng/ml) and mouse IgG (25ng/ml) 
for a time course of 24 h were collected and 50μg of whole cell lysate protein was analysed for 
the TG2 whole cell lysate activity as described in Section 2.2.11  by biotinylated cadaverine 
incorporation into fibronectin. Positive control (50 ng/ml gplTG + 10mM  CaCl2) was taken to 
be 100% TG2 activity (1.24345 ±0.254846). Data shown above is mean percentage TG2 
activity + SEM from 3 independent experiments (n=3).  
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4.3.5.2 NFκB activity and expression on treatment with TG2 antibodies 
To confirm that extracellular TG2 activity observed in the MDA MB 231 Clone 16 cells was 
not responsible for the formation of the Rel A/p65 high molecular weights as well as the 
aberrant activation of Rel A/p65 in these breast cancer cell lines, TG2 targeting antibodies were 
used. The mouse monoclonal antibody ID10, mouse monoclonal transglutaminase-inactivating 
(TG2 In Ac Ab) antibody as well as mouse monoclonal Cub 7402 were applied to the breast 
cancer cell lines. Mouse IgG was used as the negative control antibody. The MDA MB 231 WT 
and MDA MB 231 Clone 16 cells were treated with the various TG2 antibodies (final 
concentration of 25ng/ml) and negative control mouse IgG (25ng/ml) for a time course of 24 h. 
After treatment, the expression of Rel A/p65 in the cytoplasmic and nuclear fractions was 
determined by western blot (Section 2.2.2) using polyclonal rabbit anti-Rel A/p65 antibody.  
The untreated MDA MB 231 WT cells only express monomeric Rel A/p65 in the cytoplasmic 
and nuclear fractions. No change was observed in the Rel A/p65 monomer in the cytoplasmic 
and nuclear fractions, on treatment with the various TG2 antibodies. This could be attributed to 
the lack of TG2 expression and activity within these cells (Figure 4.14). The negative control 
mouse IgG, also did not demonstrate any change in the Rel A/p65 expression within these 
breast cancer cell lines.  
In the untreated MDA MB 231 Clone 16 cells, Rel A/p65 high molecular weights were 
observed in the nuclear fractions and the monomeric Rel A/p65 form was observed in the 
cytoplasmic fractions (Figure 4.14) . As described previously, this high molecular weight form 
of p65 could be representative of the high TG2 cross linking activity within these cells and this 
high molecular weight Rel A/p65 has also been shown to decrease in the presence of TG2 
specific cell permeable inhibitors. On treating the MDA MB 231 clone 16 cells with the various 
TG2 antibodies for a time course of 24 h, no significant change was observed in the Rel A/p65 
high molecular weight in the nucleus or even the monomeric Rel A/p65 in the cytoplasm.  
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These results seem to imply that the high molecular weight Rel A/ p65 band observed was 
specifically due to intracellular TG2 activity. Interfering with extracellular TG2 either through 
the binding of various antibodies (transglutaminase-inactivating antibody [(TG2 In Ac Ab)], 
ID10 and Cub 7402) did not illustrate any significant difference in the RelA/ p65 high 
molecular weight band. The negative control mouse IgG isotype treated MDA MB 231 Clone 
16 cells demonstrated no change as compared to the untreated Clone 16 cells. The increased 
constitutive activation of Rel A/p65 in the MDA MB 231 Clone 16 cells can be thus clearly 
attributed to the increased expression and intracellular activity of TG2 within these breast 
cancer cell lines.  
To further substantiate the results obtained by western blot, the NFκB/SEAP reporter assay 
(described in Section 2.2.12) was performed on the MDA MB 231 WT, MDA MB 231 Clone 
16, MCF/WT and MCF7/RT cells, on treatment with the various TG2 antibodies. Both the TG2 
expressing MDA MB 231 Clone 16 and MCF7/RT as well as TG2 null MDA MB 231 WT and 
MCF7/WT cells did not illustrate any significant change in the NFκB activity levels. The breast 
cancer cell lines treated with the various TG2 antibodies, on comparison with the untreated cell 
lines, display almost comparable levels of NFκB activity (Figure 4.15) 
With the above findings, it can be clearly established that the high and constitutive activation of 
NFκB by TG2 is an intracellular phenomenon in the MDA MB 231 Clone 16 and MCF7/RT 
cell lines. The TG2 antibodies target and inactivate the activity of TG2 on the cell surface does 
not demonstrate any significant change in the NFκB activity levels in the high TG2 breast 
cancer cell lines. This completely rules out the possibility that inhibiting extracellular TG2 
would decrease the aberrant and constitutive activation of NFκB.  
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Figure 4.14 Analysis of the expression of Rel A/p65 in the cytoplasmic and nuclear 
fractions of breast cancer after treatment with various TG2 antibodies using western blot.  
The MDA MB 231 WT (A) and MDA MB 231 clone 16 (C) cells (1x10
6
 cells) were seeded into 
60 mm petridishes and left overnight. The next day, the cells were treated with ID10, 
transglutaminase-inactivating antibody (TG2 In Ac Ab), Cub 7402 and mouse IgG for a time 
course of 24 h. After treatment, the cells were fractionated into the cytoplasmic and nuclear 
fractions as described in detail in Section 2.2.2. The sub cellular fractions were then analysed 
by western blot ting for the expression of Rel A/p65 using rabbit polyclonal anti-Rel A/p65 
antibody (1:1000). The membranes were reprobed with anti- Lamin A antibody to standardise 
for equal loading of nuclear protein. (A & C) The western blot data shown is a representation 
of three independent experiments (n=3). (B &D) Differences in expression as analysed by 
Image J analysis is representative of the mean densitometry reading obtained from three 
independent experiments + SEM.   
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Figure 4.15 Analysis of NFκB activity levels in breast cancer cell lines on treatment with 
various TG2 antibodies. 
The NFκB activity of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cell lines were analysed using the NFκB/SEAP Reporter Assay (Section 2.2.12). 5x105 cells of 
each breast cancer cell line were seeded into 6-well plates and transfected with NFκB/SEAP 
plasmid. 48 h after transfection, the breast cancer cell lines were treated with three TG2 
antibodies, ID10 (25ng/ml), transglutaminase-inactivating antibody (TG2 In Ac Ab) (25ng/ml) 
and Cub 7402 (25ng/ml) as well as mouse IgG (25ng/ml) for 24 h.  The supernatant was then 
collected for the SEAP assay. Data shown is mean concentration of SEAP + SEM from 3 
independent experiments (n=3). 
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4.3.5.3   Cell viability analysis of breast cancer cell lines in the presence of 
doxorubicin and TG2 antibodies 
From the results observed in Section 4.3.4, it can be hypothesized that inhibiting cell surface 
TG2 activity of the breast cancer cell lines, did not decrease the aberrant and constitutive 
activation of the Rel A/p65 subunit of the NFκB family. To determine whether any changes 
may be observed in the chemoresistant nature of these breast cancer cell lines, the MDA MB 
231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were treated with the 
different TG2 antibodies (ID10, transglutaminase-inactivating antibody (TG2 In Ac Ab), Cub 
7402 and Mouse IgG isotype (25ng/ml), for a time course of 24 h in the presence of 
doxorubicin. The high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT cells have 
previously been shown to be highly chemoresistant to doxorubicin and this chemoresistance 
was reduced significantly on treating these breast cancer cell lines with cell permeable TG2 
activity inhibitors (R283 and Z-DON). On treating the high TG2 expressing MDA MB 231 
Clone 16 and MCF7/RT cells with the various TG2 antibodies in the presence of doxorubicin, 
no change was observed in the viability of the cell lines as compared to the untreated cell lines. 
The chemoresistant nature of the MDA MB 231 Clone 16 and MCF7/RT cells was still 
maintained even on treatment with the TG2 antibodies, in the presence of doxorubicin. The 
mouse IgG isotype also does not affect the chemoresistant nature of the MDA MB 231 Clone 
16 and MCF7/RT against the chemotherapeutic drug, doxorubicin (Figure 4.16). The cell 
viability of the high TG2 expressing breast cancer cell lines also did not decrease in the 
presence of doxorubicin and TG2 antibodies. This was in positive correlation with the 
unchanged Rel A/p65 high molecular weights observed in the nucleus on being treated with the 
TG2 antibodies.  
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Figure 4.16 The effect of treating breast cancer cell lines with TG2 antibodies in the 
presence of doxorubicin as illustrated via XTT assay. 
The MDA MB 231WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells (3000 cells per 
well) were seeded into 96-well plates and left overnight. The next day the cells were treated 
with three different TG2 antibodies and mouse IgG (25ng/ml) for a time course of 24 h and 
doxorubicin (1μg/ml) for a time course of 72 h after which the viable cells were detected using 
XTT analysis. Untreated cells were taken as 100% viable.  Data shown above is mean 
percentage of cell viability + SEM from 3 independent experiments (n=3). 
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4.3.6 In-vitro cross linking of recombinant Rel A/p65 using guinea pig liver tissue 
transglutaminase (TG2) 
To determine if TG2 can cross link Rel A/ p65 protein in vitro, recombinant human Rel A/p65 
(100ng/ml) was treated with increasing concentrations of guinea pig liver TG2 (0.01ng/ml-
10ng/ml). The reaction was conducted in PBS (final volume of 20μl) and supplemented with 
10mM CaCl2 and 1mM DTT. To check the effect of inhibiting TG2 activity, R294 and Z-DON 
were used in the reaction, as the negative control, the reaction was supplemented with 10mM 
EDTA. Western Blotting analysis of the recombinant Rel A/p65 illustrated a monomeric band 
at 65kDa corresponding to Rel A/ p65. On being treated with a low concentration of TG2 
(0.01ng/ml), the high molecular weight Rel A/ p65 band starts appearing. Increasing the 
concentrations of TG2, showed an increase in the Rel A/p65 high molecular weight band 
observed at approximately 130kDa. The monomeric Rel A/p65 band started to disappear, 
showing high molecular weight polymers as the TG2 concentration increases from 0.01ng/ml to 
10ng/ml. When 10mM EDTA was added to the reaction tube, no high molecular weight p65 
band was observed. Also, treatment with TG2 activity inhibitors, Z-DON and R294 showed a 
decrease in the Rel A/p65 high molecular weight band as compared to the samples that had not 
been treated with inhibitors. The blot was then reprobed for TG2 to make sure that the 
concentrations of TG2 that were added corresponded to the increasing high molecular weight 
band and the decreasing monomeric band (Figure 4.17).  
These results illustrated that the presence of these Rel A/p65 high molecular weights could be 
due to TG2 activity in vitro. The Rel A/p65 high molecular weight bands seen in the TG2 high 
Clone 16 and MCF7/RT cells also could be due to the TG2 activity within these cells. This in 
vitro experiment showed that the high molecular weight bands observed are due to TG2 activity 
which can be inhibited using inhibitors of TG2 activity such as EDTA, Z-DON and R294. 
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Figure 4.17 Western blot analysis of in vitro cross linking of recombinant Rel A/p65 
protein using guinea pig liver TG2. 
100ng/ml of recombinant human Rel A/ p65 protein was taken in 1.5ml tubes for the various 
treatments. Different concentrations of guinea pig liver TG2 ranging from 0.01ng/ml to 
10ng/ml were used along with 1mM DTT and 10mM CaCl2. The negative control used was the 
recombinant human Rel A/p65 protein, 10ng/ml gplTG, 1mM DTT and 10mM EDTA. Two 
different TG2 inhibitors (R294 and Z-DON) were used as well to see if they would inhibit the 
cross linking. The reaction tubes were set up to a final volume of 20μl with PBS. The reaction 
was allowed to take place at room temperature for 1 h. After the time period, 500μM of TG2 
inhibitor R283 was added into all of the reaction tubes to stop the reaction. 20μl of Laemmli 
buffer was added into the samples and boiled for 5 min. The samples were then loaded onto an 
8% SDS PAGE gel and analyzed by western blot using rabbit polyclonal anti-Rel A/ p65 as well 
as mouse monoclonal anti-TG2 antibodies. The data presented is a representation of three 
independent experiments (n=3).  
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4.4   DISCUSSION: 
The key obstacles to successful cancer therapy include the development of metastasis and drug 
resistance. The most prevalent feature of metastatic and drug resistant tumour cells is that the 
cells become increasingly resistant to induction of apoptosis (Kerbel, et al. 1994). It has become 
very evident that certain oncogenic mutations interrupt programmed cell death, which 
subsequently initiates tumour development, further progression, drug resistance as well as 
metastasis. Numerous epigenetic and genetic disruptions have been identified in advanced 
stages of cancer and thereby confer resistance against apoptotic mechanisms. One of the most 
commonly observed features of drug resistant cancer cells is the activation of NFκB (Fesik, 
2005). The capability of cancer cells to evade apoptosis allows them to demonstrate resistance 
to chemo therapeutic drugs as well as allow tumour cells to survive and grow in unfavourable 
micro environments and in distant tissue sites (Chhabra, et al. 2009).  
Many recent studies have clearly implicated that TG2 plays a major role, in the progression and 
growth of cancer cells. Cancer cells that have been selected out for the chemoresistant nature 
displayed elevated levels of TG2 (Verma & Mehta, 2007a/2007b ; Fok, et al. 2006 ; Mehta, et 
al. 2004 ; Verma, et al. 2006 ; Satpathy, et al. 2007). Results obtained in Chapter III were in 
agreement with the previous published studies. The MDA MB 231 Clone 16 and MCF7/RT 
breast cancer cell lines exhibited high levels of TG2 expression and activity. This elevated 
expression and activity of TG2 caused these breast cancer cell lines to become chemoresistant 
to doxorubicin, and this chemoresistance was reduced on treating the MDA MB 231 Clone 16 
and MCF7/RT cells with cell permeable TG2 activity inhibitors (R283 and Z-DON). Also, 
decreasing endogenous TG2 activity and expression using TG2 specific small interfering RNA 
(siRNA) reversed this chemoresistance against doxorubicin in the MDA MB 231 Clone 16 and 
MCF7/RT cells. As shown in Chapter III, the expression of TG2 was also down regulated, 
when the high TG2 expressing breast cancer cell lines were treated in the presence of cell 
permeable TG2 inhibitors. This decrease in TG2 expression, on inhibiting TG2 activity within 
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the breast cancer cell lines, signified that another factor with a response element on the TGM2 
gene promoter was causing this change in TG2 expression. 
The oncogenic transcription factor, NFκB, has been known to play a crucial role in the 
regulation of genes that are concerned with apoptosis, drug resistance, metastasis and cell 
growth (Karin, et al. 2002). Also, NFκB has been shown to be constitutively activated in 
numerous cancers, and the role of NFκB in metastasis and chemoresistance has been well 
documented (Naugler & Karin., 2008). In the context of these breast cancer cell lines, it is very 
appealing to conclude that the expression and activity of TG2 resulted in the constitutive 
activation of NFκB. Therefore, it can be hypothesized that tumour cell types with elevated 
expression and activity of TG2, display increased NFκB activity (Mann, et al. 2006) 
Essentially, the down regulation of TG2 using cell permeable inhibitors (R283 and Z-DON) as 
well as TG2 specific siRNA resulted in a significant decrease in the activity of NFκB. 
Furthermore, aberrant high molecular weight forms of Rel A/p65 were observed in the nuclear 
fractions of the TG2 expressing breast cancer cells, which have been observed to decrease 
significantly in the presence of cell permeable TG2 inhibitors, R283 and Z-DON. Treating the 
TG2 breast cancer cell lines with TG2 specific siRNA also resulted in the decrease of the high 
molecular weight Rel A/p65, and a subsequent increase in the monomeric form of Rel A/p65 in 
the nucleus, which was not observed in the untreated or global negative siRNA treated breast 
cancer cells. The other NFκB family members such as p105/p50, Rel B and c-Rel were 
observed to be very similar in both high and no TG2 breast cancer cell lines. Moreover, treating 
the breast cancer cell lines with the TG2 activity inhibitors did not illustrate any changes in the 
levels of the other NFκB family members. The transamidating activity of TG2 was proven to be 
specific for the constitutive activation of the Rel A/p65 subunit of NFκB 
 A study, conducted by Kim et al. (Kim, et al. 2006) suggested that inhibiting the cross linking 
activity of TG2, reversed the chemoresistance of breast cancer cells lines against doxorubicin, 
mainly due to the subsequent attenuation of NFκB activation. Also, a similar conclusion was 
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suggested by Cao et al. (Cao, et al. 2008), stating that in ovarian cancer cell lines, cisplatin 
induced apoptosis was circumvented due to the constitutive activation of the NFκB survival 
pathway.  
Under resting conditions, NFκB can induce inflammation by its activation which is transient 
and known to be crucial for the survival and growth of normal cells. The constitutive activation 
of NFκB by TG2 due to the cross linking activity of TG2 may be one of the key pathways 
responsible for conferring metastatic and chemoresistant phenotypes (Verma, et al. 2008). In 
the data represented in this chapter, this hypothesis is supported and also suggests that reducing 
the endogenous activity of TG2, can result in the down regulation of NFκB constitutive activity 
and thus increases the chemosensitivity of drug-resistant breast cancer cells.  
The hypothesis that intracellular TG2 activity is responsible for the constitutive activation of 
Rel A/p65 as well as the high molecular weight form of Rel A/p65 observed in the nucleus was 
further confirmed on treating the breast cancer cell lines with various TG2 antibodies such as 
ID10,  transglutaminase-inactivating antibody (TG2 In Ac Ab)  as well as Cub 7402. Even 
though these TG2 antibodies caused a significant decrease in the cell surface TG2 activity of 
the MDA MB 231 Clone 16 cells, the NFκB activity levels, Rel A/p65 high molecular weight in 
the nucleus as well as the chemoresistant phenotype of the high TG2 breast cancer cell lines, 
remains unaltered.  
These results clearly suggest that endogenous TG2 activity was responsible for the constitutive 
activation of NFκB in breast cancer cell lines, which confers chemoresistance to breast cancer 
cell lines against doxorubicin. The next chapter will focus on elucidating the mechanistic detail 
behind the constitutive activation of NFκB by TG2 and to decipher whether the activation of 
NFκB within chemoresistant breast cancer cell lines take place through the canonical or non-
canonical pathway of NFκB activation.  
To sum up the above work, it was demonstrated that in high TG2 expressing breast cancer cell 
lines, the cross linking activity of TG2 caused the constitutive activation of the Rel A/p65 
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subunit of the NFκB family and does not affect the other NFκB family members such as 
p105/p50, Rel B, c-Rel and p100/p52. This process of constitutive activation by TG2 was 
predominantly due to the cross linking of Rel A/p65 to allow the formation of Rel A/p65 high 
molecular weight forms in the nucleus of the high TG2 expressing breast cancer cell lines. 
Treating the high TG2 breast cancer cell lines with TG2 cell permeable inhibitors as well as 
TG2 specific siRNA resulted in the down regulation of the activity of NFκB within these cell 
lines and also resulted in a significant decrease in the high molecular weight form of Rel A/p65 
observed in the nucleus. The NFκB activity and Rel A/p65 high molecular weights remain 
unaltered on being treated with cell impermeable inhibitors as well as TG2 targeting antibodies, 
which are known to target and inhibit the cell surface activity of TG2 and do not alter 
endogenous TG2 activity. Treating the breast cancer cell lines with Rel A/p65 specific siRNAs 
demonstrated that inhibiting the mRNA expression of Rel A/p65 reduced the NFκB activity 
levels in the TG2 expressing breast cancer cell lines to similar levels as the parental wild type 
cells. Moreover, a significant decrease was observed in the nuclear Rel A/p65 high molecular 
weights indicating that the high molecular weights were only made up by Rel A/p65 subunit of 
NFκB. The Rel A/p65 siRNAs also reduced the expression of TG2 within the high TG2 breast 
cancer cell lines. This could indicate that a self-regulating molecular response  loop where TG2 
constitutively activates NFκB (Rel A/p65) which in turn, directly increases the transcription of 
the TGM2 gene. Also, cell viability studies showed that inhibiting the endogenous activity of 
TG2, caused the breast cancer cell lines to become chemo sensitive to chemotherapeutic drugs 
such as doxorubicin, which could be implicated as one of the potential phenotypic 
consequences of inhibiting the TG2-NFκB molecular loop.  
There are still remaining questions to be addressed such as: (1) What is the pathway of NFκB 
activation that TG2 exercises? The classical or canonical pathway of NFκB activation that 
involves IKK or a Non-canonical pathway of NFκB activation?; (2) Does the Rel A/p65 high 
molecular weight bind to DNA and if this Rel A/p65 high molecular weight undergoes any post 
translational modifications in the cytoplasm or nucleus prior to binding to DNA?; (3) What is 
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the nature of the signal transduction that activates the TG2-NFκB loop and key events 
stemming from this loop such as triggering of epithelial-mesenchymal transition (EMT)? The 
next chapters will explore the signalling pathway, DNA binding and post translational process 
mediated by constitutive activation of Rel A/p65 by TG2.  
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5. Constitutive activation of NFκB by TG2 
is independent of IKKα/β function 
5.1   INTRODUCTION 
The family members of the NFκB proteins are known to share approximately 300 amino acids 
in their N-terminal domain known as the Rel homology domain (RHD) which contains crucial 
sequences for DNA binding, IκB binding and also sites for dimerization (Baeuerle & Henkel, 
1994). The different members vary in their C-terminal domain. Rel A/p65, Rel B as well as c-
Rel demonstrate trans-activating functions, while on the other hand the p105/p50 and p100/p52 
members include inhibitory domains. p100 and p105 are the inactive precursors of the p52 and 
p50 proteins, respectively (Baldwin, 1996).  
In a resting un-stimulated cell, the NFκB family members are localized in the cytoplasm. 
Proteolytic processing will allow the removal of the C-terminal inhibitory domains, which 
consequently allows the proteins to translocate and enter the nucleus. p52 and p50 are known to 
form heterodimers or homodimers with Rel A/p65, Rel B and c-Rel which have a 
transactivation domain (Hayden & Ghosh, 2008). The NFκB family members are sequestered in 
the cytoplasm, by their association with IκBα, IκBβ and IκBγ, which are the members of the 
inhibitory κB family, IκB (Oeckinghaus & Ghosh, 2009). The activation of NFκB can result in 
numerous stimuli, which includes the activation of membrane receptors such as tumour necrosis 
factor receptors (TNFR) and B cell receptors (BCR) as well as a variety of extracellular stimuli 
such as osmotic shock and inflammatory cytokines (Ghosh & Karin, 2002) 
The activation of these NFκB signalling cascades is due to the phosphorylation of two vital 
serine residues present on the IκB proteins. This phosphorylation modification of IκB can 
trigger the ubiquitination and degradation of IκB proteins through proteosome destruction 
machinery (Ghosh & Hayden, 2008). As an outcome, the free NFκB protein enters into the 
nucleus which subsequently activates the transcription of a variety of genes which is involved in 
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pathways that control cellular growth, apoptosis, inflammatory and immune responses as well 
as developmental processes (Karin & Ben-Neriah, 2000). The above events particularly depend 
on the activation of upstream IKK complex, which is multimeric. The IKK complex is 
composed of two highly similar kinases known as IKKα and IKKβ, one non-enzymatic protein 
called NFκB essential modulator (NEMO) or IKKγ as well as a recently identified protein 
known as ELKS (Madonna, et al. 2012). The regulatory component, NEMO is considered 
absolutely essential for the formation of the IKK complex by binding to specific conserved 
residues present on the carboxyl terminal of both the IKKα and IKKβ (Zandi, et al. 1997).  
There are two major activation pathways for NFκB that have been characterized, which have 
been regarded as the canonical or classical pathway and the non-canonical or alternative 
pathway. Both of the above pathways have been shown to rely on phosphorylation, induced by 
external signals and the degradation of the inhibitory molecule, which releases the NFκB 
protein which shuttles into the nucleus (Pahl, 1999). The signals that prompt activation, identity 
of the kinases that are activated, the inhibitory molecules and NFκB proteins involved in both 
the pathways are very different. The classical pathway is usually triggered by pro inflammatory 
cytokines (IL-1β or TNF-α), which finally leads to the degradation of IκBα, which is the 
inhibitory NFκB molecule by IKKγ/NEMO complex via a TAK1-dependent pathway (Shostak 
& Chariot, 2011). The non-canonical pathway involves the degradation partially of p100 
precursor to form the active p52 through a NIK-dependent pathway. This pathway depends on 
IKKα homo-dimer and leads ultimately to the nuclear migration of Rel B/p52 hetero-dimers. 
This pathway plays a vital role in adaptive immunity (Naumann, et al. 1993). In the canonical 
pathway of NFκB activation, the IKK complex phosphorylates IκB which then induces the 
proteasomal degradation via ubiquitination. The heterodimers and homodimers of the NFκB 
family are then capable to migrate into the nucleus and cause the activation of target genes. The 
classical or canonical pathway involves Rel A: p50 and c-Rel: p50 hetero dimers and strongly 
depends on the activity of IKKβ activity (Zandi, et al. 1998; Karin & Delhase, 2000; 
Senftleben, et al. 2001) 
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A very common feature found in breast cancer tumour types is the constitutive activation of 
NFκB, which is known to play a crucial role in cell survival, inflammation, immunity as well as 
proliferation (Hayden & Ghosh, 2008). Aberrant activation of NFκB results in the continuous 
and persistent localization of the NFκB proteins to the nucleus.  This translocation has been 
shown to disrupt the balance between cell death and cell proliferation, mainly via the up 
regulation of anti-apoptotic pathways and proteins (Karin & Lin, 2002). In some breast cancer 
cells, other mechanisms and pathways are in play that can activate the NFκB pathway. EGF in 
breast cancer cells has been shown to set off IκBα phosphorylation specifically on tyrosine 42 
via a pathway that is independent of IKKα/β. Previous studies have shown that EGF-induced 
activation of NFκB occurs without the phosphorylation of serine residues and the subsequent 
ubiquitination of IκBα, which is independent of IKK (Sethi, et al. 2007) 
Literature has shown that another prominent feature of TG2 cross-linking activity is the 
constitutive activation of NFκB in a   mechanism by which cytoplasmic IκBα is polymerized by 
TG2 and then subsequently degraded. The TG2 catalyzed cross-linking of IκBα causes the 
depletion of the inhibitory -κB protein, without affecting its phosphorylation status. This leads 
to an aberrant activation of the NFκB pathway which is thought to contribute to inflammation 
as well as cancer progression (Lee, et al. 2004). 
The aim of this chapter is to further study the pathway that mediates the constitutive activation 
of Rel A/ p65 by TG2 and the involvement of IKKα/β and IκBα in this mechanism. Using μ-
calpain inhibitor, calpeptin and IKKα/β phosphorylation inhibitor, PS1145, western blot, TG2 
whole cell lysate and cell surface activity and NFκB reporter assay were performed to detect the 
relative levels of activation and expression of TG2 and NFκB. The impact of these inhibitors on 
the chemoresistant phenotype of the high TG2 breast cancer cell lines against doxorubicin was 
also studied by XTT analysis. 
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5.2   METHODS 
5.2.1 Treatment of breast cancer cell lines with Calpeptin  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT (1x10
6
 cells/ dish) 
were seeded into 60-mm petridishes and grown overnight in 60mm petridishes to become 70-
80% confluent. The next day, the cells were treated with 50μM of calpeptin for 6 h as described 
previously by Kim et al. (Kim, et al. 2010). After treatment, the breast cancer cell lines were 
collected and analysed by western blot for IκBα and α-Tubulin.  
5.2.2 Treatment of breast cancer cell lines with PS1145 
3000 cells each of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
were seeded into each well of a 96- well plate and grown to 70-80% confluency overnight. The 
next day the breast cancer cells were treated with increasing concentrations of PS1145 (10μM, 
15μM and 20μM) for a time course of 24, 48 and 72 h. After the treatment, the breast cancer 
cell lines were analysed using XTT to determine the lowest possible concentration of PS1145 
that would maintain the cell viability of the breast cancer cell lines. The optimum concentration 
of PS1145 to treat the breast cancer cells, without any cytotoxicity to the cells was determined. 
The results were expressed as percentage of viable cells.  
Subsequent to determining the optimum concentration and time course for PS1145 treatment, 
the breast cancer cell lines (1x10
6
 cells/ dish) were seeded into 60-mm petridishes and treated 
with PS1145. After the treatment time course, the cells were analysed using western blot for 
IκBα, Rel A/p65, TG2, α-Tubulin and Lamin A, TG2 whole cell lysate and cell surface activity 
and NFκB activity. 
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5.3   RESULTS 
5.3.1   Detection of IκB in the cytoplasmic fractions of the breast cancer cell lines 
in the presence of TG2 inhibitors 
To determine the status of IκBα in these breast cancer cell lines, the cytoplasmic fractions of the 
MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT, MCF7/RT and the TG2 plasmid and 
vector plasmid transfected SKBR3 and MCF7 cell lines were analysed by Western blot using 
anti-IκBα antibody (described previously in Sections 2.2.3-2.2.6). The TG2 null MDA MB 231 
WT, MCF7/WT, SKBR3/WT and empty vector transfected SKBR3 and MCF7 cell lines 
illustrated the presence of monomeric IκBα forms in their cytoplasmic fractions. The TG2 
expressing MDA MB 231 Clone 16, MCF7/RT and TG2 transfected SKBR3 and MCF7 cell 
lines also demonstrated monomeric IκBα. However, upon extended exposure time, high 
molecular weight forms of IκBα (approximately 66kDa) were also observed in the cytoplasmic 
fractions of the high TG2 expressing MDA MB 231 Clone 16, MCF7/RT and TG2 plasmid 
transfected SKBR3 and MCF7 breast cancer cell lines. Treating the MDA MB 231 Clone 16 
and MCF7/RT cell lines with the cell permeable TG2 activity inhibitor, Z-DON, these dimeric 
forms of IκBα decreased significantly. The cell permeable inhibitor, Z-DON, does not alter the 
monomeric IκBα forms observed. The cell impermeable TG2 activity inhibitor, R294, did not 
cause any change in the IκBα dimers observed the MDA MB 231 Clone 16 and MCF7/RT cell 
lines (Figure 5.1). These results seem to imply that there is a correlation between the levels of 
TG2 and the presence of IκBα dimers in the cytoplasm of breast cancer cell lines. Also as 
shown previously, the high TG2 breast cancer cell lines that express the IκBα dimers are 
chemoresistant to doxorubicin this chemoresistance exhibited could be as a result of the 
formation of IκBα dimeric forms. Inhibiting the activity of TG2 in the MDA MB 231 Clone 16 
and MCF7/RT cell lines using Z-DON significantly decreased the activity of TG2 (Chapter III) 
as well as the presence of the IκBα dimers, consequently reducing the chemoresistant 
phenotype of these breast cancer cell lines. Studies done previously by Kim, et al.(2010), has 
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demonstrated that treating TG2 transfected MCF7 cell lines with cystamine (a TG inhibitor), 
significantly inhibited the formation of these IκBα dimers (Kim, et al. 2010).  
TG2 in these breast cancer cells seems to mediate the activation of Rel A/ p65 by catalysing the 
cross linking of the key inhibitor of NFκB, IκBα. Even in literature, Rel A/p65 cross linking has 
been shown to be mediated by TG2 along with the degradation of IκBα, which is a known TG2 
substrate (Kim, 2006).Therefore, it may be hypothesized that TG2 binds to the Rel A/p65: IκBα 
complex, cross linking the inhibitor protein, IκBα as well as the Rel A/p65 to form dimers.  
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Figure 5.1 Analysis of IκBα in the cytoplasmic fractions of breast cancer cell lines in the 
presence of TG2 activity inhibitors 
The presence of free IκBα was detected in the cytoplasmic fractions of the breast cancer cell 
lines using western blot (anti-IκBα antibody). 1x 106 cells of each breast cancer cell line was 
seeded into 60-mm petridishes and grown overnight to reach 70-80% confluency. The next day 
the breast cancer cell lines were treated with 500μM of R294 and 50μM of Z-DON. 72 h after 
treatment, the cytoplasmic fractions of the breast cancer cell lines were collected as described 
in Section 2.2.2. The sub-cellular fractions were analysed using anti-IκBα antibody (1:1000). 
The membranes were reprobed with anti-α-Tubulin to ensure that the proteins had been equally  
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loaded. (A, C, E) The western blot data shown above is representative of two independent 
experiments (n=2). (B, D, F) Differences in expression of the IκBα dimers and monomers as 
calculated by Image J analysis is represented as mean densitometry readings + SEM. *p <0.05   
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5.3.2 Western blot analysis of free IκBα in the presence of Calpeptin. 
Previous studies have suggested that TG2 mediated activation of NF-κB was accompanied by 
the formation of the IκBα polymers. These polymers have also been shown to be degraded 
through the μ-calpain system. These IκBα polymers induced by TG2 have been shown to not 
accumulate in the breast cancer cells. Inhibiting the degradation of these IκBα polymers with 
Calpeptin caused the accumulation of these IκBα polymers in the cytoplasmic fraction of cells 
(Kim et al. 2010). The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cell lines were treated with 50μM of calpeptin for a time course of 6 h and the whole cell lysate 
and cytoplasmic fractions of the breast cancer cell lines were analysed by western blot using 
anti- IκBα antibody. The high TG2 breast cancer cell lines, MDA MB 231 Clone 16 and 
MCF7/RT, illustrated the presence of high molecular weight protein bands which were 
seemingly characteristic of IκBα polymerized forms (Figure 5.2). These results seem to indicate 
that calpain is very important for the degradation of the polymerized IκBα form and inhibiting 
calpain using calpeptin increased the levels of IκBα polymers present in the MDA MB 231 
Clone 16 and MCF7/RT breast cancer cell lines. Activity of TG2 in breast cancer cell lines 
might result in the polymerization of IκBα which does not accumulate within the cells and 
undergoes rapid degradation. This could explain why only dimeric forms of IκBα were initially 
detected within the cytoplasmic fractions of the high TG2 breast cancer cell lines (Figure 5.1). 
There seems to be a strong relationship between the formation of IκBα polymers and expression 
of TG2. This link can be further confirmed on treating the Clone 16 cells with various TG2 
inhibitors and seeing if inhibiting TG2 plays a role in the amount of free IκBα present in the 
cell. 
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Figure 5.2: Evidence for calpain mediated degradation of IκBα polymers induced by TG2 
activity in breast cancer cell lines 
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells were seeded in 
60mm petridishes (1x10
6
 cells/plate) and allowed to become confluent overnight. The breast 
cancer cell lines were then treated with 50μM of Calpeptin for 6 h. The cytoplasmic fractions of 
the breast cancer cell lines were collected and subsequently analysed for IκBα expression by 
western blot using anti-IκBα (1:1000). The membranes were reprobed with anti-α-Tubulin to 
check the equal loading of proteins. (A) The western blot data shown above is a representation 
of two independent experiments (n=2). (B) Densitometry analysis was performed and is 
represented as the mean densitometry + SEM. * p<0.05  
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5.3.3 IKK inhibitor, PS1145 does not block the constitutive activation of NFκB by 
TG2 
5.3.3.1 Killing curve to determine optimum concentration of PS1145 
To establish the optimum concentration of PS1145 to treat the breast cancer cells without the 
inhibitor being cytotoxic, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and 
MCF7/RT cell lines were treated with increasing concentrations of PS1145 (10μM, 15μM and 
20μM) as described in Section 5.2.2. Using this experiment, 10μM of PS1145 for a time course 
of 24 h was selected to be the optimum concentration and longest possible time to treat the 
breast cancer cell lines, without being cytotoxic to the cells (Figure 5.3) 
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Figure 5.3 Cell viability analyses of breast cancer cell lines in the presence of increasing 
concentrations of PS1145 over a time course  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cell lines (3000 
cells/well) were seeded into 96 well plates and allowed to become 70-80% confluent overnight. 
The next day the breast cancer cell lines were treated with increasing concentrations, 10μM, 
15μM and 20μM of IKK inhibitor, PS1145. After 24, 48 and 72 h of treatment, the cell viability 
of the breast cancer cell lines was analysed using XTT (Section 2.2.13). Untreated cells were 
taken as 100% viable.  Data shown above is mean percentage of cell viability + SEM from 3 
independent experiments (n=3).   
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5.3.3.2 Activity and expression of NFκB in the presence of PS1145  
The breast cancer cell lines were treated with the IKKα/β inhibitor, PS1145 to determine the 
effect of inhibiting the canonical pathway of NFκB activation on the levels of NFκB activity 
within the cell lines. In order to test the NFκB activity levels within the breast cancer cell lines, 
NFκB/SEAP reporter assay was carried out as described in detail previously (Section 2.2.12). 
After transfecting the breast cancer cells with the NFκB/SEAP reporter plasmid, the cells were 
subsequently treated with 10μM of PS1145 for a time course of 24 h. The medium that the 
breast cancer cells were grown in was collected and assayed for the relative amount of SEAP. 
The MDA MB 231 WT, MCF7/WT, SKBR3/WT, SKBR3/RT, T47D/WT, T47D/RT and 
empty vector transfected SKBR3 cells demonstrated a considerable decrease in the NFκB 
activity levels on being treated with PS1145. This observation was comparable to the initial 
finding that these breast cancer cell lines did not express any TG2. On the other hand, the TG2 
expressing MDA MB 231 Clone 16, MCF7/RT and TG2 transfected SKBR3 breast cancer cell 
lines did not illustrate a significant decrease in the NFκB activity levels on being treated with 
PS1145 (Figures 5.4 A, B & C ). The slight decrease demonstrated in the NFκB activity could 
be attributed to the minimal effect of IKKα/β. These results could imply that, other than the 
canonical pathway of NFκB activation, another unconventional pathway of NFκB activation 
could be active in the chemoresistant cell lines. Blocking the conventional pathway of NFκB 
activation using a IKKα/β inhibitor, PS1145, does not seem to change the NFκB activity levels 
within the high TG2 breast cancer cell lines, which may indicate that the high levels of NFκB 
activity within these cell lines is due to the constitutive activation of Rel A/p65 induced by 
TG2.  
After determining the NFκB activity levels within these breast cancer cell lines, the relative 
expression of Rel A/p65 in the cytoplasmic and nuclear fractions of these breast cancer cell 
lines was detected as well. The MDA MB 231 WT and MDA MB 231 Clone 16 breast cancer 
cells were treated with 10μM of PS1145 for 24 h, after which the cytoplasmic and nuclear 
fractions of the cells were collected as described in Section 2.2.2. The sub cellular fractions 
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were then analysed using anti-Rel A/p65 antibody by western blot. The MDA MB 231 WT cells 
demonstrated a clear shift in the levels of protein expression from the nucleus to the cytoplasm 
of Rel A/p65 on being treated with PS1145. This implied that PS1145 was blocking the 
phosphorylation of IκBα by IKKα/β and the subsequent release of Rel A/p65 into the nucleus, 
which accounted for the decrease in Rel A/p65 nuclear expression. With respect to the MDA 
MB 231 Clone 16, the aberrant Rel A/p65 dimer seen in the nucleus remains significantly 
unchanged on PS1145 treatment (Figure 5.5). These results could indicate that in the high TG2 
expressing breast cancer cells lines, the canonical pathway of NFκB activation using IKKα/β is 
not involved in the activation of the aberrant Rel A/p65 dimer. The constitutive activation of 
Rel A/p65 in the TG2 expressing breast cancer cell lines can thus be suggested to be completely 
independent of IKKα/β and dependent on the intracellular transamidating activity of TG2. 
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Figure 5.4 (A, B & C) Analysis of NFκB activity levels in breast cancer cell lines on 
treatment with IKK inhibitor, PS1145 
The NFκB activity levels of the breast cancer cell lines were analysed using the NFκB/SEAP 
Reporter Assay. As described previously in Section 2.2.12, 5x10
5
 cells of each breast cancer 
cell line was seeded into each well of a 6-well plate along and left overnight to attain 
confluency. The next day, the breast cancer cell lines were transfected with NFκB/SEAP 
plasmid. 48 h after transfection, the breast cancer cell lines were treated with 10μM of PS1145 
over a time course of 24 h. The culture medium was then collected and used for subsequent 
analysis. Data shown is mean concentration of SEAP ± SE from 3 independent experiments 
(n=3). Statistical analysis was performed using ANOVA with Dunnett’s post-hoc test. * p< 0.05 
between untreated and PS1145 treated cells. # p<0.05 between cell groups. 
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Figure 5.5 Western blot analysis of Rel A/p65 in the sub cellular fractions of breast cancer 
cell lines on treatment with PS1145  
The IKKα/β inhibitor, PS1145 was used to inhibit the phosphorylation of IκBα by IKKα/β and 
subsequent activation of NFκB (Rel A/p65) via a canonical or classical pathway in the breast 
cancer cell lines. 1x10
6 
cells of each breast cancer cell line was seeded into 60-mm petridishes 
and left to become 70-80% confluent overnight. The next day the sub cellular fractions of the 
cell lines were obtained as described in Section 2.2.2. The sub cellular fractions were then 
analysed for the expression of Rel A/p65 using western blotting and anti-Rel A/p65 antibody. 
Anti-α-Tubulin and Lamin A were used as the markers of equal protein loading for the 
cytoplasmic and nuclear fractions and also to ensure that the fractions had not been cross 
contaminated. (A) The western blot data shown above is a representation of three independent 
experiments (n=3). (B) Densitometry scans were done of the western blots and are represented 
as the mean of the densitometry readings + SEM.* p<0.05 
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5.3.3.3 NFκB activity and expression in the presence of PS1145 and TG2 inhibitors 
To confirm if the constitutively activated NFκB in the high TG2 expressing breast cancer cell 
lines could be decreased using a combinatorial treatment of both TG2 inhibitors as well as 
PS1145, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT breast 
cancer cell lines were treated with 10μM PS1145 for 24 h as well as R283 (500μM) and Z-DON 
(50μM) for a time course of 72 h. The breast cancer cell lines were then analysed for the NFκB 
activity levels by using the NFκB/SEAP reporter assay (described in Section 2.2.12). The MDA 
MB 231 WT and MCF7/WT cell lines have been previously shown to express no TG2 as well 
as decreased NFκB activity levels as compared to the respective high TG2 clones. On treating 
the MDA MB 231 WT and MCF7/WT breast cancer cell lines with 10μM of PS1145 for 24 h 
resulted in a significant decrease in the NFκB activity within these cells. The cell permeable 
TG2 inhibitors, R283 and Z-DON, do not show any change in the NFκB activity levels in the 
TG2 null breast cancer cell lines. Combination treatment, including PS1145 and cell permeable 
TG2 inhibitors, R283 and Z-DON, resulted in the NFκB activity remaining comparable to the 
decrease observed on treatment with only PS1145, without any effect of the TG2 activity 
inhibitors. Conversely, the high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cell lines, did not demonstrate a noteworthy decrease in the NFκB activity levels. 
Treating the breast cancer cell lines with TG2 cell permeable inhibitors, R283 and Z-DON, 
drastically decreased the NFκB activity levels in the MDA MB 231 Clone 16 and MCF7/RT 
cell lines (Figure 5.6). A combination treatment of PS1145 and TG2 inhibitors, R283 and Z-
DON, demonstrated a similar decrease in the NFκB activity which was comparable to the NFκB 
activity of the MDA MB 231 Clone 16 and MCF7/RT cells that were treated with the TG2 cell 
permeable inhibitors only. These results seem to indicate clearly that the major amount of 
NFκB activity observed in the MDA MB 231 Clone 16 and MCF/RT breast cancer cell lines 
can be attributed to the high TG2 expression and activity levels within these breast cancer cell 
lines.  
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The sub cellular fractions of the MDA MB 231 WT and MDA MB 231 Clone 16 breast cancer 
cell lines were also collected in order to determine the expression of Rel A/p65 in the nuclear 
fractions, in the presence of TG2 inhibitors as well as PS1145, by western blotting using anti- 
Rel A/ p65 antibody. The TG2 null MDA MB 231 WT illustrated a clear increase in the Rel A/ 
p65 expression in the cytoplasmic fraction and a subsequent decrease of Rel A/p65 expression 
in the nuclear fractions, on being treated with the IKKα/β inhibitor, PS1145. On treating the 
TG2- null breast cancer cell line with TG2 inhibitors, no significant change was observed in the 
Rel A/p65 expression in the cytoplasmic or nuclear fractions. A combined treatment of PS1145 
and TG2 inhibitors on the MDA MB 231 WT cell line, did not show any additional increase in 
the cytoplasmic expression of Rel A or decrease in the nuclear expression of Rel A/p65, to the 
change observed on treating these breast cancer cell lines with only PS1145. The high TG2 
expressing MDA MB 231 Clone 16 cells do not show any significant change in the aberrant Rel 
A/p65 dimer observed in the nucleus or the monomeric Rel A/p65 observed in the cytoplasm, 
on being treated only with the IKKα/β inhibitor, PS1145. On treating these high TG2 breast 
cancer cell lines with PS1145 as well as TG2 cell permeable inhibitors, R283 and Z-DON, there 
was a significant decrease observed in the dimeric Rel A/p65 band in the nucleus of the MDA 
MB 231 Clone 16 cells (Figure 5.7). Also, treating the high TG2 breast cancer cell lines with 
cell permeable TG2 inhibitors, R283 and Z-DON, illustrated a decrease in the aberrant nuclear 
Rel A/p65 dimer concurrent with the results of Chapter IV. The decrease observed in the 
nuclear Rel A/p65 dimer of the MDA MB 231 Clone 16 breast cancer cell line, on being treated 
with only the cell permeable TG2 inhibitors as well as in combination of cell permeable TG2 
inhibitors and PS1145 is very comparable. This could imply that the decrease observed is only 
as an effect of the TG2 inhibitors and the IKK inhibitor, PS1145 does not cause any change in 
the dimeric Rel A/p65 form in the nucleus. These results seem to clearly indicate that the 
presence of the dimeric Rel A/p65 forms in the nucleus of the high TG2 breast cancer cell lines 
is independent of the conventional NFκB activation pathway wherein IKKα/β is known to be a 
key player. IKKα/β is responsible for phosphorylation of inhibitor of NFκB, IκBα, which 
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allows the free NFκB complex to translocate from the cytoplasm to the nucleus of the breast 
cancer cell lines. Since PS1145 only seems to inhibit the activity of NFκB in the TG2- null 
breast cancer cells lines, it can be inferred that the high TG2 expressing MDA MB 231 Clone 
16 and MCF7/RT display constitutively activated NFκB in the form of Rel A/ p65 dimers, 
which is independent of IKKα/β phosphorylation activity. Also, the unconventional pathway 
observed in the MDA MB 231 Clone 16 and MCF7/RT cell lines has been demonstrated to be 
completely dependent on TG2 as decreasing the intracellular activity of TG2 using R283 and Z-
DON, significantly decreased the NFκB activity levels as well as the aberrant Rel A/p65 dimer 
observed in the nucleus.  
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Figure 5.6 Analysis of NFκB activity levels in breast cancer cell lines on being treated with 
PS1145 and TG2 inhibitors 
The breast cancer cell lines were analysed for the NFκB activity levels on treatment with 
PS1145 using the NFκB/SEAP Reporter assay. 5x105 cells of each breast cancer cell line was 
seeded into 6-well plates and transfected with NFκB/SEAP plasmid. 48 h after transfection, the 
breast cancer cell lines were treated with 10μM of PS1145 for 24 h as well as TG2 inhibitors, 
R283 (500μM) and Z-DON (50μM) for 72 h and the supernatant was collected for SEAP 
analysis as described in detail in Section 2.2.12. Data shown is mean concentration of SEAP ± 
SE from 3 independent experiments (n=3). Statistical analysis was performed using ANOVA 
with Dunnett’s post-hoc test. * p< 0.05 between untreated and PS1145 treated cells; **p<0.05 
between untreated and TG2 inhibitor treated cells in the presence of PS1145. # p<0.05 between 
cell groups treated with PS1145.  
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Figure 5.7 Western blot analysis of Rel A/p65 in the cytoplasmic and nuclear fractions of 
breast cancer cell line on being treated with PS1145 and TG2 inhibitors 
The MDA MB 231 WT (A) and MDA MB 231 Clone 16 (C) cells (1x10
6 
cells per dish) were 
seeded into 60-mm petridishes and left overnight to become confluent. The following day, the 
cells were treated with 10μM of PS1145 for 24 h and TG2 inhibitors, R283 (500μM) and Z-
DON (50μM) for 72 h. After the treatment, the cells were fractionated into the cytoplasmic and 
nuclear fractions as previously described in Section 2.2.2. The sub cellular fractions were then 
analysed by western blot for the expression of Rel A/p65 using rabbit polyclonal anti- Rel A/p65 
antibody (1:1000). The membranes were then reprobed for anti-Lamin A antibody to check for 
equal protein loading. (A & C) The western blot data is a representation of three independent 
experiments (n=3). (B & D) Differences in expression of Rel A/p65 as calculated by Image J 
analysis is representative of the mean densitometry readings + SEM.  
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5.3.3.4 Activity and expression of TG2 in breast cancer cell lines on treatment with 
IKK inhibitor, PS1145 and TG2 inhibitors 
The breast cancer cell lines were analysed for the expression of TG2 in their cytoplasmic 
fractions as well as the TG2 activity at the cell surface and in their whole cell lysates, on being 
treated with TG2 activity inhibitors and PS1145. The cell surface and whole cell lysate activity 
of TG2 in the breast cancer cell lines on being treated with TG2 inhibitors and PS1145 was 
performed as previously described in Section 2.2.11.  The TG2 null MDA MB 231 WT, 
MCF7/WT did not display any cell surface or whole cell lysate TG2 activity and on treating 
these breast cancer cell lines with PS1145 and TG2 activity inhibitors no change in the TG2 
activity of these cell lines was observed . The MDA MB 231 Clone 16 cells demonstrated high 
cell surface TG2 activity as well as whole cell lysate TG2 activity. Treating the MDA MB 231 
Clone 16 cells with PS1145 did not alter the TG2 activity levels within this cell line. A 
combination treatment of TG2 activity inhibitors and PS1145 decreased the TG2 cell surface 
and whole cell lysate activity of the MDA MB 231 Clone 16 cells to a similar level as only 
treatment with TG2 activity inhibitors. The MCF7/RT cells only demonstrated whole cell lysate 
TG2 activity, which remains unaltered on treatment with PS1145. Treating the MCF7/RT cell 
lines with both PS1145 and TG2 activity inhibitors illustrated a decrease in the TG2 whole cell 
activity of these cells, however, only to the same extent as that of the TG2 inhibitors (Figure 
5.8). These results seem to imply that the activity of TG2 seen within these breast cancer cell 
lines is independent of IKKα/β function and so treating these cell lines with PS1145 does not 
affect the TG2 activity levels.  
To verify the results obtained by the TG2 cell surface and whole cell lysate activity assay, 
western blot analysis was conducted on the breast cancer cell lines to determine the level of 
TG2 expression in the cytoplasmic fractions on being treated with PS1145. The MDA MB 231 
WT and MDA MB 231 Clone 16 breast cancer cell lines were treated with 10μM of PS1145 for 
24 h after which the cytoplasmic fractions of the cell lines were obtained as described in 
Section 2.2.2. Analysis of the sub cellular fraction using anti-TG2 antibody by western blot 
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revealed no change in the expression of TG2 in the cytoplasmic fractions of the PS1145 treated 
and untreated MDA MB 231 Clone 16 (Figure 5.9). With the above results, the suggestion that 
phosphorylation of IκBα by IKKα/β was not essential for the constitutive activation of NFκB as 
well as expression and activity of TG2 within these breast cancer cell lines can be put forward.  
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(B) 
Figure 5.8  Analysis of the whole cell lysate (A) and cell surface (B) TG2 activity in breast 
cancer cell lines on being treated with PS1145 and TG2 activity inhibitors 
The cell surface and whole cell lysate TG2 activity assay of the breast cancer cell lines were 
analysed by the incorporation of biotinylated cadaverine into fibronectin. Positive control (50 
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ng/ml gplTG + 10mM  CaCl2) was taken to be 100% TG2 activity (1.28576 ± 0.29475(A); 
1.214834 ± 0.218435 (B) . Data shown above is mean percentage TG2 activity + SEM from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA with 
Dunnett’s post-hoc test. * p<0.05 between untreated and TG2 inhibitor treated cells in the 
presence on PS1145. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Constitutive activation of NFκB by TG2 is independent of IKKα/β 
function 
218 | 
 
Figure 5.9 Analysis of the expression of TG2 in the cytoplasmic fractions of breast cancer 
cell lines on treatment with PS1145  
The MDA MB 231 WT and MDA MB 231 Clone 16 (1x10
6
 cells per dish) were seeded into 60-
mm petridishes and left overnight to become 70-80% confluent. The next day the breast cancer 
cell lines were treated with 10μM of PS1145 for 24 h after which the cytoplasmic fractions of 
the cells were obtained as described in Section 2.2.2. The sub cellular fraction was then 
analysed for the expression of TG2 by western blot using mouse monoclonal anti-TG2antibody 
(Cub 74202)(1:1000). The membranes were reprobed with anti-α-Tubulin antibody to ensure 
equal loading of protein. (A) The western blot data shown is a representation of three 
independent experiments (n=3). (B) Densitometry analysis was performed using image J and is 
represented as the mean densitometry + SEM.  
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5.3.3.5 Chemo sensitivity of breast cancer cell lines in the presence of doxorubicin 
on being treated with PS1145 
As an important intracellular molecule in the NFκB signalling pathway, the role of IKKα/β was 
investigated using a IKKα/β specific inhibitor, PS1145 to treat the breast cancer cell lines. XTT 
analysis of the breast cancer cell lines in the presence of PS1145 and doxorubicin was done to 
investigate whether the presence of PS1145 would decrease chemoresistance of the high TG2 
breast cancer cell lines to doxorubicin treatment.  
The TG2 null MDA MB 231 WT and MCF7/WT cell lines showed a considerable loss in cell 
viability, in the presence of doxorubicin (1μg/ml). Treating the MDA MB 231 WT and 
MCF7/WT cell lines with PS1145 in the presence of doxorubicin, further decreased the cell 
viability. On the other hand the TG2 high MDA MB 231 Clone 16 and MCF7/RT cell lines 
demonstrated reduced loss in cell viability in the presence of doxorubicin (1μg/ml). Even on 
treating these high TG2 breast cancer cell lines with PS1145 in the presence of doxorubicin, no 
significant decrease was demonstrated in cell viability (Figure 5.10)  
These results could imply that blocking the basal activation of NFκB by the canonical pathway 
in the TG2 null MDA MB 231 WT and MCF7/WT cells rendered these cells more susceptible 
to doxorubicin. Also since the MDA MB 231 Clone 16 and MCF7/RT cells demonstrated no 
significant decrease in cell viability when treated with PS1145 in the presence doxorubicin, the 
expression and activity of TG2 in the cells could be contributing to constitutively activating the 
NFκB survival pathway in a manner independent to IKKα/β.   
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Figure 5.10 The effect of PS1145 treatment on the cell viability of breast cancer cell lines 
in the presence of doxorubicin  
3000 cells each of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cells were seeded per well into a 96-well plate and left overnight. The next day the cells were 
treated with doxorubicin (1μg/ml) for 72 h and 10μM of PS1145 for 24 h. After treatment, the 
cell viability of the breast cancer cell lines was analysed using XTT assay. Untreated cells were 
taken as 100% viable.  Data shown above is mean percentage of cell viability +SEM from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA. # p< 0.05 
between cell groups treated with PS1145 in the presence of doxorubicin.  
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5.4    DISCUSSION 
Calpeptin is a cell-permeable inhibitor of μ-calpain, which is a calcium-dependent neutral non-
lysosomal thiol protease that has been found in numerous eukaryotic cells (Suzuki, et al. 2004). 
Previous studies have shown that μ-calpain is responsible for the regulated signalling of NFκB 
in skeletal muscles. Also, reports have also shown that μ-calpain can direct free IκBα into the 
PEST domain for subsequent degradation, thus implicating calpain to be an important player in 
the activation of NFκB. In human HepG2 cells, Han et al. in 1999 demonstrated that calpain 
provided a proteolytic degradation pathway which was parallel to the ubiquitin pathway 
followed by TNFα mediated IκBα degradation (Han, et al. 1999). In WEH1231 B cells, the 
rapid degradation of IκBα was also shown not dependent on the ubiquitin proteosome pathway, 
but regulated by calpain inhibitors or even calcium chelating agents (Miyamoto, et al. 1998).  
In the high TG2 expressing breast cancer cell lines, constitutive activation of NFκB was 
observed as previously demonstrated in chapter 4. In the cytoplasmic fractions of the MDA MB 
231 Clone 16 and MCF7/RT cells, IκBα dimers were observed as opposed to the monomeric 
forms of free IκBα in the TG2 null breast cancer cell lines. Inhibiting TG2 in the MDA MB 231 
Clone 16 and MCF7/RT breast cancer cell lines has previously been shown to decrease NFκB 
activity within these cells. On treatment with the cell-permeable TG2 inhibitor, Z-DON, the 
dimeric IκBα complex has also been demonstrated to decrease. The TG2 null breast cancer cell 
lines did not demonstrate any IκBα dimers which may imply that the IκBα dimers were 
characteristic to transamidating activity of TG2.  
In the high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT cell lines, there is evidence 
to suggest that a novel system for degradation of IκBα was in function. Previous studies done 
by Kim, et al.(2010) also reported that a TG2-calpain system was active in high TG2 expressing 
breast cancer cell lines which may be a possible mechanism by which NFκB could be 
constitutively activated in these cells. In this study, treating the high TG2 breast cancer cell 
lines with the μ-calpain inhibitor calpeptin increased the presence of IκBα polymers in the 
MDA MB 231 Clone 16 and MCF7/RT cells. Also, TG2 has been shown to catalyze the cross 
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linking of IκBα protein molecules at lysine 33, 36 and 177 as well as glutamines 313, 267 and 
266 (Folk & Chung, 1985). This cross-linking of IκBα mediated by TG2 would result in the 
release of the NFκB (Rel A/p65) molecule and subsequent degradation by the μ-calpain 
proteosomal degradation pathway, which would result in accumulation of the IκBα dimers 
within the cytoplasmic fractions of the high TG2 breast cancer cell lines. In this way, TG2 
could regulate the activation of NFκB in breast cancer cell lines independent of ubiquitination. 
To determine whether the constitutive activation of NFκB (Rel A/p65) as well as the 
polymerization and subsequent degradation of IκBα was dependent on the phosphorylation of 
IκBα by IKKα/β or independent of IKKα/β and dependent on TG2,  the breast cancer cell lines 
were treated with the IKK phosphorylation inhibitor, PS1145. Studies determined that in the 
high TG2 breast cancer cell lines, treatment with PS1145 did not significantly decrease the 
NFκB activity or the formation of the Rel A/ p65 dimers in the nuclear fractions. On the other 
hand, in the TG2 null breast cancer cell lines, PS1145 significantly reduced the NFκB activity 
of the cells and also prevented the translocation of monomeric Rel A/p65 from the cytoplasmic 
and nuclear fraction. This could imply that the activity of NFκB in the TG2 breast cancer cell 
lines was reliant on TG2 activity and expression, as opposed to the classical pathway present in 
the TG2 null breast cancer cell lines, wherein the NFκB activity is dependent on 
phosphorylation of IκBα by IKK α/β. These results suggest that in breast cancer cell lines that 
display high levels of TG2, a calpain and TG2-based pathway might provide an alternative 
degradation pathway to the classical ubiquitin - proteosome pathway of IκBα degradation (Han, 
et al. 1999). Since the NFκB family member activated in the high TG2 breast cancer cell lines 
has been determined to be Rel A/p65 dimeric forms, which is independent of IκBα 
phosphorylation by IKK, the constitutive activation of Rel A/ p65 dimers can be attributed to a 
canonical pathway which is non-conventional. The effect of PS1145 treatment on the 
expression and activity levels of TG2 was further validated by western blot analysis, whole cell 
lysate and cell surface TG2 activity assays. No significant change was observed in the 
expression or activity levels of TG2 in the breast cancer cell lines on treatment with PS1145. 
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The NFκB family member Rel A/p65 has been previously shown to cause TG2 mRNA 
expression in cultured breast cancer cell lines as the TGM2 gene has been revealed to contain 
two NFκB consensus binding sites (Ai, et al. 2012 ; Caccamo, et al. 2005). Moreover, the 
chemoresistant properties of the high TG2 breast cancer cell lines could not be reversed with 
PS1145 treatment. This provides evidence to support that the constitutive activation of Rel A/ 
p65 dimers that confer chemoresistant phenotype to TG2 expressing breast cancer cell lines is 
independent of IKK function, enumerating a deviation from the classical NFκB activation 
pathway.  
To summarize the above observations, this chapter's work demonstrates that the constitutive 
activation of Rel A/ p65 dimers mediated by TG2 is via the cross linking of IκBα to form 
dimers and polymers which are degraded spontaneously through the μ-calpain proteosomal 
degradation pathway and is also independent of IKKα/β phosphorylation function. Importantly, 
inhibiting IKKα/β function using PS1145 did not reduce the chemoresistant phenotype of the 
high TG2 breast cancer cell lines or decrease the activity and expression of TG2. 
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6. Phosphorylated status of the cross 
linked Rel A/p65 dimer is necessary for 
TGM2 gene expression and 
chemoresistance  
6.1 INTRODUCTION 
The activation of the NFκB signalling pathway is dependent on various external stimuli 
(Hayden & Ghosh, 2004). The activation of this pathway will allow the translocation of the 
NFκB transcription factors from the cytoplasm to the nucleus of cells. The NFκB subunits, 
either homo-dimers or hetero-dimers, are held in the cytoplasm by a family of proteins known 
as the IκBα or inhibitors of NFκB. On receiving external stimuli, the IκBα proteins are 
phosphorylated by IKKα, IKKβ or IKKγ, ubiquitinylated and subsequently degraded 
proteolytically.  This allows the NFκB subunits to move into the nucleus (Karin & Ben-Neriah, 
2000).  
Several studies have shown that the NFκB family of proteins can be modified post- 
translationally and these alterations can greatly influence the transcriptional activity of the 
NFκB subunits (Chen, et al. 2001) For example, the S- nitrosylation of cysteine 65 of the p50 
subunit has been shown to greatly affect the binding of the p50 member to DNA (Marshall & 
Stamler, 1999) . Similarly, reports have demonstrated that Rel A/p65 can undergo 
phosphorylation as a response to some external stimulating factors (Vermeulen, et al. 2002). 
Phosphorylation of Serine 276 in Rel A/p65 by protein kinase A has been shown to be essential 
during IκBα degradation as well as for the recruitment of p300/ CREB binding protein to Rel 
A/p65 in order to activate transcription (Zhong, et al. 2002)  The phosphorylation of serine 536 
by IκB kinases and serine 529 by casein kinase II (Wang, et al. 2000) after either LPS or TNF-α 
stimulation has also been demonstrated to increase transcriptional activity (Okazaki, et al. 
2003). Studies done by Sasaki et al. in 2005 clearly demonstrated that the phosphorylation of 
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serine residues of Rel A/p65 were not associated with either p50 or IκBα and MG-132 which is 
a known proteosome inhibitor, reduced the translocation of Rel A/p65 to the nucleus but the 
phospho-Rel A/p65 remained unaffected (Sasaki, et al. 2005). Also, dominant-negative mutants 
of IκBa were shown to decrease the transcriptional activity of Rel A/p65 but the phospho-
dimeric form of serine 536 p65 remained unaltered. This seems to suggest that phospho-Ser 
536-p65 translocates into the nucleus immediately after activation and was not regulated by 
IκBα function. The implications of serine phosphorylation at residue 536 in the regulation of the 
transactivating potential of TG2 has not yet been clearly defined (Sasaki, et al. 2005). The 
direct post translational modification of Rel A/ p65 subunits of the NFκB family involves the 
phosphorylation of the C- terminal domain (Harris, et al. 2006).  
Numerous serine 536 kinases have been described such as IKKα, IKKβ, IKKε as well as NFκB 
activating kinase (Vermeulen, et al. 2003; Viatour, et al. 2005; Sakurai, et al. 1999; Sizemore, 
et al. 2002; Jiang, et al. 2003; Buss, et al. 2004; Lawrence, et al. 2005). Even though IKKε is 
structurally very similar to IKKα and IKKβ with a C-terminal leucine domain, N-terminal 
kinase domains as well as helix-loop-helix domains, IKKε only shares about 27% of primary 
sequence identity with IKKα (Kishore, et al. 2002). Studies done previously have determined 
that IKKε can directly phosphorylate Rel A/ p65, even though the exact physiological relevance 
of these events remains to be established. Mutation of the Ser 536 site to Alanine has also been 
shown to decrease the phosphorylation induced by IKKε, which may implicate that the 
phosphorylation site of IKKε on Rel A/ p65 was specific to Serine 536 (Buss, et al. 2004). 
Following genotoxic stress in cells, IKKε can enter into the nucleus of the cell in a kinase 
dependent manner, wherein IKKε can phosphorylate PML nuclear bodies allowing the retention 
of the IKKε complex in the nucleus. Within these sub nuclear bodies, IKKε can undergo SUMO 
modification which will subsequently allow the phosphorylation of the nuclear substrate 
including Rel A/ p65, that will therefore contribute to the anti-apoptotic and chemoresistant 
properties in response to damaged DNA (Renner, et al. 2010) 
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Various stimuli can induce the phosphorylation of Rel A/ p65 at serine 536 and the pathways 
that are responsible for this post-translational modification have to yet be deciphered. Previous 
results have reported that using RNA interference to block IKKα/β; dominant-negative mutants 
of IKK as well as SC-514 (a specific IKKβ inhibitor) did not block the Ser 536 phosphorylation 
of Rel A/ p65. On the other hand, over expression of IKKε has been shown to phosphorylate 
Ser 536 both in vivo and in vitro (Buss, et al. 2004). Studies conducted by Adli and Baldwin in 
2006, demonstrated that IKKε was expressed highly in breast cancer cell lines and also involved 
in the regulation of NFκB activity via the ability to control the constitutive as well as basal 
phosphorylation of Rel A/ p65 at Serine 536 (Adli & Baldwin, 2006). Decreasing the 
expression of IKKε or expressing a S536A mutant form of Rel A/ p65 suppressed the 
proliferation of cancer cells which clearly indicated that IKKε  played a crucial role in the 
regulation of the constitutive activation of NFκB  activity (Adli & Baldwin, 2006).  
Studies conducted on breast cancer cell lines illustrated that Rel A/ p65 interacted with two 
separate NFκB binding sites within the TGM2 gene promoter. In conditions of genotoxic stress, 
breast cancer cell lines demonstrated a high association of Rel A/ p65 with the TGM2 promoter. 
Also, mutating the -κB binding sites or use of NFκB pharmacological inhibitors decreased the 
TGM2 promoter activity significantly (Ai, et al. 2012). With this, a novel loop wherein Rel 
A/p65 and TG2 activated each other resulted in a sustained activation of Rel A/ p65 as well as a 
chemoresistant phenotype could be hypothesized. Numerous literature reports have also 
suggested that NFκB has transcriptional control over the baseline expression of the TGM2 gene 
in numerous cancer cells (Chen, et al. 2008 ; Kim, 2011).  
In this chapter, IKKε was identified as the Rel A/ p65 kinase that induces the phosphorylation 
of Ser 536 in response to constitutive activation by TG2. Using BX795, which is a specific 
IKKε inhibitor, the phosphorylated status of Serine 536 in Rel A/p65 was determined using 
western blot. In Chapter IV, inhibiting Rel A/p65 using siRNA demonstrated a decrease in the 
activity and expression of TG2 within breast cancer cell lines. In order to further confirm these 
findings and study the post-translational modifications of the Rel A/ p65 dimer, a NFκB p65 
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(Ser529/536) inhibitory peptide was used to detect the binding of the dimers to -κB binding 
sites on DNA.  
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6.2 METHODS 
6.2.1 Treatment of breast cancer cell lines with BX795 
BX795 was developed as a small molecule inhibitor which could significantly inhibit IKKε 
levels at low concentrations in vitro (Bain, et al. 2007) and was specific to IKKε as BX795 did 
not inhibit other protein kinases such as IKKα /IKKβ (Clark, et al. 2009). Using BX795 the role 
and regulation of IKKε in breast cancer cell lines can be determined. 3000 cells each of the 
MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cell lines were seeded 
into each well of a 96- well plate and grown to 70-80% confluency overnight. The next day the 
breast cancer cells were treated with increasing concentrations of BX795 (10μM, 15μM and 
20μM) for time courses of 24, 48 and 72 h. After the treatment, the breast cancer cell lines were 
analysed using XTT to determine the appropriate concentration of BX795 that would not be 
cytotoxic to the cells. These results were expressed as the percentage of viable cells. 
After determining the optimum concentration and time course of BX795 treatment, the breast 
cancer cell lines (1x10
6
 cells/dish) were seeded into 60 mm petridishes and treated with BX795. 
After the time course of treatment, the breast cancer cell lines were subsequently used for 
further experiments. 
6.2.2 Treatment of breast cancer cell lines with NFκB p65 (Ser529/536) inhibitory 
peptide 
The NFκB p65 (Ser529/536) inhibitory peptide set that contains Rel A/p65 inhibitor peptide as 
well as a control peptide was purchased from IMGENEX (Catalogue Number: IMG-2003). The 
NFκB p65 (Ser529/536) inhibitory peptide blocks Rel A/ p65 Serine 529/536 phosphorylation 
during NFκB activation which inhibits the binding of Rel A/ p65 to DNA. The main function of 
the NFκB p65 (Ser529/536) inhibitory peptide is to inhibit the activation of NFκB. The 
sequences of the inhibitory peptides are as follows: 
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NFκB p65 (Ser529/536) inhibitory peptide: DRQIKIWFQNRRMKWKKNGLLSGDEDFSS    
(p65 sequence is underlined) 
Control Peptide: DRQIKIWFQNRRMKWKK 
According to the manufacturer's instructions, 100μM of both the NFκB p65 (Ser529/536) 
inhibitory peptide and the control peptide was used to treat the breast cancer cell lines for a time 
course of 1 h. The NFκB p65 (Ser529/536) inhibitory peptide contains the PTD (protein 
transduction sequence) - DRQIKIWFQNRRMKWKK, renders the peptide cell permeable. The 
Control peptide in this set only consists of the PTD sequence. 
Subsequently, the cytoplasmic and nuclear fractions of the breast cancer cell lines were 
collected as described in Section 2.2.2. Western blot analysis was performed on the sub cellular 
fractions to analyse the expression of TG2, α-Tubulin as well as TG2 whole cell lysate activity 
assay.  
6.2.3 Detection of the phosphorylated status of Rel A/ p65 dimers via co-
immunoprecipitation 
Co-immunoprecipitation assays were performed to detect the phosphorylated status of Rel A/ 
p65 dimers in the breast cancer cell lines that were treated with BX795 for a time course of 48 h 
and subsequently fractionated into the cytoplasmic and nuclear fractions (Section 2.2.2). 
Briefly, rabbit anti- Rel A/ p65 polyclonal antibody and protein A beads were used to pull down 
the Rel A/ p65 immunocomplex in the pre-cleared cytoplasmic and nuclear samples. Western 
blotting was used to detect the presence of serine phosphorylation in the immunoprecipitated 
complex using mouse anti-phosphoserine monoclonal antibody (Section 2.2.8).  
6.2.4 Chromatin Immunoprecipitation (ChIP) and PCR 
The translocation of the NFκB subunit Rel A/p65 to the -κB  sites of particular NFκB gene 
promoter targets in the breast cancer cell lines was assessed via ChIP assay using the 
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ExactaChIP 
TM 
Human Rel A Chromatin Immunoprecipitation Kit  (Catalogue Number 
EC5078). The ChIP assay was performed as described in detail in Section 2.2.16.1. The 
immunoprecipitated DNA was subjected to PCR as introduced in Section 2.2.16.2. The primer 
pairs used for the PCR analysis used for the TGM2, p21 and GAPDH gene promoter is as 
summarized in Section 2.1.3. The p21 gene promoter was used as a positive control and 
GAPDH was used as the house keeping gene. The PCR samples were then further analysed by 
1.5% Agarose gel electrophoresis (in 1x TAE).    
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6.3 RESULTS 
6.3.1 Phosphorylated status of the Rel A/p65 dimer to DNA in breast cancer cell 
lines 
NFκB activity is controlled in several stages by post-translational modifications including the 
phosphorylation of the transactivating Rel A/p65 subunit at various serine sites. To determine if 
the Rel A/ p65 dimers underwent phosphorylation at serine sites, the MDA MB 231 WT, MDA 
MB 231 Clone 16, MCF7/WT and MCF7/RT breast cancer cell lines were immunoprecipitated 
with anti- Rel A/ p65 antibody and the resulting immunoprecipitates were subjected to 
immunoblotting using anti-phosphoserine antibody.  
Results shown in Figure 6.1 clearly indicated that Rel A/ p65 was phosphorylated at a serine 
residue in the nucleus of high TG2 breast cancer cell lines as revealed by the presence of a 
distinct phosphoserine pull down band in the Rel A/ p65 immunoprecipitates. The TG2-null 
MDA MB 231 WT and MCF7/WT cell lines did not display any pull down phosphoserine 
band. Furthermore, in the MDA MB 231 Clone 16 and MCF7/RT cell lines, the dimeric Rel A/ 
p65 form observed in the nucleus was found to be phosphorylated at a serine residue, while the 
monomeric Rel A/p65 in the cytoplasmic fraction as well as the nuclear fraction did not 
undergo the post translational modification.  These results clearly indicate that in the high TG2 
breast cancer cell lines, the Rel A/ p65 dimers present in the nuclear fractions underwent post 
translational modification on a serine site.  
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Figure 6.1 Analysis of the phosphorylated serine status of Rel A/ p65 dimers in the 
cytoplasmic and nuclear fractions of breast cancer cell lines using co-
immunoprecipitation. 
The phosphorylated status of the Rel A/ p65 dimers was detected in the cytoplasmic and nuclear 
fractions of the breast cancer cell lines using western blotting (anti-phosphoserine antibody). 
1x10
6 
cells of each breast cancer cell line was seeded into 60-mm petridishes and grown 
overnight to reach 70-80% confluency. The next day, the breast cancer cell lines were 
fractionated into the cytoplasmic and nuclear fractions as described in Section 2.2.2. The sub 
cellular fractions were then immunoprecipitated using anti-Rel A/p65 antibody and the immune 
complex then analysed by western blotting using anti-phosphoserine antibody (1:1000). (A) The 
western blot data shown above is a representation of three independent experiments (n=3). (B) 
Densitometry analysis was performed using Image J and the data shown is represented as the 
mean densitometry ± SE.  
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6.3.2 Treatment of breast cancer cells with IKKε phosphorylation specific 
inhibitor, BX795 
6.3.2.1 Killing curve to determine optimum concentration of BX795 
To establish the optimum concentration of BX795 to treat the breast cancer cell lines without 
the inhibitor being cytotoxic, the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and 
MCF7/RT cell lines were treated with increasing concentrations of BX795 (10μM, 15μM and 
20μM) over a time course as described in Section 6.2.1. 10μM of BX795 over a time course of 
48 h was selected to be the optimum concentration and longest possible time course to treat the 
breast cancer cell lines, without causing cytotoxicity to the cells (Figure 6.2) 
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Figure 6.2 Cell viability analyses of breast cancer cell lines in the presence of increasing 
concentrations of BX795 over a time course  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cell lines (3000 
cells/well) were seeded into 96 well plates and allowed to become 70-80% confluent overnight. 
The next day the breast cancer cell lines were treated with increasing concentrations, 10μM, 
15μM and 20μM of IKKε inhibitor, BX795. After 24, 48 and 72 h of treatment, the cell viability 
of the breast cancer cell lines was analysed using XTT (Section 2.2.13). The data shown is the 
percentage of viable cells measured in triplicate + SEM. The untreated cells (Unt) have been 
taken as 100% cell viability.   
  
 
 
 
 
0
20
40
60
80
100
120
Unt BX795
(10uM)
BX795
(15uM)
BX795
(20uM)
Unt BX795
(10uM)
BX795
(15uM)
BX795
(20uM)
Unt BX795
(10uM)
BX795
(15uM)
BX795
(20uM)
24h 48h 72h
%
 c
el
l 
v
ia
b
il
it
y
 
MDA MB 231 WT
MDA MB 231 Clone 16
MCF7/WT
MCF7/RT
100 
Chapter 6: Phosphorylated status of the cross linked Rel A/p65 dimer is necessary for 
TGM2 gene expression and chemoresistance 
236 | 
 
6.3.2.2 Detection of the phosphorylated serine status of Rel A/ p65 dimers by co-
immunoprecipitation in the presence of BX795 
Results from the previous chapters indicated that IKKα/β was not involved in the constitutive 
activation of Rel A/p65 dimers by TG2 as PS1145 failed to demonstrate any significant 
decrease in the Rel A/p65 dimers, NFκB activity, TG2 protein expression and activity as well as 
chemoresistance. To determine whether the dimeric Rel A/ p65 form was phosphorylated on 
serine residues by IKKε present in the nucleus, the effect of the IKKε phosphorylation inhibitor, 
BX795 was studied. The high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cell lines were treated with 10μM of BX795 for 48 h and immunoprecipitated using anti-
Rel A/ p65 antibody (0.5μg/sample). Protein A beads were then used to pull down the Rel A/ 
p65 immune complex which was subsequently analysed by western blotting using anti-
phosphoserine antibody to detect the presence of the phosphorylated serine antigen. The results 
obtained clearly indicated that treating the MDA MB 231 Clone 16 and MCF7/RT with BX795 
decreased the phosphorylated serine status of the Rel A/p65 dimers in the nucleus of these 
breast cancer cell lines (Figure 6.3). This also implies that the phosphorylation of a serine 
residue of Rel A/p65 dimers was as a result of IKKε activity as BX795 inhibited the serine 
phosphorylation.  
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Figure 6.3 Analysis of phosphorylated serine status of Rel A/ p65 dimers in the 
cytoplasmic and nuclear fractions of breast cancer cell lines using co-mmunoprecipitation, 
in the presence of BX795  
The phosphorylated status of the Rel A/ p65 dimers was detected in the cytoplasmic and nuclear 
fractions of the breast cancer cell lines using western blot (anti-phosphoserine antibody 
{1:1000}). 1x10
6 
cells each of MDA MB 231 Clone 16 and MCF7/RT cell line was seeded into 
60-mm petridishes and grown overnight to reach 70-80% confluency. The next day, the breast 
cancer cell lines were treated with 10μM of BX795 for a time course of 48 h. After the 
treatment, the breast cancer cell lines were fractionated into the cytoplasmic and nuclear 
fractions as described in Section 2.2.2. The sub cellular fractions were then 
immunoprecipitated using anti-Rel A/p65 antibody and the immune complex was then analysed 
by western blot using anti-phosphoserine antibody (1:1000) (A). The western blot data shown 
above is representative of three independent experiments (n=3). Densitometry scans were 
quantified (B) by Image J analysis and are represented as mean of densitometry + SEM. * p< 
0.05.  
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6.3.2.3 Western blot analysis of pSer536-Rel A/p65 in breast cancer cell lines 
Previously published literature has established that IKKε phosphorylates the serine 536 residue 
on Rel A/ p65, on being constitutively activated as a response to various cellular stimuli. To 
identify this, the cytoplasmic and nuclear fractions of the MDA MB 231 WT, Clone 16, 
MCF7/WT and MCF7/RT cells were treated with the IKKε inhibitor, BX795 as well as the cell 
permeable TG2 activity inhibitor, Z-DON and then analysed by western blotting using anti-
pSer536- Rel A/p65 antibody. The TG2 low MDA MB 231 WT and MCF7/WT cells did not 
express any pSer536- Rel A/p65 in the cytoplasmic and nuclear fractions as described in 
previous sections. On the other hand, the high TG2 expressing MDA MB 231 Clone 16 and 
MCF7/RT cells demonstrated phosphorylation at the Serine 536 residue of the Rel A/ p65 dimer 
in the nuclear fraction. The IKKε phosphorylation inhibitor, BX795 decreased the serine 536 
phosphorylation of the Rel A/p65 dimers. Also, as previous results indicated, the cell permeable 
TG2 activity inhibitor, Z-DON, decreased the Rel A/ p65 dimers which subsequently decreased 
the pSer 536- Rel A/p65 dimers (Figure 6.4) .These results clearly imply that the serine 536 
residue of the Rel A/ p65 dimer of the high TG2 breast cancer cell lines was phosphorylated as 
a post translational modification. Also, this phosphorylated serine 536 residues seemed to be a 
characteristic of the nuclear Rel A/ p65 dimers. This phosphorylation of the Rel A/ p65 dimer at 
the serine 536 residue can be attributed to the kinase activity of the IKKε member of the IKK 
family of proteins as BX795, which is a specific IKKε phosphorylation inhibitor, decreases the 
phosphorylated status of the Rel A/ p65 dimer. 
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Figure 6.4 Analysis of pSer 536 - Rel A/ p65 dimers in breast cancer cell lines in the 
presence of BX795  
The MDA MB 231 WT, MDA MB 231 Clone 16 (A), MCF7/WT and MCF7/RT (C) breast 
cancer cell lines (5x10
5 
cells/well) were seeded into 6-well plates and left overnight to become 
70-80% confluent. The next day, the breast cancer cell lines were treated with 10μM of BX795 
for 48 h and 50μM of Z-DON for 72 h. After the treatment, the breast cancer cell lines were 
fractionated into the cytoplasmic and nuclear fractions as described in Section 2.2.2. The sub 
cellular fractions were then analysed by western blotting (A & C) using anti-pSer 536- RelA/ 
p65 antibody (1:1000). The membranes were then reprobed using anti-Lamin A and anti-α-
Tubulin antibody to ensure that the protein is equally loaded. The western blot data shown 
above is a representation of three independent experiments (n=3).(B &D) Differences in the 
expression of pSer 536- RelA/ p65 dimers in the treated and untreated samples was calculated 
using Densitometry was carried out and data is shown as the mean densitometry + SEM. * p< 
0.05  
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6.3.2.4 Decreased TG2 expression and activity in breast cancer cell lines treated 
with BX795 
To determine if the phosphorylated serine status of the Rel A/p65 dimers was crucial for TG2 
expression and activity, the breast cancer cell lines were analysed for the expression of TG2 by 
western blotting in the cytoplasmic fractions as well as the whole cell lysate.TG2 activity was 
also measured on being treated with IKKε inhibitor, BX795. The MDA MB 231 WT, MDA 
MB 231 Clone 16, MCF7/WT and MCF7/RT cells were treated with 10μM of BX795 for a 
time course of 48 h and analysed by western blot for TG2 expression and TG2 whole cell lysate 
activity as described in Sections 2.2.3 - 2.2.6 and Section 2.2.11 respectively.  On analysing the 
TG2 expression within the MDA MB 231 Clone 16 and MCF7/RT cell lines, there was a clear 
indication that BX795 treatment decreased the TG2 expression within these high TG2 breast 
cancer cell lines. Inhibiting the phosphorylation of the Rel A/p65 dimer at the serine 536 site 
seems to reduce the expression of TG2. This could be because the post translational 
modification of the Rel A/ p65 dimer is essential for the expression of TG2 (Figure 6.5). To 
further verify these results, the TG2 whole cell lysate activity of the breast cancer cell lines 
were analysed. The TG2 null MDA MB 231 WT and MCF7/WT did not demonstrate any TG2 
whole cell lysate activity and on treating these breast cancer cell lines with BX795, no change 
in the TG2 levels within the cells was found The MDA MB 231 Clone 16 and MCF7/RT cell 
lines demonstrated a high level of whole cell lysate TG2 activity and treatment with BX795 
illustrated a considerable decrease in the TG2 activity within these cells (Figure 6.6). These 
results clearly indicated that the serine 536 phosphorylation of the Rel A/ p65 dimer by IKKε in 
the nucleus was essential for the expression and subsequent activity of TG2 within the MDA 
MB 231 Clone 16 and MCF7/RT breast cancer cell lines. 
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Figure 6.5 Analysis of the expression of TG2 in the cytoplasmic fractions of breast cancer 
cell lines on treatment with BX795  
The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cell lines (5x10
5
 
cells per well) were seeded into a 6 well plate and left overnight to become confluent. The next 
day the breast cancer cell lines were treated with10μM of BX795 for 48 h after which the 
cytoplasmic fractions of the breast cancer cell lines were obtained as described in Section 
2.2.2. (A) The cytoplasmic fractions were then analysed for the expression of TG2 by western 
blot using monoclonal anti-TG2 antibody (TG100) (1:1000). The membranes were reprobed 
with anti-α-Tubulin antibody to correct for protein loading. The western blot data shown is 
representative of three independent experiments (n=3). (B) Densitometry analysis was 
performed using image J and is represented as mean densitometry + SEM. * p< 0.05 
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Figure 6.6 Analysis of whole cell lysate TG2 activity in breast cancer cell lines on being 
treated with BX795  
The whole cell lysate TG2 activity of the breast cancer cell lines were analysed using the 
incorporation of biotinylated cadaverine into fibronectin as described in Section 2.2.11. 
Positive control (50 ng/ml gplTG + 10mM  CaCl2) was taken to be 100% TG2 activity (1.31038 
± 0.401384).  Data shown above is mean percentage TG2 activity + SEM from 3 independent 
experiments (n=3). Statistical analysis was performed using ANOVA. * p<0.05 between 
untreated and BX795 treated cells. 
 
 
 
 
 
Chapter 6: Phosphorylated status of the cross linked Rel A/p65 dimer is necessary for 
TGM2 gene expression and chemoresistance 
243 | 
 
6.3.2.5 Analysis of IκBα dimers and p50/p105 NFκB subunits in breast cancer cell 
lines on being treated with BX795 
To determine if treatment with IKKε phosphorylation inhibitor, BX795 had any effect on the 
IκBα dimer and p50/p105 expression, western blot analysis was performed on the cytoplasmic 
and nuclear fractions of the breast cancer cell lines. The MDA MB 231 WT and MDA MB 231 
Clone 16 breast cancer cell lines were treated with 10μM of BX795 for a time course of 48 h 
and then analysed by western blotting using anti-IκBα antibody and anti-p50/p105 antibody. On 
analysis of the cytoplasmic fractions of the breast cancer cell lines using anti-IκBα antibody, the 
TG2 null MDA MB 231 WT cells illustrated the presence of monomeric IκBα, which does not 
change on being treated with BX795. As previously demonstrated, the high TG2 MDA MB 231 
Clone 16 showed the presence of IκBα dimers in the cytoplasmic fractions. Treating the MDA 
MB 231 Clone 16 cells with BX795 did not change the status of the IκBα dimers within these 
cells (Figure 6.7 A). This could imply that inhibiting the phosphorylation of IKKε did not cause 
any change in the IκBα dimers in the high TG2 breast cancer cell lines. Furthermore, the 
p50/p105 subunit also remains unchanged in the high and low TG2 expressing breast cancer 
cell lines. These results indicate that inhibiting the kinase function of IKKε does not have any 
effect on the p50/p105 subunit of NFκB (Figure 6.7 C) 
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Figure 6.7 Western blot analysis of IκBa and p50/p105 NFκB subunit of NFκB in breast 
cancer cells on being treated with BX795 
The MDA MB 231 WT and MDA MB 231 Clone 16 cells were seeded into 6-well plates (5x10
5
 
cells/well) and left overnight to become 70-80% confluent. The next day the breast cancer cell 
lines were treated with 10μM of BX795 for 48 h after which the cytoplasmic and nuclear 
fractions were derived as described in section 2.2.2 and analysed by western blotting (A & C) 
using anti-IκBa antibody (1:1000) and anti- p50/p105 antibody (1:500). The membranes were 
then reprobed with anti-α- Tubulin and anti- Lamin A to correct for protein loading. The 
western blot data shown above is a representation of two independent experiments (n=2). (B& 
D) Densitometry analysis was performed using image J and represented as mean densitometry 
+ SEM.  
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6.3.2.6 Chemosensitivity of breast cancer cell lines on treatment with BX795 and 
TG2 inhibitors in the presence of doxorubicin. 
XTT analysis of the breast cancer cell lines in the presence of doxorubicin and BX795 and TG2 
cell permeable inhibitors (R283 and Z-DON) was performed to investigate whether treatment 
with BX795 would increase the chemosensitivity of high TG2 breast cancer cell lines in 
response to doxorubicin treatment in a comparable manner to the TG2 cell permeable inhibitors 
as described previously. The TG2 low MDA MB 231 WT and MCF7/WT cell lines 
demonstrated a considerable decrease in the loss of cell viability, in the presence of 1μg/ml of 
doxorubicin and further treatment with 10μM of BX795 or TG2 inhibitors, R283 (500μM) and 
Z-DON (50μM) did not change the chemosensitive phenotype of these breast cancer cell lines. 
On the other hand, the high TG2 expressing MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cell lines that were inherently resistant to 1μg/ml of doxorubicin illustrated a 
considerable loss in the cell viability on being treated with 10μM of BX795 (Figure 6.8). This 
decrease in cell viability was consistent with the decrease observed on decreasing the TG2 
activity levels within these high TG2 breast cancer cell lines.  These results are clearly 
indicative that the phosphorylation of serine 536 of the Rel A/ p65 dimer is essential for the 
chemoresistance against doxorubicin in the MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cell lines. 
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Figure 6.8 The effect of BX795 and TG2 cell permeable inhibitor treatment on the cell 
viability of breast cancer cell lines in the presence of doxorubicin 
3000 cells each of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cells were seeded per well into a 96-well plate and left overnight. The next day the cells were 
treated with 10μM of BX795 for 48 h, 500μM of R283 and 50μM of Z-DON for 72 h  in the 
presence of 1μg/ml of doxorubicin for 72 h. After treatment, the cell viability of the breast 
cancer cell lines was analysed using XTT assay. Untreated cells were taken as 100% viable.  
Data shown above is mean percentage of cell viability + SEM from 3 independent experiments 
(n=3). Statistical analysis was performed using ANOVA with Dunnett’s post-hoc test. * p<0.01 
between cells treated with either BX795 or TG2 inhibitors in the presence of doxorubicin.  
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6.3.3 Treatment of breast cancer cell lines with NFκB p65 (Ser529/536) inhibitory 
peptide 
6.3.3.1 Decreased TG2 expression and activity in the presence NFκB p65 
(Ser529/536) inhibitory peptide  
Previous  published data (Kim, et al. 2006), has clearly shown that during a DNA damage 
response, expression of TG2 is significantly up regulated and the use of  pharmacological 
inhibitors of NFκB can inhibit this event. This could imply that high levels of Rel A/p65 sub 
unit could bind to the TGM2 gene promoter (Ai, et al. 2012) The MDA MB 231 WT, MDA MB 
231 Clone 16, MCF7/WT and MCF7/RT cells were transfected with NFκB p65 (Ser529/536) 
inhibitory peptide as described in Section 6.2.2 and the whole cell lysates of these breast cancer 
cell lines were collected (Section 2.2.2). The whole cell lysate fractions of these breast cancer 
cell lines treated with NFκB  p65 (Ser529/536) inhibitory peptide and negative control peptide 
were analysed for  TG2 activity (Section 2.2.11) and the cytoplasmic and nuclear fractions 
were analysed for the TG2 expression using western blot analysis (Sections 2.2.3-2.2.6). The 
MDA MB 231 WT and MCF7/WT cells do not express any TG2 activity in the whole cell 
lysate fractions, which remains unchanged on being treated with NFκB  p65 (Ser529/536) 
inhibitory peptide. On the contrary, the MDA MB 231 Clone 16 and MCF7/RT cells that are 
known to exhibit TG2 activity show a significant decrease in the TG2 activity levels on being 
treated with the NFκB p65 (Ser529/536) inhibitory peptide (Figure 6.9). The negative control 
inhibitory peptide does not cause any change in the TG2 activity levels of the breast cancer cell 
lines. Similarly, the MDA MB 231 Clone 16 and MCF7/RT cells also illustrated a significant 
decrease in the expression of TG2 on being treated with the NFκB p65 (Ser529/536) inhibitory 
peptide (Figure 6.10). These results seem to clearly indicate that inhibiting the binding of Rel 
A/p65 dimers to DNA causes a significant decrease in the TG2 activity and expression in the 
high TG2 breast cancer cell lines. This further confirms that Rel A/ p65 has a -κB binding site 
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on the TGM2 gene promoter which allows the control of TG2 expression and activity within the 
high TG2 breast cancer cell lines.  
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Figure 6.9 Analysis of TG2 whole cell lysate activity in the presence of NFκB  p65 
(Ser529/536) inhibitory peptide  
The whole cell lysate fractions of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT 
and MCF7/RT after treatment with 100μM of NFκB p65 (Ser529/536) inhibitory peptide and 
negative control inhibitory peptide over a time course of 1 h were collected and analysed for 
the TG2 activity as described in Section 2.2.11 by biotinylated cadaverine incorporation into 
fibronectin. Positive control (50 ng/ml gplTG + 10mM  CaCl2) was taken to be 100% TG2 
activity (1.29836 ± 0.31932).  Data shown above is mean percentage TG2 activity ± SE from 3 
independent experiments (n=3). Statistical analysis was performed using ANOVA. * p<0.05 
between untreated and p65 inhibitory peptide treated cells. 
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Figure 6.10 Western blot analysis of TG2 expression in breast cancer cell lines in the 
presence of NFκB p65 (Ser529/536) inhibitory peptide  
NFκB p65 (Ser529/536) inhibitory peptide was used to inhibit the binding of Rel A/p65 dimers 
to the -κB  site on the TGM2 gene promoter. 5x105 cells (per well) each of MDA MB 231 WT, 
MDA MB 231 Clone 16, MCF7/WT and MCF7/RT were seeded into 6 well plates and left 
overnight. The next day, the breast cancer cells were treated with 100μM of NFκB p65 
(Ser529/536) inhibitory peptide and negative control inhibitory peptide over a time course of 1 
h. After the treatment, the cytoplasmic fractions of the breast cancer cell lines were collected as 
described in detail in Section 2.2.2. The sub cellular fraction was then analysed for TG2 
expression by western blot as described in sections 2.2.3-2.2.6 using mouse monoclonal anti-
TG2antibody (1:1000).  The membranes were reprobed with anti-α-Tubulin antibody to correct 
for equal protein loading. (A & C) The western blots shown here is a representation of three 
independent experiments (n=3). (B & D) Densitometry analysis was performed using Image J 
and is represented as the mean densitometry + SEM. * p< 0.05.  
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6.3.3.2 Reduced chemoresistance of breast cancer cell lines on being treated with 
NFκB p65 (Ser529/536) inhibitory peptide in the presence of doxorubicin 
In order to analyse if the binding of the pSer 536 Rel A/ p65 dimers was crucial for the 
chemoresistant phenotype of the high TG2 breast cancer cell lines, XTT analysis was performed 
after treating the cell lines with  NFκB  p65 (Ser529/536) inhibitory peptide in the presence of 
doxorubicin (1μg/ml).The TG2 null MDA MB 231 WT and MCF7/WT cells illustrated a 
considerable loss in the cell viability in the presence of 1μg/ml of doxorubicin, which also 
decreases similarly on being treated with the NFκB  p65 (Ser529/536) inhibitory peptide. 
Previous results have already established that the MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cells were chemoresistant to 1μg/ml of doxorubicin. On being treated with NFκB  p65 
(Ser529/536) inhibitory peptide, the TG2 high MDA MB 231 Clone 16 and MCF7/RT breast 
cancer cell lines demonstrated a decrease in the cell viability in the presence of doxorubicin 
(Figure 6.11). These results clearly imply that blocking the binding of Rel A/p65 dimer to DNA 
using the NFκB p65 (Ser529/536) inhibitory peptide increased the chemosensitivity of the high 
TG2 breast cancer cell lines. Inhibiting the binding of the Rel A/p65 dimer to the -κB binding 
site of the TGM2 gene promoter decreased the TG2 expression and activity within the MDA 
MB 231 Clone 16 and MCF7/RT cell line which subsequently reduced the chemoresistance of 
these breast cancer cell lines. The TG2 expression and activity within the MDA MB 231 Clone 
16 and MCF7/RT cell lines seems to be key in conferring drug resistance against doxorubicin in 
these cell lines. This also suggests that there is a regulatory loop between TG2 and Rel A/ p65 
dimers and sustained activation of this TG2/NFκB loop has effects on breast cancer behaviour 
such as chemoresistance against doxorubicin.  
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Figure 6.11 The effect of NFκB p65 (Ser529/536) inhibitory peptide on the cell viability of 
breast cancer cell lines in the increasing concentrations of doxorubicin 
3000 cells each of the MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT 
cells were seeded per well into a 96- well plate and left overnight. The next day the cells were 
treated with 100μM of NFκB p65 (Ser529/536) inhibitory peptide for 1 h and 1μg/ml of 
doxorubicin for a time course of 72 h. After treatment, the cell viability of the breast cancer cell 
lines were analysed using XTT. Untreated cells were taken as 100% viable.  Data shown above 
is mean percentage of cell viability + SEM from 3 independent experiments (n=3). Statistical 
analysis was performed using ANOVA. * p<0.01 between cells untreated and treated with p65 
inhibitory peptide in the presence of doxorubicin.  
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6.3.4 Binding of p-Ser536-RelA/ p65 dimer to the -κB site on the TGM2 gene 
promoter. 
6.3.4.1 Chromatin Immunoprecipitation of Rel A/p65 bound to the -κB site on the 
TGM2 promoter 
To determine whether binding of pSer536 Rel A/p65 dimers was required to drive the 
expression of TG2 in the breast cancer cell lines, the Rel A/ NFκB p65 ExactaChIP Chromatin 
IP kit (Catalogue #: ECP5078) was utilized to study the binding of the p-Ser536 Rel A/p65 
dimer to the -κB site on the TGM2 promoter in the breast cancer cell lines. The MDA MB 231 
WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT breast cancer cell lines were treated 
with cell permeable and cell impermeable inhibitors TG2 activity inhibitors, IKKε  
phosphorylation inhibitor, NFκB  p65 (Ser529/536) inhibitory peptide and control peptide over 
specific time courses. Subsequently, chromatin immunoprecipitation was performed on the 
breast cancer cell lines as described in Section 6.2.4. The isolated ChIP-DNA was used to 
perform the PCR as described above (Section 6.2.4) with the primers that are specific for the -
κB site on the TGM2 promoter. The -κB binding site present on the p21 promoter was used as 
the positive control for the ChIP-DNA. The breast cancer cells that lacked expression and 
activity of TG2 (MDA MB 231 WT and MCF7/WT) failed to show any binding activity of Rel 
A/p65 to the TGM2 gene promoter. Results shown in Figure 6.12 clearly revealed that in the 
high TG2 breast cancer cell lines, anti- Rel A/p65 antibody could pull down the -κB binding 
site on the TGM2 promoter. Treating the MDA MB 231 Clone 16 and MCF7/RT cells with 
NFκB p65 (Ser529/536) inhibitory peptide and BX795 inhibited this binding completely. This 
further validated that the TGM2 gene promoter had an NFκB binding site which would allow 
the continuous regulation of a TG2-NFκB cycle. Also, this seems to suggest that the 
phosphorylated serine 536 status of the Rel A/ p65 dimers was crucial to allow binding of the 
NFκB subunit to the TGM2 gene promoter site.  
Chapter 6: Phosphorylated status of the cross linked Rel A/p65 dimer is necessary for 
TGM2 gene expression and chemoresistance 
254 | 
 
However, the MDA MB 231 Clone 16 and MCF7/RT breast cancer cell lines did not show any 
decrease or loss in DNA binding, on being treated with the cell permeable inhibitors R283 and 
Z-DON. As per the results obtained in the previous Chapters, treating the high TG2 breast 
cancer cell lines with cell permeable TG2 activity inhibitors (R283 and Z-DON) demonstrated a 
decrease in the TG2 activity and protein expression as well as a decline in the formation of the 
Rel A/ p65 dimers within these cell lines. This could imply that even though the formation of 
Rel A/ p65 dimers was inhibited using R283 and Z-DON, it can be hypothesized that the non-
cross linked   Rel A/p65 could still bind to the -κB site on the TGM2 promoter. Nevertheless, in 
spite of the binding of Rel A/p65 subunits to the -κB site on the TGM2 gene promoter, the 
breast cancer cell lines treated with R283 and Z-DON illustrated a decrease in the TG2 protein 
expression within the cells.  
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(A) 
 
(B) 
 
Figure 6.12 (A & B) Analysis of Rel A/p65 dimers binding to -κB site on TGM2 (A) and 
p21 gene (B) promoter using Chromatin Immunoprecipitation (ChIP) 
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Chromatin Immunoprecipitation was performed on formaldehyde fixed MDA MB 231 WT, 
MDA MB 231 Clone 16, MCF7/WT and MCF7/RT breast cancer cell extracts using Rel A/p65 
specific antibody 2.2.15.1. PCR was carried out on the immunoprecipitates, using specific sets 
of primers (Shown in Section 2.2.15.2), to amplify the TGM2 promoter sequence containing the 
-κB binding sites as well as the p21 promoter sequence containing the -κB binding sites. The 
data presented is a representation of three independent experiments (n=3).  
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6.3.4.2 PCR for TG2 mRNA expression 
Results from the previous section demonstrated that the pSer536 Rel A/p65 dimers were able to 
bind to the -κB site on the TGM2 gene promoter, even on being treated with TG2 cell 
permeable inhibitors, R283 and Z-DON. However, this did not agree with the results obtained 
from previous chapters as treating the breast cancer cell lines with R283 and Z-DON clearly 
decreased the TG2 protein expression within the high TG2 and chemoresistant breast cancer 
cell lines. To verify the previous obtained results the mRNA expression of TG2 protein was 
determined by PCR. Total RNA was extracted from the breast cancer cell lines using TRIZOL 
reagent (Invitrogen) according to the manufacturers' instructions and PCR was subsequently 
performed. The PCR was conducted using TGM2 gene and GAPDH gene primers as detailed in 
Section 2.2.14. The PCR product was then subsequently analysed by agarose gel 
electrophoresis using 1.5% agarose gel in 1x TAE.  
The results contained from the PCR illustrated that treating the high TG2 MDA MB 231 Clone 
16 and MCF7/RT breast cancer cell lines with cell-permeable inhibitors R283 and Z-DON 
completely inhibited the mRNA expression of TGM2. The NFκB p65 (Ser529/536) inhibitory 
peptide as well as IKKε kinase inhibitor BX795 had a similar effect on the TGM2 gene 
expression. The cell impermeable inhibitor, R294 did not inhibit the mRNA expression of TG2, 
which was similar to results obtained from the western blot analysis of TG2 protein levels in the 
MDA MB 231 Clone 16 and MCF7/RT breast cancer cell lines (Figure 6. 13).  This may imply 
that the Rel A/p65 observed bound to the -κB site on the TGM2 gene promoter was a monomer 
and since the TGM2 gene expression and subsequent protein expression was inhibited on 
treatment with R283 and Z-DON cell permeable TG2 activity inhibitors the cross linked 
dimeric form of Rel A/p65 could thereby be considered crucial for the gene expression of 
TGM2.  
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(A)
 
(B) 
 
Figure 6.13 PCR analysis of the TGM2 and GAPDH gene expression in breast cancer cell 
lines in various inhibitor treatments 
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The MDA MB 231 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT breast cancer cell 
lines (5x10
5
 cells/well) were seeded into 6-well plates and left overnight to become confluent. 
The next day the breast cancer cell lines were treated with 500μM of R283, 500μM of R294 and 
50μM Z-DON for 72 h, 10μM of BX795 for 48 h and NFκB p65 (Ser529/536) inhibitory peptide 
as well as control peptide for 1 h. After the treatments, RNA was prepared (Section 2.2.14.1) 
and then subsequently analysed by PCR using TGM2 and GAPDH gene primers. The results 
shown above are a representation of two independent experiments conducted (n=2).  
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6.4   DISCUSSION 
Numerous nuclear modifications of the NFκB subunits can greatly affect DNA binding as well 
as interactions with repressors and activators of gene expression (Chen, et al. 2005). The 
protein modifications of the NFκB subunits may vary between cell lines as well as variation in 
the NFκB subunit inducing stimuli. Indeed, the results obtained in this Chapter demonstrate that 
the Rel A/p65 dimer phosphorylation at the Ser 536 residue is essential for the expression of the 
TGM2 gene as well as inducing chemoresistance in the high TG2 breast cancer cell lines. Co-
immunoprecipitation experiments have shown that the Rel A/ p65 dimers were phosphorylated 
at a serine residue. Since the previous chapters indicated that PS1145 which was an IKKα/β 
specific inhibitor did not alter the status of the Rel A/p65 dimers or even the TG2 activity and 
expression within the high TG2 breast cancer cell lines, an IKKε kinase inhibitor, BX795 was 
applied. Blocking the phosphorylation of the Rel A/ p65 dimer using BX795 resulted in 
decreased TG2 expression and activity within the high TG2 MDA MB 231 Clone 16 and 
MCF7/RT breast cancer cell lines. Concurrent with this decrease in TG2 expression and 
activity, the chemosensitivity of the high TG2 breast cancer cell lines against doxorubicin was 
also reduced. These results clearly indicated that the serine phosphorylation of the nuclear Rel 
A/ p65 dimer by IKKε is essential for the expression and activity of TG2 as well as 
chemoresistance in these breast cancer cell lines.  
Literature seems to suggest that IKKε kinase function is most characteristic of a Ser 536 residue 
phosphorylation (Perkins, 2006). To verify if the case was similar in the breast cancer cell lines, 
NFκB p65 (Ser529/536) inhibitory peptide which would specifically inhibit the phosphorylation 
of Serine 536, which would subsequently impede the binding of Rel A/p65 to DNA was 
utilized. The NFκB p65 (Ser529/536) inhibitory peptide significantly decreased the TG2 
activity as well as expression within the breast cancer cell lines. Furthermore, the 
chemoresistant phenotype of the MDA MB 231 Clone 16 and MCF7/RT breast cancer cell lines 
was also altered considerably. These results seem to clearly indicate that the phosphorylation of 
Rel A/p65 dimers at the Ser 536 residue was crucial for the chemoresistance against 
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doxorubicin as well as TG2 expression within the breast cancer cell lines. Further studies were 
conducted with ChIP assay to identify gene networks as well as expression mechanisms by 
determining whether Rel A/p65 dimers would interact with the -κB binding site on the TGM2 
gene promoter. The NFκB p65 (Ser529/536) inhibitory peptide as well as IKKε kinase 
inhibitor, BX795 clearly inhibited the binding of the Rel A/p65 dimers to the -κB  site on the 
TGM2 gene promoter. However, the cell permeable TG2 inhibitors, R283 and Z-DON which 
previously demonstrated  reduced the TG2 protein expression levels, did not inhibit the binding 
of Rel A/p65 dimers to the -κB  site on the TGM2 gene promoter.   
 To verify this, PCR analysis was conducted on RNA samples collected from the breast cancer 
cell lines using TGM2 gene primers. The NFκB p65 (Ser529/536) inhibitory peptide and 
BX795 inhibited the expression of TGM2 gene in MDA MB 231 Clone 16 and MCF7/RT 
breast cancer cell lines. Also, the cell permeable TG2 inhibitors, R283 and Z-DON inhibited the 
expression of the TGM2 gene. This clearly indicated that there was a self-regulating molecular 
feedback loop wherein TG2 constitutively activates NFκB and in turn, NFκB directly up 
regulates the gene transcription of TGM2. A clear relationship between the expression and 
activity of TG2 in cultured breast cancer cell lines and the increased binding of Rel A/p65 
binding to DNA has been characterised using EMSA (Mann, et al. 2006). Other groups have 
also documented that there is an intricate relationship between the protein abundance and 
transcript levels of TG2 as well as NFκB activity (Ai, et al. 2012; Kim, et al. 2006). 
Furthermore, the pharmacological inhibition and RNAi mediated knockdown of TG2 results in 
decreased DNA interaction with NFκB (Mann, et al. 2006). With these results, it clearly seems 
that TG2 is essential to maintain the constitutive activation of NFκB.  
To summarize the above observations, the work in this chapter demonstrated that the serine 
phosphorylation of Rel A/p65 dimers by IKKε was vital for the TG2 expression and activity 
levels within the breast cancer cell lines. Also, blocking the serine phosphorylation reduced the 
chemoresistance of the high TG2 breast cancer cell lines against doxorubicin. Furthermore, 
NFκB p65 (Ser529/536) inhibitory peptide was used to detect if Ser 536 was specifically the 
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residue phosphorylated on the Rel A/p65 dimers. This inhibitory peptide blocks the binding of 
the Rel A/p65 dimers to the -κB binding site on the TGM2 gene promoter as well as reduces 
chemoresistance to doxorubicin. Analysis of the TGM2 gene expression demonstrated that 
inhibiting TG2 activity using R283 and Z-DON, BX795 and NFκB p65 (Ser529/536) inhibitory 
peptide decreased the TGM2 gene expression within the breast cancer cell lines. Importantly, a 
novel TG2-NFκB regulatory loop seems to be playing a vital role maintaining the continuous 
expression and activity of TG2 which constitutively activates NFκB in chemoresistant breast 
cancer cells.  
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7.  Epithelial to Mesenchymal Transition 
in Breast Cancer cell lines 
7.1 INTRODUCTION 
Epithelial to Mesenchymal Transition can be defined as the loss of epithelial characteristics and 
the acquisition of a mesenchymal phenotype. During this process, cancer cells attain molecular 
changes that allow aberrant cell to cell adhesive interactions and dysfunctional cell junctions. 
These characteristics tend to promote cancer cell invasion and subsequent progression into the 
surrounding microenvironment. Such a transformation has profound implications in the process 
of breast cancer metastasis and there is evidence to support that numerous tumours contain a 
unique subpopulation of stem - like cells with mesenchymal attributes that are chemoresistant 
(Foroni, et al. 2012). EMT is known to play a very important role in the process of tumour 
metastasis and invasion. Also, it has been hypothesized that EMT is likely to occur in particular 
stages of tumour progression such as intravasation and invasion wherein tumour cells dissociate 
and move to organ/tissue sites distant from the primary site (Gupta & Massague, 2006 ; 
Thompson, et al. 2005). EMT is a crucial developmental process in which epithelial cells lose 
their polarity and epithelial nature and acquire a mesenchymal phenotype which possesses 
increase motility behaviour (Thiery & Sleeman, 2006).  
EMT is characterized by the loss of adhesion markers such as occludins and E-cadherin, 
decrease of epithelial markers such as cytokeratins, increase of mesenchymal markers such as 
vimentin, up regulated invasiveness, motility and metastasis. Furthermore, a process called 
"cadherin-switching" which involves the up-regulation of mesenchymal cadherins such as N- 
cadherin and down regulation of E-cadherin has also been associated with EMT (Thiery, 2002 ; 
Maeda, et al. 2005). As demonstrated in previous Chapters, there is significant evidence to 
support that increased levels of TG2 activity and expression confers drug resistance as well as 
metastatic properties to breast cancer cells (Mehta, et al. 2004; Mangala, et al. 2007). Stable 
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expression of TG2 in mammary epithelial cells is known to be associated with EMT and also 
concurrent with the constitutive activation of NFκB (Kumar, et al. 2010; Verma, et al. 2008; 
Mann, et al. 2006; Kim, et al. 2006).  
TGF-β1 has been implicated in inducing TG2 expression (Quan, et al. 2005) and  TG2 can 
activate TGF-β1 (Nunes, et al. 1997). In TG2 transfected MCF10A epithelial cells, no 
activation of TGF-β signalling was observed and also in the absence of TG2, TGF-β1 failed to 
induce EMT, implying that TGF-β1 has no role to play in inducing EMT in the absence of TG2 
(Kumar, et al. 2010). This suggested that TG2 is a crucial downstream effector of TGF-β 
induced EMT. Supplementary studies are required to further validate tumour potential of 
MCF10A transfected with TG2 cells, even though in vitro data is clearly available to support 
the hypothesis that stable transfection of TG2 is enough to induce a drug resistant and 
metastatic phenotype (Kumar, et al. 2010). EMT induced by TG2 has been largely associated 
with TGF- β1  signalling with the increase of CD44high/CD24-/low cell population, the ability to 
self-renew and form mammospheres (Kumar, et al. 2010).   
Previous studies have demonstrated that the dysfunctional expression of TG2 in epithelial cells 
causes the constitutive activation of Akt, NFκB and FAK (Mann, et al. 2006 ; Kim, et al. 2006 ; 
Verma, et al. 2008). All of these above pathways are known to be closely related to promoting 
metastasis, conferring drug resistance and regulation of EMT (Wang, et al. 2009 ; Kalluri & 
Weinberg, 2009). Active NFκB is thought to be the hallmark of advanced stage tumours (Karin, 
et al. 2002 ; Parsad, et al. 2010). Constitutive activation of NFκB is known to function in the 
chemoresistance and death inducing stimuli and also promotes EMT and induces metastasis 
(Huber, et al. 2004; Orlowski, et al.  2002).  The induction of EMT by NFκB has been 
accredited to the increased stability of Snail along with the increased production of ICOP2 
signalosome 2 that is known to inhibit the ubiquitination and degradation of Snail. The 
constitutive activation of NFκB in MCF10A mammary epithelial cells, induces EMT due to an 
increase in the expression in Zeb1 and Zeb2 expression (Kumar, et al. 2010). With regard to 
these observations,, it can be hypothesized that EMT induced by TG2 can result in the 
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constitutive activation of NF-κB and subsequently the increased expression of Snail, Zeb 1 and 
Zeb 2 (Chua, et al. 2007). Also, in recent studies, TG2 has been shown to associate with NF-κB 
and the recruitment of TG2 to the promoter region of Snail which leads to the regulation of 
transcription (Kim, et al. 2010). 
The aim of this chapter is to further investigate the influence of increased TG2 expression and 
activity on the EMT like phenotype of the breast cancer cell lines. Using breast cancer cell lines 
that express varying levels of TG2, western blot analysis of various epithelial and mesenchymal 
markers such as E- cadherin, N- cadherin and fibronectin was performed to detect the effect of 
high TG2 levels in inducing EMT in breast cancer cells. TGF-β1 activity assay following the 
use of TG2 inhibitors (R283, R294 and Z-DON) will also be used to investigate whether TG2 
induced EMT in these breast cancer cell lines was due to activation of the TGF-β1 signalling 
pathway.  
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7.2 METHODS 
7.2.1 Detection of Epithelial and Mesenchymal markers in breast cancer cell lines 
After 72 h of incubation with TG2 cell permeable (R283 and Z-DON) and cell impermeable 
(R294) activity inhibitors, whole cell lysates were collected and the protein concentration was 
detected as introduced in Section 2.2.3. Western blot was performed to detect the presence of 
E- cadherin, N- cadherin, fibronectin and TGF-β receptor I and II using appropriate primary and 
secondary antibodies (Section 2.2.4- 2.2.6). Signals were further detected using the 
Chemiluminescence (ECL) system kit.  
7.2.2 TGF-β1 Activity Assay    
Using the Human/Mouse TGF β 1 ELISA kit from e-Bioscience (88-8350), the breast cancer 
cell lines were assayed for TGF-β1 in the medium. The MDA MB 231 WT, MDA MB 231 
Clone 16, MCF7/WT and MCF7/RT cells were seeded into 24-well plates and left overnight as 
per the instructions of the kit. The breast cancer cells were initially grown in serum replacement 
medium and treated with cell permeable (R283 and Z-DON) and cell impermeable (R294) TG2 
activity inhibitors over a time course of 72 h. After the treatment, the cell medium was collected 
from each cell line and assayed for TGF-β1. The Corning Costar 9018 plate provided along 
with the kit was coated with 100μl/ well of capture antibody diluted in coating buffer, sealed 
and incubated overnight at 4
o
C. The wells were washed 5 times with wash buffer (250μl/well). 
The wells were then blocked with 1x assay diluent (200μl/well) and incubated at room 
temperature for 1 h. The wells were washed 5 times again with wash buffer. The samples 
(culture medium) were then acidified to be activated and subsequently neutralized. To 100μl of 
sample, 20μl of 1N HCl was added and incubated at room temperature for 10 min and then 
neutralized with 20μl of 1N NaOH. Standards were also diluted using the assay diluent and 
100μl of standard was added per well. 100μl of sample was added into each well and incubated 
at room temperature for 2 h. The wells were then washed five times with Wash Buffer. 100μl of 
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Avidin-HRP was added per well and incubated at room temperature for 30 min. The wells were 
then washed seven times with wash buffer. 100μl of substrate solution was added into each well 
and incubated at room temperature for 15 min after which 50μl of stop solution was added to 
each well. The plate was then read using a plate reader at 450nm.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Epithelial to Mesenchymal Transition in breast cancer cells 
269 | 
 
7.3 RESULTS 
7.3.1 TGF-β induced Epithelial to Mesenchymal Transition (EMT) in breast 
cancer cell lines 
Recent studies have indicated that the EMT gene signature of TG2 transfected MCF10A 
mammary epithelial cells closely resembled TGF-β induced EMT (Xu, et al. 2009). To verify 
this, the expression of TGF-β receptor I and II was determined in the MDA MB 231 WT, MDA 
MB 231 Clone 16, MCF7/WT and MCF7/RT cell lines (Figure 7.1)  
Furthermore, the MDA MB 21 WT, MDA MB 231 Clone 16, MCF7/WT and MCF7/RT cells 
were assayed for the relative TGF-β1 presence in the medium in the presence of TG2 activity 
inhibitors as described in Section 7.2.2. Both the high and low TG2 breast cancer cell lines did 
not express any TGF-β1 activity. The cell permeable and cell impermeable TG2 activity 
inhibitors subsequently had no effect on the TGF-β1 activity levels of the breast cancer cell 
lines (Figure 7.2). These results clearly indicate that the chemoresistant phenotype, that could 
be as a result of EMT in these breast cancer cell lines, is completely independent of TGF-β1 
signalling and activity.  
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Figure 7.1 Analysis of expression of TGF-β Type I and II receptors of breast cancer cell 
lines using Western blot  
The breast cancer cell lines (1x10
6 
cells per well) were seeded into 60mm petridishes and left to 
become confluent. The whole cell lysate fractions of the breast cancer cell lines were collected 
as described in detail in Section 2.2.2. 50μg of whole cell lysate proteins were then analysed by 
western blot for the expression of TGF-β Type I and II receptors using rabbit polyclonal anti-
TGF-β Type I and II receptor antibody (1:1000). The membranes were then reprobed with anti-
α-Tubulin antibody to correct   for equal loading of protein. (A)The western blot data shown is 
a representation of three independent experiments (n=3). (B) Densitometry of the westerns was 
quantified by Image J analysis is represented as mean densitometry + SEM.  
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Figure 7.2 Analysis of TGF-β1 levels in breast cancer cell lines in the presence of TG2 
activity inhibitors 
The TGF-β1 levels in the cell culture medium of the breast cancer cell lines were analysed 
using the Human/ Mouse TGF β 1 ELISA (2nd Generation) kit from eBioscience. 0.5 x 105 cells 
of each breast cancer cell line was seeded into 24- well plates with serum-replacement medium 
and treated for 72 h with R283 (500μM), R294 (500μM) and Z-DON (50μM). After the time 
course of treatment, the supernatant was collected and analysed as described in Section 7.2.1. 
The concentration of TGF-β1 (pg/ml) calculated in the culture supernatant is represented as the 
mean + SEM from three independent experiments (n=3).  
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7.3.2 Analysis of various Epithelial to Mesenchymal Transition (EMT) markers in 
breast cancer cell lines 
Previous studies have reported that chemoresistant and metastatic breast cancer cell lines 
express high levels of TG2 and this high expression and activity of TG2 contributed to 
increased invasion, survival and drug resistance (Mehta, et al. 2004;  Mangala, et al. 2007). In 
order to understand the role of TG2 in metastatic and mesenchymal transformation, breast 
cancer cell lines with varying expression levels of TG2 were analysed using western blotting. 
The high TG2 expressing MDA MB 231 Clone 16 cells did not express any E-cadherin or N- 
cadherin which was similar to the TG2 null MDA MB 231 WT breast cancer cells. On the other 
hand, the TG2 null MCF7/WT breast cancer cells expressed more E- cadherin as compared to 
their high TG2 drug resistant counterpart MCF7/RT cells. Moreover, the drug resistant 
MCF7/RT cells also expressed N- cadherin. The fibronectin expression in the TG2 null MDA 
MB 231 WT and MCF7/WT cells was less than the TG2 expressing MDA MB 231 Clone 16 
and MCF7/RT cells (Figure 7.3).  
These results seem to imply that TG2 expression does not correlate with the expression of EMT 
markers in the MDA MB 231 WT and MDA MB 231 Clone 16 breast cancer cell lines. The 
decrease or loss of epithelial cell markers like E- cadherin and the de novo increase in 
expression of mesenchymal markers such as N- cadherin and fibronectin are the molecular 
changes that drive the morphological changes during EMT (Thiery, et al. 2009).The expression 
of E- cadherin and N- cadherin seemed to correlate with the TG2 expression only in the 
MCF7/WT and MCF7/RT breast cancer cell lines. Even though the high TG2 breast cancer cell 
lines were resistant to doxorubicin, TG2- induced expression of EMT markers did not promote 
this phenotype. Also, TG2 induced expression of EMT markers seems to be unique to the 
MCF7 cell line as the MDA MB 231 WT and MDA MB 231 Clone 16 do not show any 
difference in the expressions of these markers.  
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Figure 7.3 Analysis of the expression of epithelial and mesenchymal markers in the whole 
cell lysate fractions of breast cancer cell lines using western blot 
The breast cancer cells (5x10
5 
cells per well) were seeded into 6-well petridishes and left to 
become confluent. The whole cell lysate fractions of the breast cancer cell lines were analysed 
by western blot for the expression of E- cadherin, N- cadherin, and fibronectin using rabbit 
polyclonal anti-E-cadherin (1:1000), mouse monoclonal anti-N-cadherin (1:1000) and rabbit 
polyclonal anti- fibronectin (1:2000) antibodies respectively. The membranes were then 
reprobed with anti-α-Tubulin antibody to correct for equal loading of protein. (A) The western 
blot data shown is a representation of three independent experiments (n=3). (B) Differences in 
expression are calculated by Image J analysis and is represented as mean densitometry + SEM.    
*p <0.05.  
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7.4 DISCUSSION 
Recent studies of the underlying molecular pathways that regulate the progression of tumours to 
a drug resistant and metastatic phenotype points to EMT as a key event (Thiery, et al. 2009). 
Accumulating evidence points to prolonged EMT as being important in cancer progression by 
altering the relatively immobile epithelial cells into fibroblast like cells with decreased 
intracellular adhesion, increased invasiveness and motility of cancer cells (Micalizzi & Ford, 
2009 ; Wang , 2009 ; Kalluri, 2009 ; Kalluri & Weinberg, 2009). Experiments conducted by 
Kumar et al. in 2010 (Kumar, et al. 2010) illustrated that expression of TG2 confers drug 
resistance and promotes invasiveness in transformed as well as normal epithelial cells by the 
induction of EMT. This could suggest that TG2 serves as the main driver of the metastatic and 
drug resistant phenotype in cancer cells. A similar observation was also noted between 
metastasis and EMT induced by TG2 in ovarian cancer cells (Shao, et al. 2009). Numerous 
cancer cells relies deeply on the EMT programme for successful invasion, intravasation, 
extravasation as well as subsequent colonization by cancer cells (Thiery, et al. 2009). EMT 
causes the loss of epithelial markers such as desmocollin, occludin, desmoplakin and E- 
cadherin which decreases the cell to cell adhesion and allows the motility of these cancer cells 
(Thiery, 2002).  In order to investigate whether TG2 was responsible for driving any of the 
EMT induced molecular alterations in the chemoresistant and metastatic breast cancer cell lines, 
the protein expression of various EMT markers such as  FN, E- cadherin and N- cadherin was 
analysed using western blotting. Importantly, the high TG2 MDA MB 231 Clone 16 cell failed 
to display any difference in the expression of the mesenchymal markers that were a signatory of 
EMT in spite of the high chemoresistance against doxorubicin as compared to the TG2 null 
MDA MB 231 WT breast cancer cells. The MCF7/ RT cell line illustrated a loss in expression 
of E-Cadherin and an increase in N-Cadherin expression as compared to its drug sensitive low 
TG2 counterpart, MCF7/WT. The other EMT marker, FN was expressed less in both the TG2 
null MDA MB 231 WT and MCF7/WT as compared to the high TG2 expressing MDA MB 231 
Clone 16 and MCF7/RT breast cancer cell lines.  
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In the same manner, TGF-β1 has been considered to be a strong inducer of EMT in both normal 
as well as pathological conditions (Xu, et al. 2009; Thiery, et al. 2009).  Addition of TGF-β1 to 
epithelial cells induced EMT in culture. Classical TGF-β signalling requires the binding of 
TGF-β to Type II receptors, phosphorylation of Type I receptors and consequently the 
phosphorylation of Smad 3 and Smad 2. This phosphorylated Smad 2/3 forms a trimeric form 
with Smad 4 which then translocates into the nucleus wherein interaction between co-activators, 
co-repressors and transcription factors occurs to promote expression of mesenchymal markers 
and suppression of epithelial markers. Furthermore, activation of Rho GTPases, ERL MAP 
kinases and PI3 Kinase/ AKT has been hypothesized to be implicated in EMT induced by TGF-
β (Deng, et al. 2010; Santibáñez, et al. 2010). It has also been demonstrated by previous studies 
that TGF-β1 induces the expression of TG2 (Quan, et al. 2005) and TG2 can in turn activate 
matrix bound TGF-β1 (Nunes, et al. 1997), implicating that there is cross talk between TG2 and 
TGF-β1. The high TG2 breast cancer cell lines did not show any difference in the TGF β Type I 
and II receptors as compared to the TG2 null breast cancer cell lines. No increase of TGF-β1 
activity was observed in the high TG2 MDA MB 231 Clone 16 and MCF7/RT breast cancer 
cell line and inhibiting TG2 activity with cell permeable inhibitors did not alter the TGF-β1 
activity levels within these cells.  This seems to suggest that TG2 was not a downstream 
mediator of TGF-β1 induced EMT in these breast cancer cell lines. In contrast, studies 
conducted by Kumar et al. in 2010 reported that in the absence of TG2 expression, TGF-β1 
failed to induce EMT in breast cancer cell lines (Kumar, et al. 2010) (Mann, et al. 2012). 
 276 | 
 
 
 
 
 
Chapter 8: Discussion 
 
 
 
 
 
 
 
 
 
Chapter 8: Discussion 
277 | 
 
8.  Discussion 
One of the major obstacles that limit the success of current chemotherapy in the treatment of 
breast cancer is the acquisition of cancer drug resistance. Mechanisms that may contribute to 
the chemoresistant phenotype could be inherent biological features or can be induced as a 
response to anti-tumour drugs (Sui, et al. 2011). Developing methods to inhibit and overcome 
such a chemoresistance phenotype in breast cancer cells have become the topic of immense 
research.  
Tissue transglutaminase (TG2) is the most ubiquitous and diverse member of the TG family that 
can catalyze the post-translational modification of proteins through the incorporation of a 
primary amine at glutamine residues or cross link proteins by the formation of  ε-(γ-glutamyl) 
lysine isopeptide bonds in the presence of Ca
2+
 (Mehta, et al. 2010). Moreover, TG2 can bind as 
well as hydrolyze ATP and GTP which allows it to function as a G- protein in numerous cell 
signalling processes (Iismaa, et al. 1997 ; Baek, et al. 2001). Within the intracellular 
environment of a cell, the transamidating activity of TG2 is rigidly modulated by the binding of 
GTP or GDP to the protein, while in the extracellular environment the transamidating activity 
of TG2 is detected since activating levels of Ca
2+
 are present (Collighan & Griffin, 2009). TG2 
can also function as a kinase, protein disulphide isomerase as well as a scaffolding protein 
(Wang, et al. 2012 ; Agnihotri, et al. 2013). TG2 has been considered to be a multi functional 
protein as it can localize into the nucleus, cytoplasm and also be exported outside from the cell 
(Chen & Mehta, 1999 ; Griffin, et al. 2002) 
Key roles of TG2 in regulating physiological processes includes protection of cells from 
external and endogenous stress, tissue repair to sustain homeostasis in response to cell stress 
and damage as well as forms a component of the cell defence mechanism (Agnihotri, et al. 
2013). One of the most interesting features of TG2 is that it can modulate opposing functions 
depending on the predominant activity and cellular localization. GTP/ GDP, Ca
2+
 and redox 
potential are the three main regulators of TG2 activity. When Ca
2+
 ions bind to TG2, the 
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enzyme becomes catalytically active and is found in the 'open' confirmation. Since intracellular 
Ca
2+
 levels are usually low, TG2 is found in the closed conformation and functions as a 
scaffolding protein where it may be involved in regulating intracellular signalling pathways. 
Alterations in the intracellular calcium levels as a response to cell damage would induce 
catalytic activity of TG2 that results in the cross linking of intracellular proteins and 
subsequently cell death  (Kiraly, et al. 2011; Nicholas, et al. 2003). 
In many inflammatory diseases, increased expression and transamidating activity of TG2 was 
observed to be a common feature (Kim, 2006). It is increasingly (Kiraly, et al. 2011) evident 
that inflammatory responses play a crucial role during the process of tumour progression, 
invasion and metastasis. Modulation of the survival, growth and progression patterns of the 
cancer cells is achieved by cross talk with the immune and stromal cells that infiltrate around 
the tumour cells (Grivennikov, et al. 2010). In this manner, numerous findings have 
demonstrated that the presence of increased levels of TG2 in cancer cells could have a link with 
increased metastasis, chemoresistance as well as a poor prognosis for the patient. (Verma & 
Mehta, 2007a ; Mangala, et al. 2007 ; Satpathy, et al. 2007 ; Park, et al. 2010). These reports 
suggest that a link exists between inflammation, TG2 and the progress of chemoresistant and 
metastatic cancer.  
Published literature has shown that TG2 is over expressed in various cancer cell types such as 
malignant melanoma (Fok, et al. 2006), lung carcinoma (Park, et al. 2010), breast carcinoma 
(Mehta, et al. 2004), glioblastoma (Yuan, et al. 2007), ovarian carcinoma (Hwang, et al. 2008) 
and pancreatic carcinoma (Verma, et al. 2006). Experimental studies carried out on metastatic 
human lung carcinoma clearly implicated TG2 as one of the 11 selectively amplified genes 
(Jiang, et al. 2003) and also TGM2 gene was demonstrated to be expressed differentially in 
pancreatic cancers (Iacobuzio-Donahue, et al. 2003).  
Current data clearly supports that TG2 plays a very crucial, but under recognized role in 
shaping of the breast cancer phenotype. Many groups have illustrated that TG2 expression 
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widely varies within panels of mammary epithelial cell lines as cultured breast cancer cells (Ai, 
et al. 2008; Mehta, et al. 2004). Previous studies have reported that breast cancer cells that had 
been selected out for chemoresistance displayed high levels of the Ca
2+
 -dependent protein cross 
linking enzyme, TG2, however the mechanistic detail behind the link between TG2 and 
resistance is still to be established (Devarajan, et al. 2002 ; Herman, et al. 2006).  Ectopically 
expressing recombinant TG2 in MCF10A mammary epithelial cell line resulted in gene 
expression alterations, which was concurrent with the cells acquiring an invasive phenotype 
(Kumar, et al. 2010). Further studies also indicated that the expression of TG2 in the MCF10A 
cells lines also increased the stem cell like properties(CD44 
high
/ CD24
low/-  
such as augmented 
self-renewal and growth in the form on mammospheres (Kumar, et al. 2010).   This observation 
was in line with the studies done using MDA MB 231 cells which established that high 
expression of TG2 was associated with increased cell motility in vitro  (Mehta, et al. 2004).  All 
of the above findings clearly paved the way to a possibility that the expression of TG2 could be 
used as a biomarker for determining prognostic significance of breast cancer and also associated 
with increased malignancy.  
Another very significant finding that revolved around the acquisition of the tumorigenic 
phenotype was observed in the doxorubicin resistant MCF7 breast cancer cell lines that 
expressed heightened levels of TG2 in comparison to the doxorubicin sensitive MCF7 parental 
line (Mehta, 1999). Consistent with this finding, other labs have also demonstrated the effect of 
TG2 in doxorubicin resistance using diverse cell model systems. The chemoresistant phenotype 
was clearly due to high levels of TG2 as the knock down of TG2 mediated by siRNA 
expression, reduced the doxorubicin resistance (Yuan, et al. 2005 ; Han & Park, 1999; Herman, 
et al. 2006 ; Yuan, et al. 2007 ; Cao, et al. 2008).  
The exact mechanism that regulates induction of TG2 expression and chemoresistance has yet 
to be understood. A straightforward relationship between chemoresistance against doxorubicin 
and expression levels of TG2 has been reported by several groups. Epigenetic profiling and 
proteomic analysis of breast cancer cells resistant to doxorubicin validated the function of TG2 
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to increase doxorubicin resistance (Park, et al. 2009 ; Chekhun, et al. 2007). Activation of EGF 
signalling is another mechanism of TG2 induction that could contribute to the tumorigenic 
potential of breast cancer by increasing doxorubicin chemoresistance (Antonyak, et al. 2004). 
Furthermore, under conditions of stress, TG2 expression can also modulate activation of 
different epigenetic mechanism, survival pathways and transcription factors like NFκB and 
HIF-1α (Dyer, et al. 2011 ; Jang, et al. 2010 ; Mehta, et al. 2010) 
The over expression of TG2 in many cancer cells has often been correlated with the constitutive 
activation of NFκB (Verma & Mehta, 2007a). In addition, specific inhibitors of TG2 activity 
can decrease the activation of NFκB. The ability of TG2 to constitutively activate NFκB has 
been illustrated in doxorubicin resistant breast cancer cells. Fascinatingly, the NFκB activity 
mediated by TG2 induction was seen in both EGFR negative and positive breast cancer cells 
(Kim, et al. 2006). NFκB is an oncogenic transcription factor that activates numerous genes 
responsible for cancer cell survival, proliferation, angiogenesis, and metastasis and drug 
resistance. The main modulation of NFκB occurs via the association with IκB proteins. As a 
response to external stimuli, the IκBα bound to NFκB is phosphorylated and then degraded by 
the proteasomal degradation pathway. This results in the release of free NFκB dimers that 
translocate into the nucleus and transcribe genes that contain the -κB response element (Karin, 
2006).  
p53 is a prominent tumour suppressor that regulates cell cycle and controls the process of aging 
in mammals. Several cell lines have wild type p53 which is required to initiate DNA damage 
induced apoptosis. p53 has been shown to be crucial in regulating steps that are crucial for 
apoptosis, such as the transcriptional activation of Bax (Yin, et al. 1997), generation of ROS 
(Polyak et al. 1997), mitochondrial cytochrome c release as well as caspase activation (Henkels 
and Turchi, 1999). Even though much is known about p53 dependent apoptotic pathways, p53 
independent pathways of DNA damage induced apoptosis in cells that lack expression of p53, 
or even have mutated or non-functional p53has yet to be deciphered (Kita and Nakashima, 
2002; Matsui et al. 2001). Studies have shown that in cell lines that lack p53, doxorubicin can 
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induce apoptosis by increasing peroxide levels, mitochondrial depolarization, activate 
cytoplasmic caspase 3 as well as elicit cytochrome c release from mitochondria (Tsang, et al. 
2003).  
Studies conducted by Mishra and Murphy in 2006 (Mishra & Murphy, 2006), demonstrated that 
TG2 can phosphorylated p53 at serine residues 20 and 15. By phosphorylation of p53 induced 
by TG2, the interaction between Mdm2 and p53 significantly reduces, which subsequently 
disrupts apoptosis (Mishra & Murphy, 2006).  
In agreement to this, the MDA MB 231 and MCF7 cell lines differ greatly in the type of p53 
protein expressed. The MDA MB 231 cells have been shown to have a mutant p53 protein as a 
result of an arginine to lysine mutation at residue 280, whereas the MCF7 cells express wild 
type p53 (Gurtner, et al. 2010). In cancers where mutant p53 is expressed, the aberrant form of 
p53 is commonly known to be more stable that the wild type p53 and so is present at higher 
levels (Hupp, et al. 2000). Such a mutant form of p53 does not only not retain its tumour 
suppressive nature but can also sometimes illustrate increased oncogenic characteristics (Hui, et 
al. 2006).  
TG2 has been demonstrated to regulate NFκB activity via different mechanisms. TG2 can 
directly form a complex with p50/p65 dimers in the cytosol, which modifies the affinity of the 
NFκB molecule to its inhibitory substrate, IκBα (Verma & Mehta, 2007a).  IκBα  has also been 
shown to be a good substrate for TG2 transamidating activity and the cross linking of IκBα 
protein creates an insoluble polymer in the cytoplasm that can no longer bind to the NFκB 
subunits (Lee, et al. 2004). However activation of TG2 in an intracellular environment where 
TG2 is tightly controlled needs to take place for this mechanism. In the nucleus, TG2 has been 
shown to associate with Rel A/ p65 in the nucleus and can target non- canonical genes, 
including TG2 that results in a positive regulatory loop in chemoresistant cells (Verma & 
Mehta, 2007a).  
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In spite of these developments, the exact mechanistic detail as to how TG2 induces the 
constitutive activation of NFκB which leads to the acquisition of chemoresistance against 
doxorubicin in breast cancer cells is not known. The aim of this project was to establish the 
mechanistic detail behind the drug resistance against doxorubicin and TG2 levels in breast 
cancer cells.  
In order to establish the role of TG2 in conferring chemoresistance to doxorubicin, breast 
cancer cell lines that expressed varying levels of TG2 were used. No detectable TG2 antigen 
was observed in the MDA MB 231 WT, MCF7/WT, SKBR3/WT and T47D/WT cells, which 
provide an ideal model to study the role of TG2 in chemoresistance against doxorubicin. The 
MDA MB 231 Clone 16 and MDA MB 231 Clone 9 were selected out from their parental wild 
type and expressed high and low TG2 respectively (Mehta, et al. 2004). On culturing the 
MCF7/WT, SKBR3/WT and T47D/WT in the presence of increasing concentrations of 
doxorubicin, the TG2 expression in the MCF7/WT and SKBR3/WT cell lines gradually 
increased. This was not the case with the T47D cell lines, which seems to suggest that another 
mechanism of chemoresistance against doxorubicin in these breast cancer cell lines. The TG2 
expressing MCF7 cells and low TG2 SKBR3 were established as MCF7/RT and SKBR3/RT 
(doxorubicin resistant) cells. Furthermore, in the TG2 plasmid transfected MCF7 and SKBR3 
cells, TG2 expression and activity could be detected in the cell lysates. Detection of the cellular 
localization of TG2 activity and expression in the breast cancer cells suggested that TG2 
expression and transamidating activity was predominant in the cytoplasm. The cell viability 
analysis conducted on the breast cancer cell lines in the presence of increasing concentrations of 
doxorubicin suggested that the high TG2 expressing breast cancer cells were more 
chemoresistant to doxorubicin as compared to the TG2 null breast cancer cell lines. In the 
presence of cell permeable TG2 activity inhibitors (R283 and Z-DON), the chemoresistance of 
the high TG2 breast cancer cells decreased significantly.  However no significant decrease was 
shown with the cell impermeable inhibitor, R294 .With these results, a key relationship between 
the expression and intracellular activity levels of TG2 and chemoresistance against doxorubicin 
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in breast cancer could be established. Concurrent with this decrease in TG2 activity and 
chemoresistance against doxorubicin of the breast cancer cell lines, treatment with the cell 
permeable R283 and Z-DON also causes a down regulation in the expression levels of TG2. 
This seems to suggest that the regulation of TG2 expression in the breast cancer cells is under 
the control of a "factor" whose activation was dependent on the intracellular activity of TG2. 
Similar results were observed in the TG2 transfected MCF7 and SKBR3, where the presence of 
TG2 activity and expression conferred these cells resistant to doxorubicin, which could be 
reversed in the presence of cell permeable TG2 inhibitors (R283 and Z-DON). Down regulating 
the mRNA TG2 levels in the high TG2 breast cancer cells using TG2 specific siRNA illustrated 
the same effect on the chemoresistant phenotype of the cells. An intracellular pathway that is 
dependent on the activity and expression of TG2 in breast cancer cells seems to be a crucial 
event in mediating chemoresistance against doxorubicin. However, it should be noted that the 
high and low TG2 expressing breast cancer cells were susceptible to cisplatin, suggesting that 
TG2 expression and activity may be specific to conferring chemoresistance against doxorubicin 
in breast cancer.   
Among the well-known regulators of TG2, Rel A/ p65 has been well document as studied 
(Brown, 2013). Even though previous work has documented that TG2 constitutively activates 
Rel A/ p65 in breast cancer cells, the exact mechanism of activation remains unknown. The 
high TG2 breast cancer cell lines as well as TG2 transfected breast cancer cell lines that 
demonstrated to be chemoresistant to doxorubicin, proved to have higher levels of NFκB 
activity as compared to their TG2 null parental cell lines. In the presence of cell permeable TG2 
inhibitors, R283 and Z-DON, the NFκB activity of the high TG2 breast cancer cells decreases 
significantly. Further investigation of Rel A/ p65 protein expression in the cytoplasmic and 
nuclear fractions of the breast cancer cell lines revealed that in the nucleus of the high TG2 
breast cancer cell lines, Rel A/ p65 was present at a molecular weight of approximately 130kDa 
that represented the dimeric form of Rel A/ p65. This Rel A/ p65 dimer was also found to be 
absent in the cytoplasmic fractions of the high TG2 breast cancer cells as well as the TG2 null 
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breast cancer cell lines. In addition to this, treating the high TG2 breast cancer cells with cell 
permeable TG2 activity inhibitors, R283 and Z-DON, resulted in a significant decrease of the 
Rel A/ p65 dimers. This decrease of Rel A/ p65 dimers was concurrent with the decrease in the 
TG2 expression and activity levels within the cells and also loss of chemoresistance against 
doxorubicin. These results seem to implicate the transamidating activity of TG2 in the 
constitutive activation of Rel A/ p65 which in turn may be related to the expression of TG2. 
Cell impermeable TG2 activity inhibitor, R294, did not demonstrate such a decrease, suggesting 
that the constitutive activation of Rel A/ p65 and formation of Rel A/p65 dimers was dependent 
on intracellular TG2 activity as opposed to extracellular activity. This clearly implies that 
intracellular TG2 activity was responsible for the aberrant Rel A/ p65 dimer formation and also 
for conferring chemoresistance against doxorubicin in breast cancer.  
Co-immunoprecipitation assays were used to pull down the TG2- Rel A/ p65 complex in the 
nuclear fractions of the high TG2 MDA MB 231 Clone 16 and MCF7/RT. However, no 
interaction was observed in the nuclear fractions between TG2 and Rel A/ p65. Hence the 
possibility of any direct interaction between Rel A/ p65 dimers and TG2 in the nucleus of the 
breast cancer cells was ruled out completely. Since TG2 expression and activity was observed 
only in the cytoplasm, as determined by microscopy techniques as well as western blot, the 
formation of the Rel A/ p65 dimer was thought to occur in the cytoplasm and then subsequently 
translocated into the nucleus, where it could be detected. The presence of these aberrant Rel A/ 
p65 dimers in the nucleus of the high TG2 breast cancer cells could account for the increased 
constitutive activation of NFκB.  
To further investigate these Rel A/ p65 dimers were in fact only of Rel A/p65 the mRNA 
expression of Rel A/ p65 was blocked using specific targeting siRNAs. Inhibiting Rel A/ p65 
clearly reduced the expression of both the Rel A/ p65 monomers and polymers in the high and 
low/no TG2 breast cancer cells, indicating that the protein band observed in the nuclear 
fractions of the high TG2 breast cancer cell lines was likely to be composed of only Rel A/ p65 
and no other NFκB family members. The remaining NFκB activity observed in the high TG2 
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breast cancer cells could be accounted for by the other NFκB family members. To further rule 
out the involvement of other NFκB family members in the high TG2 breast cancer cell lines, the 
levels of p50/p105, Rel B, c-Rel and p52/p100 was determined after treatment with TG2 
activity inhibitors. No change was observed in any other NFκB family member other than Rel 
A/ p65, implying that the constitutive activation of NFκB induced by TG2 is primarily the Rel 
A/ p65 subunit. Knocking down the TG2 mRNA expression in the high TG2 MDA MB 231 
Clone 16 and MCF7/RT cells using TG2 specific siRNA resulted in the decrease of the Rel A/ 
p65 dimers and a concurrent increase in the monomeric Rel A/ p65 of the nuclear fractions. 
Also, inhibiting TG2 mRNA expression down regulated the NFκB activity levels as well as 
chemoresistance against doxorubicin. Investigation of the regulation of sustained TG2 
expression in chemoresistant breast cancer cells revealed that inhibiting the intracellular 
transamidating activity of TG2 with the cell permeable inhibitors R283 and Z-DON, decreased 
the protein expression of TG2.Furthermore, treating the high TG2 MDA MB 231 Clone 16 and 
MCF7/RT breast cancer cells with Rel A/ p65 siRNAs considerably decreased the activity and 
expression of TG2, consequently reversing the chemoresistant phenotype. Along with the 
findings about Rel A/ p65 dimers, it is therefore possible that the Rel A/ p65 dimers may be 
responsible in regulating transcription of TG2 within these breast cancer cells.  
 IκBα is the main inhibitory protein responsible for sequestering NFκB subunits in the 
cytoplasm in a resting cell. In response to external stimuli, IκBα proteins are phosphorylated 
and subsequently degraded, releasing the free and active NFκB subunits to translocate into the 
nucleus and bind to the -κB sites on the promoters of target genes (Bergqvist, et al. 2008). 
Numerous reports have suggested that cytoplasmic IκBα can be polymerized by TG2 and 
subsequently degraded. The cross linking of IκBα induced by TG2 causes the depletion of IκBα 
without the affecting the phosphorylation status and leads to the activation of NFκB subunits, 
Rel A/ p65. This can contribute to the increase in inflammation and progression of cancer (Kim, 
2006; Mehta & Han., 2011). To determine the interaction between IκBα and TG2 in the 
cytoplasmic fraction, the breast cancer cell lines were treated with TG2 activity inhibitors and 
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TG2 specific siRNA. The high TG2 breast cancer cell lines showed the presence of polymeric 
forms of IκBα in the cytoplasm which was inhibited on treating the cells with only the cell 
permeable TG2 inhibitors, R283 and Z-DON. On the other hand, in the low/null TG2 breast 
cancer cells only IκBα was observed in the cytoplasm. These results seem to suggest that the 
transamidating activity of cytoplasmic TG2 was responsible for the polymerization of IκBα, 
which resulted in the constitutive activation of NFκB and hence continued chemoresistance in 
the breast cancer cells. Inhibiting the μ-calpain proteasomal degradation pathway with 
Calpeptin illustrated the increasing presence of IκBα polymers in the cytosolic fractions of the 
high TG2 breast cancer cell lines which was absent in the TG2 null cells. Previous studies have 
shown that TG2 can catalyse the formation of cross links between free  IκBα  molecules at 
lysines 33, 36 and 177 and glutamines 266, 267, 313 (Park, et al. 2006).  
To confirm that the constitutive activation of Rel A/p65 induced by TG2 was via a 
unconventional pathway that does not involve IKKα/β, the breast cancer cells were treated with 
the kinase inhibitor PS1145. The NFκB activity of the high TG2 breast cancer cell lines were 
not significantly reduced, but the low/null TG2 cell lines showed greatly reduced NFκB 
activity. Furthermore, treating the high TG2 breast cancer cells with PS1145 did not alter the 
status of the Rel A/p65 dimers in the nucleus, TG2 expression and activity levels also remained 
unchanged. Inhibiting IKKα/β with PS1145 also did not significantly reduce chemoresistance 
against doxorubicin in high TG2 breast cancer cells, indicating that the constitutive activation of 
NFκB mediated by TG2 was not dependent on IKKα/β function.  Similar results were also 
reported in studies conducted by Kumar & Mehta in 2012 where mammary epithelial breast 
cells, MCF10A cells that were transfected with TG2 and treated with parthenolide (IκB kinase 
inhibitor), showed no difference in the target EMT genes that are regulated by NFκB (Kumar & 
Mehta, 2012). These observations clearly indicated that the TG2 induced constitutive activation 
of NFκB is independent on the conventional IKK pathway.  
Studies have demonstrated that the phosphorylation of the NFκB protein was essential for 
regulating NFκB activation. This phosphorylation can occur in the nucleus or in the cytoplasm 
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and has also been shown to be cell type specific as well as stimuli specific. Also, the specific 
site of phosphorylation differs and also leads to a specific effect of NFκB on target gene 
activation (Ryu, et al. 2011 ; Viatour, et al. 2005). To determine whether, the Rel A/ p65 dimers 
undergo any post translational modification, the high TG2 MDA MB 231 Clone 16 and 
MCF7/RT breast cancer cell lines were analysed by co-immunoprecipitation assays. With this, 
the possibility that the Rel A/ p65 dimers were phosphorylated at a serine residue was 
confirmed. Also, the phosphoserine Rel A/ p65 was only seen in the nuclear fractions of the 
high TG2 breast cancer cell lines. This clearly suggested that the Rel A/ p65 dimers underwent 
phosphorylation at a serine residue in order to increase transcriptional activation  of the  NFκB  
subunits.  The phosphorylation /dephosphorylation of Rel A/ p65 at serine residues can be 
carried out by a variety of different kinases and phosphatases respectively (Perkins, 2012), 
which raises the possibility that specific kinases have functions of special significance in 
activating defined  signalling pathways (Buss, et al. 2012). Since, the co-immunoprecipitations 
clearly revealed that the phosphorylation of the Rel A/ p65 dimers occurs only in the nucleus, 
kinases that are found in the nuclear compartment were further analysed.  Such a 
phosphorylation of Rel A/ p65 in the nucleus has been demonstrated previously by several 
groups (Madrid, et al. 2001 ; Jiang, et al. 2003 ; Yang, et al. 2003 ; Sasaki, et al. 2005) . Co-
immonoprecipitation studies have also shown that phospho-Rel A/ p65 does not associate with  
IκBα  or p50, both in the nucleus and cytoplasm. Additionally, phospho- Rel A/ p65 has been 
implicated to exist independent of the canonical  NFκB  complex of p65 and p50 (Sasaki, et al. 
2005).  
Among the well characterized phosphoserine sites on nuclear Rel A/ p65 is serine 536  which is 
mainly mediated by IKKε which is a well known non canonical IKK (Adli & Baldwin, 2006 ; 
Mattioli, et al. 2004). Experiments using IKKε specific inhibitor BX795 showed that inhibiting 
IKKε activity decreased the phosphoserine status of the nuclear Rel A/ p65 dimers. To further 
confirm if the nuclear Rel A/ p65 dimer was phosphorylated at the Serine 536 site, a specific 
pSer 536 p65 antibody was used. As expected the nuclear Rel A/ p65 dimers were specifically 
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phosphorylated at the serine 536 site, which could be inhibited by the IKKε inhibitor, BX795. 
In addition to the reduction on the phosphoserine status of the Rel A/ p65 dimers, the TG2 
expression and activity in the high TG2 breast cancer cell lines also decreased significantly. 
Moreover, the chemoresistant nature of the high TG2 breast cancer cell lines in the presence of 
doxorubicin was also reversed. The phosphorylation of Rel A/ p65 in the nucleus by IKKε and 
its relevance in the progression of cancer has been reported previously. Overexpression of IKKε 
and Rel A/ p65 in cancer cell lines has been accounted for leading to the phosphorylation of Rel 
A/ p65 specifically at Serine 536 (Buss, et al. 2004 ; Adli & Baldwin, 2006). The regulation of 
the phosphorylation of Ser 536 in Rel A/ p65 subunits occurs on the C- terminal of the TAD 
and originally demonstrated by Sakurai et al. in 1999 (Sakurai, et al. 1999). Ever since, 
numerous other groups have confirmed that IKKs are directly responsible for phosphorylating 
p65 at Ser 536 (Sizemore, et al. 2002 ; Sakurai, et al. 2003 ; Kishore, et al. 2003). Also, even in 
cell lines thay were deficient for IKKα or IKKβ or transfected with dominant negative forns of 
IKKα and IKKβ, pSer 536 p65 was still observed  (Yang, et al. 2003; Sizemore, et al. 2002). 
Phosphorylation of serine 536 on Rel A/ p65 by IKKε accounts for the post translational 
modification specifically in cases where Rel A/ p65 was not bound to IκB or dependent on IKK 
for activation (Buss, et al. 2004). As a response to DNA damaging agents that can activate  
NFκB  in the absence of IKKα/β function, IKKε plays a crucial role in the phosphorylation Rel 
A/ p65 (Tergaonkar, et al. 2003). Although, it had become apparent that IKKε was responsible 
for phosphorylation of Ser 536 in Rel A/ p65, the contribution of such a post translational 
modification on Rel A/ p65 transactivation through this site was yet to be stabished by 
analyzing  NFκB  target genes.  
Initial results had illustrated that inhibiting the transamindating activity of intracellular TG2 
using R283 and Z-DON as well as Rel A/ p65 specific siRNA to inhibit Rel A/ p65 mRNA 
expression, greatly reduced the TG2 protein levels in the high TG2 breast cancer cell lines. This 
clearly suggested that Rel A/ p65 was essential to regulate the expression of TG2 in 
chemoresistant breast cancer cell lines. The Rel A/ p65 subunit has also been shown previously 
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to be sufficient as well as necessary to drive the expression of TG2 within cultured breast 
cancer cell lines (Ai, et al. 2012). The effects of the transactivation of Rel A/ p65 on TG2 
expression was found to be quite direct as the TGM2 gene contains a  -κB  binding site 
consensus (Ai, et al. 2008) and Rel A/ p65 was shown to associate with these binding sites as 
evaluated by ChIP assay. Using the NF-κB p65 (Ser529/536) inhibitory peptide, the serine 536 
phosphorylation of the Rel A/ p65 was inhibited which consequently inhibited the binding of 
the Rel A/ p65 dimers to the -κB binding sites on their target genes. The expression and activity 
along with the chemoresistance of the high TG2 breast cancer cell lines was inhibited and this 
clearly suggested that the phosphorylation of serine 536 residues on Rel A/ p65 dimers was 
essential for these NFκB subunits to bind to the -κB site on the TGM2 gene promoter. 
Furthermore, ChIP analysis confirmed that both the IKKε inhibitor, BX795 and NF-κB p65 
(Ser529/536) inhibitory peptide inhibited the binding of Rel A/ p65 dimers to the -κB site on 
the TGM2 gene promoter. However, the cell permeable TG2 activity inhibitors, R283 and Z-
DON, that down regulated the formation of the Rel A/ p65 dimers and TG2 expression, failed to 
block the binding of the Rel A p65 to the -κB  site on the TGM2 gene promoter. The TGM2 
gene expression was determined subsequently in the presence of the cell permeable TG2 
activity inhibitors, R283 and Z-DON, and a clear significant decrease was observed in the 
TGM2 gene expression in the high TG2 breast cancer cell lines, This could account for the 
consequent decrease in the TG2 protein and activity levels as well as chemoresistance against 
doxorubicin observed in the high TG2 breast cancer cells. The results of these experiments were 
further confirmed by reference  to  previous work conducted that reported the presence of  the 
single -κB  binding site within the TGM2 gene promoter as deciphered by EMSA 
(Electrophoretic mobility shift assay) (Caccamo, et al. 2005 ; Mirza, et al. 1997).   
Taken  together, all this current evidence clearly supports the existence of a novel regulatory 
feedback loop wherein TG2 transamidating activity was responsible for constitutively activating 
Rel A/ p65 by cross linking and these Rel A/ p65 dimers were phosphorylated at the serine 536 
residue which in turn drives the expression of TG2. Additionally, high expression and activity 
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of TG2 and constitutive activation of NFκB has been demonstrated to take place both in 
primary cultured breast cancer cells as well as breast tumours (Ai, et al. 2012). This regulatory 
loop seems to be self-sustaining because the expression of TG2 and activity of NFκB is 
substantially lower in normal epithelial cell lines as compared to cultured cancer cell lines. Such 
a self-amplifying regulatory-loop results in an obvious chemoresistant phenotype in high TG2 
expressing breast cancer cells (Brown, 2013).  NFκB directs the expression of various pro 
survival and anti-apoptotic genes as a response to cytotoxic damage induced by 
chemotherapeutic agents (Karin, 2006).  
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Figure 8.1 Schematic representation of TG2-NFκB regulatory loop 
Another key event reported to be regulated by this TG2/ NFκB  feedback loop is the activation 
of EMT (Epithelial to Mesenchymal transition), by down regulation of genes responsible for 
maintaining the epithelial integrity, E- Cadherin and increase in the molecules required for 
mesenchymal and invasive phenotypes such as TGF-β1, N- Cadherin, Vimentin and  FN 
(Kumar, et al. 2010). However, in spite of the presence of the self-sustained TG2/ NFκB  
regulatory loop in the chemoresistant breast cancer cell lines, there was no significant difference 
observed in the EMT markers (E-cadherin, N-cadherin and TGFβ1 activity) between the high 
and null TG2 MDA MB 231 breast cancer cell lines (Clone 16 and WT respectively. The 
MCF7/WT cells did express high levels of E-cadherin which seems to have decreased in the 
MCF7/RT breast cancer cell lines. Similarly, in the MCF/RT cell lines, expression of N- 
cadherin was observed. Such a "cadherin-switch" could account for the EMT characteristics in 
the MCF7 cell lines. Also, studies have demonstrated that expression of TG2 in MCF10A cells 
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resulted in the reduction of E- cadherin expression and up regulation of various EMT markers 
(Kumar, et al. 2010).  
The continuous activation of the TG2/ NFκB loop might even have other effects on the 
behaviour of tumour cells other than the ones detailed above. Via this loop TG2 expression may 
affect the structure of the ECM, and the increased expression of extracellular TG2 may change 
the motility and invasiveness of the cancer cells. Furthermore, the activity of extracellular TG2 
has been shown to cross link integrins which results in the continuous activation of FAK at the 
membrane of the cell which supports the activation of AKT kinase (Verma, et al. 2006 ; Kang, 
et al. 2004).  Recently, a study conducted by Wang and Griffin demonstrated that inhibiting the 
cell surface TG2 activity of MDA MB 231 Clone 16 breast cancer cells resulted in a decrease in 
S100A4 polymer formation as well as subsequent cell migration. Furthermore, this study also 
revealed that activation of PKCα can link the α5β1 integrin and syndecan 4 co signalling 
pathways in facilitating the cell migration mediated by S100A4 and TG2 (Wang & Griffin, 
2013).  
From the viewpoint of therapeutics, switching off the TG2/ NFκB regulatory loop has an 
apparent benefit for treating chemoresistant and invasive breast cancer. A lot of effort has been 
put into developing IKK kinase activity inhibitors that would block the constitutive activation 
of  NFκB  subunits (Gilmore & Herscovitch, 2006). However, since current research has 
indicated that the transamidating activity of TG2 is responsible for constitutively activating Rel 
A/ p65 via a mechanism that is independent of IKK function, such inhibitory molecules would 
not have any effect on the TG2/ NFκB regulatory loop. The development and use of novel cell 
permeable TG2 activity inhibitors in combination with chemotherapeutic drugs holds 
considerable promise in disrupting this signalling loop and improving the therapeutic measures 
for treatment of chemoresistant breast cancer.  
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9. Future Direction 
Following the investigations that have been described in this thesis, a number of future projects 
could be taken up, which involve using breast cancer tissue samples as well as knock out mouse 
models: 
 Other breast cancer cell lines which are from both of glandular as well as ductal origin 
should be tested for TG2 activity, Rel A/p65 high molecular weight forms as well as 
chemoresistance against doxorubicin to investigate if the chemoresistant phenotype was 
specific to certain breast cancer cell line origins. 
 The MDA MB 231 Clone 16 and MCF7/RT breast cancer cells that have been 
determined to be chemoresistant to doxorubicin, but chemosusceptible to cisplatin. 
These high TG2 expressing breast cancer cells should be repeatedly cultured in 
increasing concentrations of doxorubicin so as to develop cisplatin resistant breast 
cancer cell lines. Subsequent protein analysis of TG2 levels and Rel A/p65 high 
molecular weight forms could help determine if the chemoresistant phenotype of breast 
cancer cells induced by TG2 was specific to doxorubicin or similar anthracylin drugs.  
 Transient transfection of Wild Type TG2 plasmid into TG2 null breast cancer cell lines 
to establish stable breast cancer cell lines that express high amount of TG2. Protein 
expression and activity assays and well as cell viability tests could then be used to 
determine whether similar result are observed as with the high TG2 MDA MB 231 
Clone 16 and MCF7/RT breast cancer cell lines. 
 It would of further interest to transfect the TG2 null breast cancer cell lines with mutant 
forms of TG2 pertaining to the active catalytic site as well as the GTP binding site to 
confirm that TG2 activity was chiefly responsible to confer chemoresistant phenotype 
against doxorubicin as well as the formation of high molecular weight Rel A/p65 as 
well as IκBα forms. 
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 Further upstream inhibitors of the NFκB activation pathways could be used to further 
confirm the exact activation pathway, either canonical or non-canonical, of Rel A/p65 
high molecular weight forms.  
 Mass Spectrometry analysis of the high molecular weight Rel A/p65 form could help 
establish the exact nature of these supposedly dimeric forms. 
 Obtaining metastatic breast cancer tissue samples and immunohistochemistry staining 
with different antibodies specific for TG2 and Rel A/p65. 
 Using these metastatic breast cancer tissues, staining of inflammatory cells such as 
macrophages and neutrophils will allow determining infiltration of cells into these 
tumour sites. 
 DNA micro array studies would further help determine gene expression patterns of 
chemoresistant genes or drug efflux genes that may be responsible in conferring a 
chemoresistant phenotype against doxorubicin in highTG2 breast cancer cells 
In summary, such future studies would further help understand the exact mechanistic 
phenomenon behind chemoresistant breast cancer cell lines and allow development of 
therapeutics which would help increase prognosis.  
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Appendix 1: List of Abbreviations 
AD Alzheimer's disease 
ATP Adenosine 5'- triphosphate 
Aβ Amyloid beta- protein 
BAFF B cell activating factor 
BCR B cell receptor 
BSA Bovine Serum Albumin 
Ca
2+
 Free Calcium ions 
CaCl2 Calcium Chloride 
CCl4 Carbon tetrachloride 
CD Celiac disease 
cDNA Complementary deoxyribonucleic acid 
ChIP Chromatin Immunoprecipitation 
CO2 Carbon dioxide 
DAPI 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
DEPC Diethylpyrocarbonate 
DEPC Diethyl pyrocarbonate 
DLK Dual leucine zipper bearing kinase 
DMEM Dulbecco's modified Eagles' medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
Dox Doxorubicin 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylene diamine tetra acetic acid 
EGF Epithelial growth factor 
EGTA Ethylene glycol tetra acetic acid 
EMT Epithelial to mesenchymal transition 
ER Oestrogen receptor 
ERK Extracellular signal regulated kinase 
FAK Focal adhesion kinase 
FBS Foetal Bovine serum 
FITC Fluorescein isothiocyanate 
FN Fibronectin 
FXIII Factor XIII 
FXIII A Factor XIII subunit A 
FXIII B Factor XIII subunit B 
GDP Guanosine 5'diphosphate 
GFD Gluten free diet 
gplTG Guinea pig liver transglutaminase 
GTP Guanosine 5'- triphosphate 
GTPase Guanosine 5'- triphosphatase 
h hour/ hours 
HD Huntington's disease 
HDAC Histone deacetlyase 
HRP Horseradish  peroxidase 
HS Heparan sulphate 
IgG Immunoglobulin 
IKK Inhibitor of -κB kinase 
IL-1 Interleukin -1 
IL-1β Interleukin -1 beta 
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IL-6 Interleukin - 6 
IκB Inhibitor of -κB 
KCl Potassium chloride 
kDa Kilodalton 
KOH Potassium hydroxide 
LiCl Lithium Chloride 
LPS Lipopolysaccharides 
M Molar 
MAPK Mitogen activated protein kinase 
MEK MAPK kinase 1 
min minute/ minutes 
ml Milliliters 
mM Millimolar 
mRNA Messenger ribonucleic acid 
MT-MMPs Memebrane type- metalloproteinase 
NEMO NFκB essential modulator 
NFκB Nuclear factor kappa - light chain enhancer of activated B 
cells 
NIK NFκB inducing kinase 
nM Nanomolar 
nm Nanometer 
NO Nitric oxide 
o
C Degree Celcius 
OPD o-phenylenediamine 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffer saline 
PCD Programmed cell death 
PCR Polymerase chain reaction 
PDI Protein disulphide isomerase 
pH Negative log of hydrogen ion concentration 
PI3K Phosphoinositide 3- kinases 
PKCα Protein kinase C alpha 
PKCδ Protein kinase C delta 
PLC Phospholipase  C 
PMSF Phenylmethylsulfonyl fluoride 
PNRC Perinuclear recycling compartment 
PNPP para-Nitrophenylphosphate 
PS1145 n-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-3-
pyridinecarboxamide dihydrochloride 
pSer536 Phosphorylates serine 536 residue 
RA Retinoic acid 
Rb Retinoblastoma gene 
RBC Red blood cells 
RHD Rel homology domain 
RNase Ribonuclease 
ROS Reactive oxygen species 
RPMI-1640 Roswell Park Memorial Institute 
SDS Sodium dodecyl sulphate 
SDS- PAGE Sodium dodecyl sulphate- polyacrylamide gel 
electrophoresis 
SEAP Secreted alkaline phosphatase 
siRNA Small interfering ribonucleic acid 
TAA Triazole acetic acid 
TAD Transactivation domain 
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TEMED N,N,N’,N’-tetramethylene diamine 
TG Transglutaminase 
TG2 Tissue transglutaminase 
TGFβ1 Transforming growth factor beta 1 
TLR Toll like receptor 
TNFR Tumour necrosis factor receptor 
TNFα Tumour necrosis factor - alpha 
Tris Tris (Hydroxymethyl)-amino ethane 
Triton X -100 t-Ocylphenoxypolyethoxyethanol 
Unt Untreated 
v/v volume/volume 
w/v weight/ volume 
WCL Whole cell lysate 
x g G- force 
XTT Sodium 3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis 
(4-methoxy-6-nitro) benzene sulfonic acid hydrate 
Z-DON Z-DON-Val-Pro-Leu-OMe 
μ Micro 
μl Microlitre 
μM Micromolar 
  
  
 
